
<html lang="en"     class="pb-page"  data-request-id="75bbafeb-d750-4347-b80f-5020882b0f2a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.8b00882;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2018.61.issue-18;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia" /></meta><meta name="dc.Creator" content="Hanna  Cho" /></meta><meta name="dc.Creator" content="Injae  Shin" /></meta><meta name="dc.Creator" content="Eunhye  Ju" /></meta><meta name="dc.Creator" content="Seunghye  Choi" /></meta><meta name="dc.Creator" content="Wooyoung  Hur" /></meta><meta name="dc.Creator" content="Haelee  Kim" /></meta><meta name="dc.Creator" content="Eunmi  Hong" /></meta><meta name="dc.Creator" content="Nam Doo  Kim" /></meta><meta name="dc.Creator" content="Hwan Geun  Choi" /></meta><meta name="dc.Creator" content="Nathanael S.  Gray" /></meta><meta name="dc.Creator" content="Taebo  Sim" /></meta><meta name="dc.Description" content="GNF-7, a multitargeted kinase inhibitor, served as a dual kinase inhibitor of ACK1 and GCK, which provided a novel therapeutic strategy for overriding AML expressing NRAS mutation. This SAR study w..." /></meta><meta name="Description" content="GNF-7, a multitargeted kinase inhibitor, served as a dual kinase inhibitor of ACK1 and GCK, which provided a novel therapeutic strategy for overriding AML expressing NRAS mutation. This SAR study w..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 28, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00882" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00882" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00882" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00882" /></link>
        
    
    

<title>First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00882" /></meta><meta property="og:title" content="First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0019.jpeg" /></meta><meta property="og:description" content="GNF-7, a multitargeted kinase inhibitor, served as a dual kinase inhibitor of ACK1 and GCK, which provided a novel therapeutic strategy for overriding AML expressing NRAS mutation. This SAR study with GNF-7 derivatives, designed to target NRAS mutant-driven AML, led to identification of the extremely potent inhibitors, 10d, 10g, and 11i, which possess single-digit nanomolar inhibitory activity against both ACK1 and GCK. These substances strongly suppress proliferation of mutant NRAS expressing AML cells via apoptosis and AKT/mTOR signaling blockade. Compound 11i is superior to GNF-7 in terms of kinase inhibitory activity, cellular activity, and differential cytotoxicity. Moreover, 10k possessing a favorable mouse pharmacokinetic profile prolonged life-span of Ba/F3-NRAS-G12D injected mice and significantly delayed tumor growth of OCI-AML3 xenograft model without causing the prominent level of toxicity found with GNF-7. Taken together, this study provides insight into the design of novel ACK1 and GCK dual inhibitors for overriding NRAS mutant-driven AML." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00882"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00882">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00882&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00882&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00882&amp;href=/doi/10.1021/acs.jmedchem.8b00882" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 8353-8373</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00832" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b00884" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Hanna Cho</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hanna Cho</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hanna++Cho">Hanna Cho</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Injae Shin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Injae Shin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Injae++Shin">Injae Shin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eunhye Ju</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eunhye Ju</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eunhye++Ju">Eunhye Ju</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Seunghye Choi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Seunghye Choi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Seunghye++Choi">Seunghye Choi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wooyoung Hur</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wooyoung Hur</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Kinomics Research Center, Korea Institute of Science and Technology (KIST), 5 Hwarangro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wooyoung++Hur">Wooyoung Hur</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8034-0501" title="Orcid link">http://orcid.org/0000-0002-8034-0501</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haelee Kim</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haelee Kim</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Daegu-Gyeongbuk Medical Innovation Foundation, 2387 dalgubeol-daero, Suseong-gu, Daegu 42019, Republic of Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haelee++Kim">Haelee Kim</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eunmi Hong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eunmi Hong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Daegu-Gyeongbuk Medical Innovation Foundation, 2387 dalgubeol-daero, Suseong-gu, Daegu 42019, Republic of Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eunmi++Hong">Eunmi Hong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nam Doo Kim</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nam Doo Kim</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Daegu-Gyeongbuk Medical Innovation Foundation, 2387 dalgubeol-daero, Suseong-gu, Daegu 42019, Republic of Korea</div><div class="loa-info-affiliations-info">NDBio Therapeutics Inc., 32 Songdogwahak-ro, Yeonsu-gu, Incheon 21984, Republic of Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nam+Doo++Kim">Nam Doo Kim</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hwan Geun Choi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hwan Geun Choi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Daegu-Gyeongbuk Medical Innovation Foundation, 2387 dalgubeol-daero, Suseong-gu, Daegu 42019, Republic of Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hwan+Geun++Choi">Hwan Geun Choi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nathanael S. Gray</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nathanael S. Gray</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States</div><div class="loa-info-affiliations-info">Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nathanael+S.++Gray">Nathanael S. Gray</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5354-7403" title="Orcid link">http://orcid.org/0000-0001-5354-7403</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Taebo Sim</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Taebo Sim</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea</div><div class="loa-info-affiliations-info">Chemical Kinomics Research Center, Korea Institute of Science and Technology (KIST), 5 Hwarangro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +82-2-958-6437. E-mail: <a href="/cdn-cgi/l/email-protection#8bffe9f8e2e6cbe0e2f8ffa5f9eea5e0f9"><span class="__cf_email__" data-cfemail="245046574d49644f4d57500a56410a4f56">[email protected]</span></a>, <a href="/cdn-cgi/l/email-protection#fe8a9c8d9793be95918c9b9fd09f9dd0958c"><span class="__cf_email__" data-cfemail="641006170d09240f0b1601054a05074a0f16">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Taebo++Sim">Taebo Sim</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3015-2059" title="Orcid link">http://orcid.org/0000-0003-3015-2059</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00882&amp;href=/doi/10.1021%2Facs.jmedchem.8b00882" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 8353–8373</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 28, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 June 2018</li><li><span class="item_label"><b>Published</b> online</span>28 August 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 September 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00882" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00882</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8353%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DHanna%2BCho%252C%2BInjae%2BShin%252C%2BEunhye%2BJu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D18%26contentID%3Dacs.jmedchem.8b00882%26title%3DFirst%2BSAR%2BStudy%2Bfor%2BOverriding%2BNRAS%2BMutant%2BDriven%2BAcute%2BMyeloid%2BLeukemia%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8373%26publicationDate%3DSeptember%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00882"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2617</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00882" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Hanna&quot;,&quot;last_name&quot;:&quot;Cho&quot;},{&quot;first_name&quot;:&quot;Injae&quot;,&quot;last_name&quot;:&quot;Shin&quot;},{&quot;first_name&quot;:&quot;Eunhye&quot;,&quot;last_name&quot;:&quot;Ju&quot;},{&quot;first_name&quot;:&quot;Seunghye&quot;,&quot;last_name&quot;:&quot;Choi&quot;},{&quot;first_name&quot;:&quot;Wooyoung&quot;,&quot;last_name&quot;:&quot;Hur&quot;},{&quot;first_name&quot;:&quot;Haelee&quot;,&quot;last_name&quot;:&quot;Kim&quot;},{&quot;first_name&quot;:&quot;Eunmi&quot;,&quot;last_name&quot;:&quot;Hong&quot;},{&quot;first_name&quot;:&quot;Nam&quot;,&quot;last_name&quot;:&quot;Doo Kim&quot;},{&quot;first_name&quot;:&quot;Hwan&quot;,&quot;last_name&quot;:&quot;Geun Choi&quot;},{&quot;first_name&quot;:&quot;Nathanael&quot;,&quot;last_name&quot;:&quot;S. Gray&quot;},{&quot;first_name&quot;:&quot;Taebo&quot;,&quot;last_name&quot;:&quot;Sim&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;28&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;8353-8373&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00882&quot;},&quot;abstract&quot;:&quot;GNF-7, a multitargeted kinase inhibitor, served as a dual kinase inhibitor of ACK1 and GCK, which provided a novel therapeutic strategy for overriding AML expressing NRAS mutation. This SAR study with GNF-7 derivatives, designed to target NRAS mutant-driven AML, led to identification of the extremely potent inhibitors, 10d, 10g, and 11i, which possess single-digit nanomolar inhibitory activity against both ACK1 and GCK. These substances strongly suppress proliferation of mutant NRAS expressing AML cells via apoptosis and AKT/mTOR signaling blockade. Compound 11i is superior to GNF-7 in terms of kinase inhibitory activity, cellular activity, and differential cytotoxicity. Moreover, 10k possessing a favorable mouse pharmacokinetic profile prolonged life-span of Ba/F3-NRAS-G12D injected mice and significantly delayed tumor growth of OCI-AML3 xenograft model without causing the prominent level of toxicity found with GNF-7. Taken together, this study provides insight into the design of novel ACK1 and GCK dual inhi&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00882&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00882" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00882&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00882" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00882&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00882" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00882&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00882&amp;href=/doi/10.1021/acs.jmedchem.8b00882" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00882" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00882" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00882%26sid%3Dliteratum%253Aachs%26pmid%3D30153003%26genre%3Darticle%26aulast%3DCho%26date%3D2018%26atitle%3DFirst%2BSAR%2BStudy%2Bfor%2BOverriding%2BNRAS%2BMutant%2BDriven%2BAcute%2BMyeloid%2BLeukemia%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D18%26spage%3D8353%26epage%3D8373%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291149" title="Apoptosis">Apoptosis</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/18" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/jmcmar.2018.61.issue-18/20180927/jmcmar.2018.61.issue-18.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">GNF-7, a multitargeted kinase inhibitor, served as a dual kinase inhibitor of ACK1 and GCK, which provided a novel therapeutic strategy for overriding AML expressing NRAS mutation. This SAR study with GNF-7 derivatives, designed to target NRAS mutant-driven AML, led to identification of the extremely potent inhibitors, <b>10d</b>, <b>10g</b>, and <b>11i</b>, which possess single-digit nanomolar inhibitory activity against both ACK1 and GCK. These substances strongly suppress proliferation of mutant NRAS expressing AML cells via apoptosis and AKT/mTOR signaling blockade. Compound <b>11i</b> is superior to GNF-7 in terms of kinase inhibitory activity, cellular activity, and differential cytotoxicity. Moreover, <b>10k</b> possessing a favorable mouse pharmacokinetic profile prolonged life-span of Ba/F3-NRAS-G12D injected mice and significantly delayed tumor growth of OCI-AML3 xenograft model without causing the prominent level of toxicity found with GNF-7. Taken together, this study provides insight into the design of novel ACK1 and GCK dual inhibitors for overriding NRAS mutant-driven AML.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33247" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33247" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The small GTPase, RAS, plays the role of a molecular switch that regulates signal transduction in response to extracellular stimuli. In this role, it participates in diverse cellular events such as cell cycle, differentiation, and survival. Malfunctioning RAS is strongly related to tumorigenesis. Mutations in the RAS gene, which encode overactive RAS proteins, are found in 30% of all human tumors. Among the three mutants, HRAS, KRAS, and NRAS, KRAS is most frequently present in various types of cancers including lung (35%), colon (45%), and pancreatic (90%).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> NRAS mutations are also common in acute myeloid leukemia (AML),<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> appearing in 10% of AML patients.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> AML has remained a devastating and life-threatening disease with poor prognosis,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> especially for patients 65 years or older whose median overall survival is less than one year.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Therefore, there exists an unmet medical need to create further innovative therapeutic strategies for overcoming AML even though enormous efforts<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> have been devoted to developing targeted therapies for AML treatment including FLT3 inhibitors, PLK inhibitors, IDH inhibitors, DNMT inhibitor, LSD1 inhibitor, DOT1L inhibitors, HDAC inhibitors, BET inhibitors, and BCL-2 inhibitors.</div><div class="NLM_p">The high relevance and crucial role of its mutations in cancers has made RAS an attractive therapeutic target for cancer treatment.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> However, despite being subjected to intensive efforts over several decades, no efficacious pharmacological RAS inhibitors have been identified. This is caused by the extraordinarily high affinity of RAS for its substrates, GTP and GDP, as well as the presence of a surface in this protein that does not participate in high-affinity interactions with small molecules.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Thus, other strategies have been explored to inhibit the function of hyperactivated RAS.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> One involves targeting effectors such as RAF,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> MEK,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and ERK<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> in canonical RAS<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and PI3K/AKT<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> pathways. Although many substances which function in this manner are under clinical evaluation, rapid drug resistance and complex feedback mechanisms are major hurdles for this approach to drug development.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Blocking RAS localization by preventing farnesylation of RAS has also been investigated. In spite of displaying in vitro anticancer effects, farnesyltransferase inhibitors (FTIs)<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> generally have poor clinical outcomes. Furthermore, genetic approaches have been employed to identify new target genes that interact with oncogenic RAS in a lethal manner. Although this strategy led to identification of STK33 as an effective target, more significant effort is required to discover active candidates.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p">As part of a program to explore a promising anticancer strategy that focuses on blocking signaling by the oncogenic NRAS mutation, we recently identified dual inhibition of ACK1 and GCK as a novel therapeutic target to overcome NRAS mutant-driven acute myeloid leukemia (AML).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Both ACK1 and GCK are noncanonical effectors of the RAS pathway. Activated cdc42-associated kinase 1 (ACK1 or TNK2) is a nonreceptor tyrosine kinase originally identified as an inhibitory regulator of cdc42. Recent studies have highlighted the oncogenic properties of ACK1<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> by showing that it directly phosphorylates Tyr176 of AKT and thus activates AKT in a PI3K-independent manner.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Germinal center kinase (GCK/MAP4K2) belongs to the STE20 family of serine/threonine kinases associated with the JNK pathway and inflammatory process.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p">In a previous study, we showed that the multikinase inhibitor GNF-7<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> effectively and selectively suppresses proliferation of primary AML patient-derived cells harboring mutant NRAS as well as AML cell lines expressing mutant NRAS. Through mechanistic analysis using small molecule kinase inhibitors and RNA interference studies and in situ kinase profiling (KiNativ method), we ascertained that the effect of GNF-7 on NRAS mutant AML cells is associated with a synthetic lethal interaction between ACK1 and GCK. This synthetically lethal effect of GNF-7 significantly reduces the disease burden and prolongs overall survival in an AML xenotransplantation mice model.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p last">The current study was designed to discover new inhibitors of ACK1 and GCK, which are more potent and/or less toxic than GNF-7, in order to overcome AML caused by the NRAS mutant. In the effort described below, a structure–activity relationship (SAR) study was carried out exploring the effects on NRAS mutant AML cells as well as ACK1 and GCK enzymes of GNF-7 derivatives, which possess the dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one scaffold. We observed that among the 29 synthetic GNF-7 derivatives prepared in this study, <b>10d</b> and <b>11i</b> exhibit much higher enzymatic inhibition and cellular activities compared with GNF-7. Moreover, <b>11i</b> clearly exceeds GNF-7 in terms of kinase-inhibitory activity, cellular potency, and differential cytotoxicity. We observed that another derivative, <b>10k</b>, having a favorable mouse PK profile, significantly prolonged the life-span of Ba/F3-NRAS-G12D injected mice without prominent toxicity found in GNF-7, which makes <b>10k</b> superior to GNF-7.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81847" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81847" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> General Procedure for Synthesis of GNF-7 Derivatives</h3><div class="NLM_p">By employing a more efficient synthetic route for the preparation GNF-7 than the one previously reported,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> we were able to generate derivatives that contain a variety of different moieties at the R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> positions identified in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch3" aria-label="3">3</a>, and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. The synthetic route developed to prepare GNF-7 along with <b>10a</b>–<b>k</b> and <b>11a</b>–<b>i</b>, given in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, begins with chlorination of the commercially available pyrimidine derivative <b>1</b> using POCl<sub>3</sub> and DIPEA to yield the corresponding chloride <b>2</b>.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Reaction of <b>2</b> with 2-methyl-5-nitroaniline produced aniline derivative <b>3</b>, which upon reaction with methylamine provided <b>4</b>. Cyclic urea formation promoted by reaction of <b>4</b> with triphosgene formed the key intermediate <b>5</b>, which was utilized in routes to generate GNF-7 and derivatives containing various R<sub>1</sub> and R<sub>2</sub> replacements. Reduction of the nitro group in <b>5</b> to give <b>6</b> followed by acylation with 3-(trifluoromethyl)benzoyl chloride provided amide <b>7</b>, which through Buckwald amination with various aniline derivatives is transformed to GNF-7 and R<sub>1</sub>-substituted analogues <b>10a</b>–<b>k</b>. Similarly, a sequence involving reaction of <b>5</b> with 6-methylpyridin-3-amine (giving <b>8</b>), nitro group reduction (giving <b>9</b>), and amide coupling with various carboxylic acids produced R<sub>2</sub>-substituted analogues <b>11a</b>–<b>i</b>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of GNF-7 (left) and representative GNF-7 analogues (right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of GNF-7, <b>10a</b>–<b>k</b>, and <b>11a</b>–<b>i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagent and conditions: (A) POCl<sub>3</sub>, DIPEA, toluene, 110 °C, 77%; (B) 2-methyl-5-nitroaniline, NaI, K<sub>2</sub>CO<sub>3</sub>, acetone, 50 °C, 74%; (C) MeNH<sub>2</sub> (2 M in MeOH solution), DIPEA, 1,4-dioxane, 60 °C, 77%; (D) triphosgene, TEA, THF, 70 °C, 63%; (E) Fe powder, NH<sub>4</sub>Cl, THF/MeOH/H<sub>2</sub>O, 80 °C, 87%; (F) 3-(trifluoromethyl)benzoyl chloride, K<sub>2</sub>CO<sub>3</sub>, DCM, rt, 73%; (G) various amines, K<sub>2</sub>CO<sub>3</sub>, Xphos, Pd<sub>2</sub>(dba)<sub>3</sub>, 2-butanol, 100 °C, 13–84% or ammonia solution, DMSO, 150 °C, 28%; (H) 6-methylpyridin-3-amine, K<sub>2</sub>CO<sub>3</sub>, Xphos, Pd<sub>2</sub>(dba)<sub>3</sub>, 2-butanol, 100 °C, 65%; (I) Fe powder, NH<sub>4</sub>Cl, THF/MeOH/H<sub>2</sub>O, 80 °C, 81%; (J) various carboxylic acids, HATU, DIPEA, DMF, rt, 30–61%.</p></p></figure><div class="NLM_p">A modification of the routes shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> was used to prepare R<sub>3</sub>-substituted analogues. As shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, pyrimidine trichloride <b>2</b> was first converted to <b>12</b>, which contains <i>N</i>-(3-amino-4-methylphenyl)-3-(trifluoromethyl)benzamide group present in GNF-7 and a handle to introduce various R<sub>3</sub> substituents to create analogues <b>13a</b>–<b>e</b>. In addition, cyclic urea forming reactions of <b>13a</b>–<b>e</b> produced <b>14a</b>–<b>e</b>, which were then transformed to <b>15a</b>–<b>e</b> by using Buchwald amination with 6-methylpyridin-3-amine.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>15a</b>–<b>e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagent and conditions: (A) <i>N</i>-(3-amino-4-methylphenyl)-3-(trifluoromethyl)benzamide, NaI, K<sub>2</sub>CO<sub>3</sub>, acetone, 50 °C, 69%; (B) various amines, THF, 60 °C or aniline, TEA, <i>n</i>-butanol, 120 °C; (C) triphosgene, TEA, THF, 70 °C; (D) 6-methylpyridin-3-amine, K<sub>2</sub>CO<sub>3</sub>, Xphos, Pd<sub>2</sub>(dba)<sub>3</sub>, 2-butanol, 100 °C, 12–27% over 3 steps.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Structure–Activity Relationships</h3><div class="NLM_p">IC<sub>50</sub> values for all synthetic GNF-7 analogues against both ACK1 and GCK kinases were determined using an in vitro biochemical kinase assay. The growth inhibitory activities (GI<sub>50</sub>s) of these substances in the NRAS-G12D transformed Ba/F3 cell line were also estimated. The first phase of this effort, focusing on optimization of the R<sub>1</sub> substituent (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), showed that <b>10a</b>, containing an aniline head group, displays a 6-fold lower activity (IC<sub>50</sub> = 47 nM) against GCK compared with that of GNF-7 (IC<sub>50</sub> = 8 nM) while its potency against ACK1 (IC<sub>50</sub> = 37 nM) is nearly equal to that of GNF-7. This finding is consistent with information gained from a previous docking study,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> which suggested that the pyridine nitrogen in GNF-7 contributes to binding with GCK through hydrogen bonding with Tyr27. ACK1 lacks a residue analogous to Tyr27 in GCK.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Enzymatic Inhibitory Activities against ACK1 and GCK and Antiproliferative Activities on Ba/F3-NRAS-G12D Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0013.gif" alt="" id="gr5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0014.gif" alt="" id="gr6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Radiometric biochemical kinase assay results.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">GI<sub>50</sub> represents the concentration at which a compound causes half-maximal growth inhibition. NRAS-G12D-transformed Ba/F3 cells and parental Ba/F3 cells were treated with inhibitors for 72 h in a dose escalation. Average GI<sub>50</sub> values with SD (<i>n</i> = 3, duplicate) are shown.</p></div></div><div></div></div><div class="NLM_p">Both <b>10b</b> containing the 4-(4-ethylpiperazin-1-yl)-phenylamine head group that is present in the pan-FGFR inhibitor BGJ398<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and <b>10c</b> containing a 6-(4-ethylpiperazin-1-yl)pyridin-3-amine group were found to have a kinase inhibitory activity against GCK that is in the range of that of the parent GNF-7, indicating that the nitrogen on the ethylpiperazine ring could form a hydrogen bond with Tyr27 of GCK. Similarly, replacement of ethylpiperazine group in <b>10c</b> with piperazinyl ethanone (<b>10d</b>) and ethylpiperazinyl methanone groups (<b>10e</b>) led to a significant increase in kinase inhibitory activity (<b>10d</b>, GCK IC<sub>50</sub> = 1 nM, ACK1 IC<sub>50</sub> = 8 nM; <b>10e</b>, GCK IC<sub>50</sub> = 2 nM, ACK1 IC<sub>50</sub> = 13 nM). Taken together, these results demonstrate that extended head groups in GNF-7 analogues may enable additional interaction with both ACK1 and GCK and thus increase binding affinity.</div><div class="NLM_p">Compared with that of GNF-7, the antiproliferative activities of <b>10d</b> and <b>10e</b> on Ba/F3-NRAS-G12D cells were moderately greater or the same as GNF-7 (GI<sub>50</sub>s of 0.059 and 0.107 μM, respectively) in spite of their higher enzymatic inhibition activities. Compared to GNF-7, <b>10a</b>–<b>e</b> exhibited lower differential cytotoxicities against Ba/F3-NRAS-G12D cells relative to parental Ba/F3 cells which serve as a control. It is of note that compared with GNF-7, <b>10d</b> possesses increased kinase inhibitory activity against both ACK1 (8 nM of IC<sub>50</sub>) and GCK (1 nM of IC<sub>50</sub>) and a higher cellular activity on Ba/F3-NRAS-G12D cells.</div><div class="NLM_p">We also explored analogues that contain an aminopyrazole R<sub>1</sub> substituent that is present in NG25, a dual TAK1 and GCK inhibitor.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The kinase inhibitory and cellular activities of <b>10f</b>, bearing a 1-methyl-pyrazole group, are comparable to those of GNF-7 and to other substances (<b>10b</b>–<b>e</b>) containing a piperazinyl group. Notably, <b>10g</b> exhibited a slightly higher enzymatic inhibitory activity (GCK IC<sub>50</sub> = 5 nM, ACK1 IC<sub>50</sub> = 9 nM) relative to GNF-7, which indicates that 1,3-dimethyl pyrazole group may fit in the hydrophobic pocket adjacent to the hinge region in the kinases. Also, the cellular activity and differential cytotoxicity of <b>10g</b> on Ba/F3 cells are comparable to those of GNF-7.</div><div class="NLM_p">In contrast to analogues with aromatic groups at the R<sub>1</sub> position, derivatives containing aliphatic amine groups (<b>10h</b>, <b>10i</b>, and <b>10j</b>) generally displayed lower kinase inhibitory activities and antiproliferative activities on Ba/F3-NRAS-G12D cells, whereas <b>10h</b> bearing a cyclopropylamine group has similar IC<sub>50</sub> and GI<sub>50</sub> values to those of aniline bearing <b>10a</b>. This observation suggests that the cyclopropyl moiety, which has pseudo double-bond character,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> can participate in π–π stacking interactions in the hydrophobic pocket near the hinge region. In contrast, <b>10i</b>, having a bulky and flexible cyclohexyl group, has substantially diminished potency compared with those of <b>10h</b> and <b>10j</b>. Compared with GNF-7, <b>10k</b> exhibited a comparable inhibitory activity against ACK1 and a 3-fold less potency against GCK (IC<sub>50</sub> = 28 nM). Overall, the data gained from the SAR study with analogues containing different R<sub>1</sub> groups suggest that aromatic amine groups containing an additional hydrogen bonding acceptor have enhanced kinase inhibitory activities against both ACK1 and GCK.</div><div class="NLM_p">Our attention next focused on optimization of the R<sub>2</sub> group (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The inhibitory effect of the aryl-CF<sub>3</sub> group in GNF-7 was assessed using the unsubstituted analogue <b>11a</b>. Interestingly, the inhibitory potency of <b>11a</b> against GCK (IC<sub>50</sub> = 1080 nM) is greatly less than that of GNF-7 while its activity against ACK1 (IC<sub>50</sub> = 21 nM) is the same as that of GNF-7, indicating that CF<sub>3</sub> group is essential for kinase inhibitory activity on GCK but not ACK1. The 4-methyl aryl group containing analogue, <b>11b</b>, has a 5-fold reduced kinase-inhibitory activity against GCK (IC<sub>50</sub> = 39 nM) and antiproliferative activity (GI<sub>50</sub> = 0.387 μM) on Ba/F3-NRAS-G12D cells. In contrast, the in vitro potencies of <b>11b</b> against ACK1 (IC<sub>50</sub> = 20 nM) and parental Ba/F3 cells (GI<sub>50</sub> = 0.870 μM) were retained.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Enzymatic Inhibitory Activities against ACK1 and GCK and Antiproliferative Activities on Ba/F3-NRAS-G12D Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0015.gif" alt="" id="gr7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0016.gif" alt="" id="gr8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Radiometric biochemical kinase assay results.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">GI<sub>50</sub> represents the concentration at which a compound causes half-maximal growth inhibition. NRAS-G12D-transformed Ba/F3 cells and parental Ba/F3 cells were treated with inhibitors for 72 h in a dose escalation. Average GI<sub>50</sub> values with SD (<i>n</i> = 3, duplicate) are shown.</p></div></div><div></div></div><div class="NLM_p">The effects of additional substituents at the <i>meta</i> or <i>para</i> positions of the tail aryl ring in GNF-7 were explored using <b>11c</b>–<b>i</b>. The results showed that addition of <i>meta</i>-morpholine (<b>11c</b>) and 4-piperidinol moiety (<b>11d</b>) resulted in slight decreases in inhibitory activity against GCK (<b>11c</b>, IC<sub>50</sub> = 45 nM; <b>11d</b>, IC<sub>50</sub> = 72 nM) and antiproliferation of Ba/F3-NRAS-G12D cells (<b>11c</b>, GI<sub>50</sub> = 0.284 μM; <b>11d</b>, GI<sub>50</sub> = 0.118 μM). Moreover, introduction of a <i>meta</i>-4-methylimidazole group (<b>11e</b>) also brought about a slight reduction in kinase inhibitory activities (GCK IC<sub>50</sub> = 27 nM, ACK1, IC<sub>50</sub> = 53 nM) and cellular Ba/F3-NRAS-G12D cellular activity (GI<sub>50</sub> = 0.238 μM) compared with that of GNF-7.</div><div class="NLM_p">In exploring the effect <i>para</i>-aryl substituents, we found that <b>11f</b> possessing <i>para</i>-pyrrole moiety has a marginally increased activity against ACK1 (IC<sub>50</sub> = 10 nM) but not against GCK (IC<sub>50</sub> = 24 nM), while <b>11g</b> containing a <i>para</i>-piperazine moiety has retained kinase inhibitory activity against both ACK1 and GCK (ACK1 IC<sub>50</sub> = 28 nM, GCK IC<sub>50</sub> = 10 nM). On the basis of these results, we conclude that <i>para</i>- rather than <i>meta</i>-substitution is more suitable for altering inhibitory activities against both ACK1 and GCK. Indeed, <b>11h</b>, having a piperazinylmethylphenyl substituent, has a 2-fold increased potency (IC<sub>50</sub> = 5 nM) against GCK kinase compared to that of <b>11g</b>. Furthermore, <b>11i</b>, containing a 3-(dimethylamino)pyrrolidinemethylphenyl group, has enhanced kinase inhibitory activities against both ACK1 (IC<sub>50</sub> = 6 nM) and GCK (IC<sub>50</sub> = 2 nM) compared with GNF-7. Also, <b>11i</b> has a significantly increased anticellular proliferation potency (GI<sub>50</sub> = 0.023 μM) on Ba/F3-NRAS-G12D relative to GNF-7. It should be emphasized that <b>11i</b> compared to GNF-7 possesses a higher differential cytotoxicity against Ba/F3-NRAS-G12D cells relative to parental Ba/F3 cells.</div><div class="NLM_p">The effects of R<sub>3</sub> groups on inhibitory activities were explored by replacing the methyl group in GNF-7 with more sterically bulky aliphatic groups, phenyl groups, and benzyl group. The results show that as the size of the R<sub>3</sub> substituent increases (<b>15a</b>–<b>c</b>, <b>15e</b>), both enzymatic activities and cellular activities decrease. Although the phenyl group in <b>15d</b> causes a slightly increased kinase inhibitory activity against ACK1 (IC<sub>50</sub> = 15 nM), it causes a decreased activity against GCK and cellular activity compared with GNF-7 in which R<sub>3</sub> substituent is methyl group.</div><div class="NLM_p">The observations made in the SAR study suggest that 3-(dimethylamino)pyrrolidinemethylphenyl and methyl are optimal R<sub>2</sub> and R<sub>3</sub> groups, respectively. Moreover, the results indicate that that the R<sub>1</sub> substituents in <b>10d</b>–<b>g</b> are superior to that in GNF-7 in terms of enzymatic inhibitory activities. As a result, the activities of analogues <b>17a</b>–<b>d</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>), containing a combination of the optimal R<sub>2</sub>/R<sub>3</sub> substituent and the R<sub>1</sub> substituents present <b>10d</b>–<b>g</b>, were assessed. Contrary to expectations, compared with those of <b>11i</b>, none of these compounds exhibited enhanced enzymatic inhibitory activities against ACK1 or GCK (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Compared with GNF-7, <b>17a</b>–<b>d</b> have lower differential cytotoxicities against Ba/F3-NRAS-G12D cells relative to parental Ba/F3 cells even though they displayed comparable cellular activities against BaF3-NRAS-G12D cells.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>17a</b>–<b>e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagent and condition: (A) 4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)benzoic acid, HATU, DIPEA,DMF, rt, 65%; (B) various amines, K<sub>2</sub>CO<sub>3</sub>, Xphos, Pd<sub>2</sub>(dba)<sub>3</sub>, 2-butanol, 100 °C, 34–62%.</p></p></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Enzymatic Inhibitory Activities against ACK1 and GCK and Antiproliferative Activities on Ba/F3-NRAS-G12D Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0017.gif" alt="" id="gr9" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0018.gif" alt="" id="gr10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Radiometric biochemical kinase assay results.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">GI<sub>50</sub> represents the concentration at which a compound causes half-maximal growth inhibition. NRAS-G12D-transformed Ba/F3 cells and parental Ba/F3 cells were treated with inhibitors for 72 h in a dose escalation. Average GI<sub>50</sub> values with SD (<i>n</i> = 3, duplicate) are shown.</p></div></div><div></div></div><div class="NLM_p">On the basis of the results of the SAR study presented above, the antiproliferative activities of selected analogues in the human AML cell lines, OCI-AML3 (NRAS-Q61L) and U937 (NRAS wt), were assessed (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). In this assessment, a higher differential cytotoxic effect on OCI-AML3 (NRAS mt) cell lines relative to U937 (NRAS wt) is a positive finding. GI<sub>50</sub>s on OCI-AML3 cells were found to be in the range of 0.030–0.466 μM. The four GNF-7 derivatives, <b>10b</b>, <b>10c</b>, <b>10f</b>, and <b>11i</b>, have remarkable potencies against OCI-AML3 cells (GI<sub>50</sub>s range from 0.030 to 0.042 μM) and reasonable antiproliferative activities against U937 cells (GI<sub>50</sub> = ca. 1 μM). On the basis of their cellular selectivities against OCI-AML3 cells (NRAS mt) over U937 cells (NRAS wt), five derivatives, <b>10c</b>, <b>10e</b>, <b>11b</b>, <b>11f</b>, and <b>11i</b>, were found to be superior to GNF-7. This is especially true for <b>11f</b>, which displayed an exceptional cellular selectivity (ca. 100-fold) against OCI-AML3 cells over U937 cells. It is worth recalling that <b>11i</b> exhibits the highest differential cytotoxicity against Ba/F3-NRAS-G12D cells relative to parental Ba/F3 cells. Thus, this effort has led to the identification of promising new GNF-7 analogues that have strong antiproliferative activities and high cellular selectivities against NRAS mutant expressing AML cell lines. It should be noted that <b>11i</b> clearly surpasses GNF-7 in terms of cellular potency and selectivity on NRAS mutation cells (Ba/F3-NRAS-G12D and OCI-AML3) as well as enzymatic inhibitory activities against ACK1 and GCK.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Antiproliferative Activities of the Selected GNF-7 Analogues against OCI-AML3 and U937 Cells</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">entry</th><th class="colsep0 rowsep0" align="center" char="±">OCI-AML3 (NRAS Q61L) GI<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">U937 (NRAS wt) GI<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GNF-7</td><td class="colsep0 rowsep0" align="char" char="±">0.219 ± 0.058</td><td class="colsep0 rowsep0" align="center">4.377 ± 0.081</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10b</b></td><td class="colsep0 rowsep0" align="char" char="±">0.040 ± 0.002</td><td class="colsep0 rowsep0" align="center">0.839 ± 0.317</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10c</b></td><td class="colsep0 rowsep0" align="char" char="±">0.030 ± 0.001</td><td class="colsep0 rowsep0" align="center">1.412 ± 0.276</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10d</b></td><td class="colsep0 rowsep0" align="char" char="±">0.179 ± 0.017</td><td class="colsep0 rowsep0" align="center">2.483 ± 0.499</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10e</b></td><td class="colsep0 rowsep0" align="char" char="±">0.122 ± 0.040</td><td class="colsep0 rowsep0" align="center">6.479 ± 0.383</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10f</b></td><td class="colsep0 rowsep0" align="char" char="±">0.042 ± 0.031</td><td class="colsep0 rowsep0" align="center">1.125 ± 0.129</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10g</b></td><td class="colsep0 rowsep0" align="char" char="±">0.208 ± 0.034</td><td class="colsep0 rowsep0" align="center">2.463 ± 1.679</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10j</b></td><td class="colsep0 rowsep0" align="char" char="±">0.367 ± 0.065</td><td class="colsep0 rowsep0" align="center">8.531 ± 0.039</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10k</b></td><td class="colsep0 rowsep0" align="char" char="±">0.466 ± 0.120</td><td class="colsep0 rowsep0" align="center">4.967 ± 1.052</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11b</b></td><td class="colsep0 rowsep0" align="char" char="±">0.394 ± 0.025</td><td class="colsep0 rowsep0" align="center">19.375 ± 1.775</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11c</b></td><td class="colsep0 rowsep0" align="char" char="±">0.260 ± 0.064</td><td class="colsep0 rowsep0" align="center">2.805 ± 0.134</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11d</b></td><td class="colsep0 rowsep0" align="char" char="±">0.143 ± 0.002</td><td class="colsep0 rowsep0" align="center">2.180 ± 0.785</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11f</b></td><td class="colsep0 rowsep0" align="char" char="±">0.267 ± 0.092</td><td class="colsep0 rowsep0" align="center">>25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11i</b></td><td class="colsep0 rowsep0" align="char" char="±">0.037 ± 0.005</td><td class="colsep0 rowsep0" align="center">1.973 ± 0.182</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">GI<sub>50</sub> represents the concentration at which a compound causes half-maximal growth inhibition. OCI-AML3 and U937 cells were treated with inhibitors for 72 h. Average GI<sub>50</sub> values with SD (<i>n</i> = 3, duplicate) are shown.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Microsomal Stability and Mouse PK Profiling</h3><div class="NLM_p">With selected compounds (<b>10b</b>, <b>10c</b>, <b>10d</b>, <b>10e</b>, <b>10f</b>, <b>10g</b>, <b>10k</b>, and <b>11i</b>) displaying distinctive in vitro potency, we evaluated their microsomal stability to estimate metabolic clearance in liver. The remaining amount of each compound after 30 min incubation in liver microsomes of human, dog, rat, and mouse was measured (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Briefly, the microsomal stabilities of compounds with five-membered aromatic pyrazole rings (<b>10f</b>, <b>10g</b>) or the primary amine (<b>10k</b>) as head group are comparable to those of GNF-7. The presence of piperazine moiety in a head group (<b>10b</b>, <b>10c</b>, <b>10d</b>, and <b>10e</b>) caused poor microsomal stability. <b>11i</b>, possessing additional substituents at the <i>meta</i> position of the GNF-7 tail, showed the little reduced stability compared with GNF-7. We next assessed inhibitory activities of the compounds against four cytochromes P450 (CYPs) and found that <b>10k</b> had little or no inhibition effects on CYP1A2, CYP2C9, CYP2D6, and CYP3A4 at 10 μM. Especially, <b>10k</b> is far superior to GNF-7 in terms of CYP2C9 inhibition profile. We also investigated the mouse pharmacokinetic property (PO, 10 mg/kg) of <b>10k</b> (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Compound <b>10k</b> exhibited excellent oral systemic exposure (AUC<sub>inf</sub> = 52464.8 ng h/mL, AUC<sub>last</sub> = 36363.7 ng h/mL, <i>C</i><sub>max</sub> = 2406.7 ng/mL), thus we chose this compound for in vivo efficacy study using mouse leukemia model.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Microsomal Stability<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> and CYP Inhibition<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a> Profile</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">microsomal stability (%)</th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">CYP remaining activity (%)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">entry</th><th class="colsep0 rowsep0" align="center" char=".">human</th><th class="colsep0 rowsep0" align="center" char=".">dog</th><th class="colsep0 rowsep0" align="center" char=".">rat</th><th class="colsep0 rowsep0" align="center" char=".">mouse</th><th class="colsep0 rowsep0" align="center" char=".">1A2</th><th class="colsep0 rowsep0" align="center" char=".">2C9</th><th class="colsep0 rowsep0" align="center" char=".">2D6</th><th class="colsep0 rowsep0" align="center">3A4</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GNF-7</td><td class="colsep0 rowsep0" align="char" char=".">78.6</td><td class="colsep0 rowsep0" align="char" char=".">55.3</td><td class="colsep0 rowsep0" align="char" char=".">84.8</td><td class="colsep0 rowsep0" align="char" char=".">80.5</td><td class="colsep0 rowsep0" align="char" char=".">93.2</td><td class="colsep0 rowsep0" align="char" char=".">27.0</td><td class="colsep0 rowsep0" align="char" char=".">68.4</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10b</b></td><td class="colsep0 rowsep0" align="char" char=".">46.7</td><td class="colsep0 rowsep0" align="char" char=".">21.3</td><td class="colsep0 rowsep0" align="char" char=".">19.7</td><td class="colsep0 rowsep0" align="char" char=".">20.9</td><td class="colsep0 rowsep0" align="char" char=".">92.1</td><td class="colsep0 rowsep0" align="char" char=".">34.3</td><td class="colsep0 rowsep0" align="char" char=".">79.8</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10c</b></td><td class="colsep0 rowsep0" align="char" char=".">29.8</td><td class="colsep0 rowsep0" align="char" char=".">21.4</td><td class="colsep0 rowsep0" align="char" char=".">19.2</td><td class="colsep0 rowsep0" align="char" char=".">21.2</td><td class="colsep0 rowsep0" align="char" char=".">89.7</td><td class="colsep0 rowsep0" align="char" char=".">23.0</td><td class="colsep0 rowsep0" align="char" char=".">68.0</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10d</b></td><td class="colsep0 rowsep0" align="char" char=".">47.3</td><td class="colsep0 rowsep0" align="char" char=".">38.0</td><td class="colsep0 rowsep0" align="char" char=".">75.4</td><td class="colsep0 rowsep0" align="char" char=".">49.1</td><td class="colsep0 rowsep0" align="char" char=".">87.2</td><td class="colsep0 rowsep0" align="char" char=".">15.6</td><td class="colsep0 rowsep0" align="char" char=".">83.1</td><td class="colsep0 rowsep0" align="center">88.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10e</b></td><td class="colsep0 rowsep0" align="char" char=".">24.6</td><td class="colsep0 rowsep0" align="char" char=".">23.3</td><td class="colsep0 rowsep0" align="char" char=".">38.3</td><td class="colsep0 rowsep0" align="char" char=".">24.2</td><td class="colsep0 rowsep0" align="char" char=".">81.8</td><td class="colsep0 rowsep0" align="char" char=".">29.0</td><td class="colsep0 rowsep0" align="char" char=".">32.8</td><td class="colsep0 rowsep0" align="center">94.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10f</b></td><td class="colsep0 rowsep0" align="char" char=".">78.8</td><td class="colsep0 rowsep0" align="char" char=".">71.3</td><td class="colsep0 rowsep0" align="char" char=".">98.4</td><td class="colsep0 rowsep0" align="char" char=".">73.3</td><td class="colsep0 rowsep0" align="char" char=".">88.0</td><td class="colsep0 rowsep0" align="char" char=".">42.9</td><td class="colsep0 rowsep0" align="char" char=".">78.8</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10g</b></td><td class="colsep0 rowsep0" align="char" char=".">69.2</td><td class="colsep0 rowsep0" align="char" char=".">69.9</td><td class="colsep0 rowsep0" align="char" char=".">82.3</td><td class="colsep0 rowsep0" align="char" char=".">74.7</td><td class="colsep0 rowsep0" align="char" char=".">88.2</td><td class="colsep0 rowsep0" align="char" char=".">38.3</td><td class="colsep0 rowsep0" align="char" char=".">72.0</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10k</b></td><td class="colsep0 rowsep0" align="char" char=".">84.4</td><td class="colsep0 rowsep0" align="char" char=".">67.9</td><td class="colsep0 rowsep0" align="char" char=".">81.3</td><td class="colsep0 rowsep0" align="char" char=".">80.0</td><td class="colsep0 rowsep0" align="char" char=".">89.2</td><td class="colsep0 rowsep0" align="char" char=".">68.1</td><td class="colsep0 rowsep0" align="char" char=".">82.2</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11i</b></td><td class="colsep0 rowsep0" align="char" char=".">57.5</td><td class="colsep0 rowsep0" align="char" char=".">43.1</td><td class="colsep0 rowsep0" align="char" char=".">76.5</td><td class="colsep0 rowsep0" align="char" char=".">58.7</td><td class="colsep0 rowsep0" align="char" char=".">67.5</td><td class="colsep0 rowsep0" align="char" char=".">55.1</td><td class="colsep0 rowsep0" align="char" char=".">4.9</td><td class="colsep0 rowsep0" align="center">21.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Liver microsomal stability (% remaining during 30 min at 1 μM).</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">% of control activity at 10 μM.</p></div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Mouse Oral PK Property of <b>10k</b><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center"><b>10k</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose (mg/kg)</td><td class="colsep0 rowsep0" align="center">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>inf</sub> (ng·h/mL)</td><td class="colsep0 rowsep0" align="center">52464.8 ± 20913.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>last</sub> (ng·h/mL)</td><td class="colsep0 rowsep0" align="center">36363.7 ± 5340.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="center">2406.7 ± 434.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="center">12.4 ± 7.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="center">2.7 ± 1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT<sub>inf</sub> (h)</td><td class="colsep0 rowsep0" align="center">18.1 ± 11.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last"><b>10k</b> was formulated as a solution in 10% DMAC, 10% Tween80, 80% HP-β-CD (20% in water).</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Docking Study of <b>10d</b>, <b>10k</b>, and <b>11a</b></h3><div class="NLM_p">To gain an insight into the binding mode of the GNF-7 analogues, molecular docking studies were performed using GNF-7, <b>10d</b>, <b>10k</b>, and <b>11a</b> and the kinases ACK1 and GCK (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The results suggest that these four inhibitors make a hinge contact through a pair of hydrogen bonds with Ala208 of ACK1 and Cys93 of GCK, respectively. The amide linker in these compounds also participates in interactions with ACK1 and GCK through a pair of H-bonds, which is a typical binding mode of type II kinase inhibitors. While the pyridine nitrogen of GNF-7 forms a hydrogen bond with the hydroxyl group of Tyr27 in GCK, no such interaction exists with Phe137 of ACK1, which might be responsible for the higher potency of GNF-7 against GCK than against ACK1 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a). The nitrogen on piperazinylethanone moiety of <b>10d</b> contributes additional hydrogen bonding interactions with Asp215 of ACK1 and Glu100 of GCK, respectively (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b). This interaction might serve as a driving force for improved binding affinity to each of the kinases. Especially, the four hydrogen bonds existing between <b>10d</b> and Cys93/Tyr27/Glu100 in GCK could be the source of its exceptional inhibitory activity against GCK (IC<sub>50</sub> = 1 nM). It is of note that <b>10k</b> possesses high inhibitory activities against both ACK1 and GCK even though it does not participate in hydrophobic interactions in the hinge region besides a pair of hinge contact (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>c). The trifluoromethylphenyl group in the tail parts of GNF-7, <b>10d</b>, and <b>10k</b> is likely ideal for binding in the hydrophobic pocket of GCK. The results of a previous docking study of NG25 on GCK also demonstrated that the hydrophobic pocket composed of Ile64 and Gln60 provides a suitable binding site for the trifluoromethylphenyl group.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> In this regard, the unsubstituted phenyl tail of <b>11a</b>, lacking the CF<sub>3</sub> moiety, might be too small to tightly interact with GCK (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>d). Accordingly, <b>11a</b> displays a greatly decreased activity against GCK (IC<sub>50</sub> = 1080 nM). Unlike GCK, no such binding site exists in ACK1 for interaction with the CF<sub>3</sub>. Therefore, <b>11a</b>, which lacks the CF<sub>3</sub> group, has a similar level of inhibitory activity against ACK1 compared with GNF-7.</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0002.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding models of inhibitors on ACK1 (left) and GCK (right). (a) GNF-7, (b) <b>10d</b>, (c) <b>10k</b>, and (d) <b>11a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> X-ray Cocrystal Structure of ACK1-<b>10d</b> Complex</h3><div class="NLM_p">We determined X-ray cocrystal structure of <b>10d</b> bound to the kinase domain of ACK1 (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Unfortunately, X-ray cocrystal structure of GCK-<b>10d</b> complex could not be obtained. The X-ray cocrystal structure reveals that <b>10d</b> is bound on ACK1 as a typical type II kinase inhibitor. The amide linker of <b>10d</b> forms hydrogen bonds with the K158-E177 salt bridge as well as with the backbone amino group of D270 at a distance of 3.1 and 2.9 Å. The trifluoromethylphenyl group of <b>10d</b> binds to the hydrophobic pocket, thereby forcing the DFG F271 out of the ATP binding pocket. The nitrogen on the pyrimidine ring and the NH group between the pyrimidine and the pyridine make a pair of hydrogen bonds with the A208 in the hinge region at a distance of 2.6 and 2.8 Å. The pyrimidine ring orients for π–π interaction with F271. The side chains of the L184, L189, L243, F248, I190, and L259 improve binding affinity of <b>10d</b> through hydrophobic interaction. In contrast to molecular docking analysis (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b) suggesting a hydrogen bond interaction between the piperazine moiety of <b>10d</b> and D215-ACK1, the X-ray cocrystal structure reveals that a water molecule forms a hydrogen bonding with the nitrogen on piperazine of <b>10d</b> at a distance of 3.3 Å as well as with the backbone amino group of S212 at a distance of 2.5 Å. This water-mediated hydrogen bond network contributes to the affinity of <b>10d</b> on ACK1 and leads to the higher potency of <b>10d</b> against ACK1 compared with GNF-7.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Data Collection and Refinement Statistics for ACK1 in Complex with <b>10d</b><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">ACK1-<b>10d</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">wavelength (Å)</td><td class="colsep0 rowsep0" align="left">0.97950</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">resolution range (Å)</td><td class="colsep0 rowsep0" align="left">50.00–2.20 (2.24–2.20)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">space group</td><td class="colsep0 rowsep0" align="left"><i>P</i>1 21 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">unit cell</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>a</i>, <i>b</i>, <i>c</i></td><td class="colsep0 rowsep0" align="left">71.18, 43.12, 93.890</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">α, β, γ</td><td class="colsep0 rowsep0" align="left">90, 98.34, 9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">multiplicity</td><td class="colsep0 rowsep0" align="left">3.8 (2.9)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completeness (%)</td><td class="colsep0 rowsep0" align="left">98.2 (87.0)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mean <i>I</i>/σ (I)</td><td class="colsep0 rowsep0" align="left">18.64 (1.36)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Wilson <i>B</i>-factor</td><td class="colsep0 rowsep0" align="left">40.26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i>-merge</td><td class="colsep0 rowsep0" align="left">0.147 (0.906)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i>-work</td><td class="colsep0 rowsep0" align="left">0.2060 (0.2996)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i>-free</td><td class="colsep0 rowsep0" align="left">0.2566 (0.3242)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. of atoms</td><td class="colsep0 rowsep0" align="left">4074</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">macromolecules</td><td class="colsep0 rowsep0" align="left">3885</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ligands</td><td class="colsep0 rowsep0" align="left">96</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">water</td><td class="colsep0 rowsep0" align="left">93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein residues</td><td class="colsep0 rowsep0" align="left">481</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RMS (bonds)</td><td class="colsep0 rowsep0" align="left">0.009</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RMS (angles)</td><td class="colsep0 rowsep0" align="left">1.44</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ramachandran favored (%)</td><td class="colsep0 rowsep0" align="left">96.76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ramachandran outlier (%)</td><td class="colsep0 rowsep0" align="left">0.22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">clash score</td><td class="colsep0 rowsep0" align="left">4.57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">average <i>B</i>-factor</td><td class="colsep0 rowsep0" align="left">50.69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">macromolecules</td><td class="colsep0 rowsep0" align="left">50.78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ligands</td><td class="colsep0 rowsep0" align="left">50.62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solvent</td><td class="colsep0 rowsep0" align="left">46.99</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Statistics for the highest-resolution shell is shown in parentheses.</p></div></div></div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0003.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray crystal structure of <b>10d</b> bound to ACK1 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZXB">5ZXB</a>). (a) Overall fold of the ACK1-<b>10d</b> complex structure. Some residues (135–137, 161–169, and 272–292) are missing in the structure due to a lack of electron density. (b) Protein residues are represented by white, and <b>10d</b> is designated by gold. Sulfur is displayed in yellow, nitrogen in blue, oxygen in red, and fluoride in cyan. Lys158 is eliminated for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Kinase Selectivity Profile of <b>10k</b></h3><div class="NLM_p">To assess the kinase selectivity of <b>10k</b>, kinome-wide inhibition profiling was performed at 1 μM (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> and Supporting Information, <a class="ref internalNav" href="#notes1" aria-label="Table S1">Table S1</a>). Among a total of 351 kinases, 33 kinases were inhibited more than 90%, including a number of tyrosine kinases (c-Src, YES, LCK, BMX, LYN, FYN, FMS, FGR, CSK, HCK, RET, ABL2, PDGFRβ, DDR2, DDR1, EphB1, KDR, BLK, ABL1, PDGFR<i>α</i>, JAK1, JAK2, FGFR2, FGFR1, EphA1), SIK1, RAF family (ARAF, BRAF, RAF1), and p38 family (p38α, 38β) as well as ACK1 and GCK. This indicates that <b>10k</b> is a multitargeted kinase inhibitor, like GNF-7. <b>10k</b> is capable of inhibiting several kinases besides ACK1 and GCK, suggesting that off-target effects are associated with the antiproliferative activity of <b>10k</b>.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0004.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Kinome-wide selectivity profiling of <b>10k</b> at 1 μM. Kinases showing >90% inhibition are indicated with red circles. Illustration is reproduced courtesy of Cell Signaling Technology, Inc. (<a href="http://www.cellsignal.com" class="extLink">www.cellsignal.com</a>). (b) The list of 33 kinases out of 351 kinases showing >90% inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">To investigate whether off-targets also contribute to the antiproliferative activities of nonselective GNF7 analogues, we knocked down both ACK1 and GCK in OCI-AML3 cells using electroporation method and assessed the antiproliferative activities of several analogues (Supporting Information, <a class="ref internalNav" href="#notes1" aria-label="Figure S1">Figure S1</a>). The double siRNA-mediated ACK1/GCK knockdown in OCI-AML3 cells resulted in about 40% inhibition of cell growth. Treatment of ACK1/GCK dual inhibitors to the double-knockdown OCI-AML3 cells further suppressed the cell growth. The knockdown experiment results suggest that other targets besides ACK1 and GCK are involved in the antiproliferative activities of these compounds.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Effects on AKT/mTOR and GCK Signalings</h3><div class="NLM_p">To validate the results of the SAR study in a cellular context, Western blot analysis in Ba/F3-NRAS-G12D and OCI-AML3 cell lines was performed. Considering both in vitro potency and metabolic stability, we chose derivatives <b>10d</b>, <b>10e</b>, <b>10g</b>, <b>10k</b>, and <b>11i</b>. After 2 h treatment with each compound, the cells were subjected to Western blot analysis. As a consequence of our previous observation that GNF-7 suppresses AKT/mTOR signaling and GCK downstream in Ba/F3-NRAS-G12D cells,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> we examined the phosphorylation level of p70S6K1, AKT, JNK, and p38 in both Ba/F3-NRAS-G12D and OCI-AML3 cell lines (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a,b). All five compounds at 1 μM were found to attenuate phosphorylation of p70S6K1, JNK, and p38 and moderately suppressed phosphorylation of AKT (S473). Analogue <b>10d</b>, which possesses an excellent in vitro potency, dramatically abolished phosphorylation of downstream molecules, which is consistent to our SAR study. Similar results were observed using OCI-AML3 cells. All compounds (<b>10d</b>, <b>10e</b>, <b>10g</b>, <b>10k</b>, <b>11i</b>, and GNF-7) caused a decreased level of phosphorylation of p70S6K1, AKT (S473), JNK, and p38 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b). Compound <b>10k</b> displayed a moderate suppression of AKT/mTOR signaling while it completely abolished GCK signaling at 1 μM.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0005.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect on downstream signaling inhibition. The phospho-p70S6K1, phospho-AKT (S473), phospho-JNK, and phospho-p38 levels in Ba/F3-NRAS-G12D (a) and OCI-AML3 (b) treated with indicated compounds for 2 h. Compounds at 1 μM attenuated phosphorylation of each molecule. Actin was used for loading control. (c) <b>10d</b> and <b>10k</b> block both AKT/mTOR signaling and GCK signaling in a dose-dependent manner in OCI-AML3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">We further examined dose dependent inhibition of compound <b>10d</b> and <b>10k</b> in OCI-AML3 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>c). <b>10d</b> and <b>10k</b> showed dose-dependent diminish of p70S6K1, AKT, and p38 phosphorylation. This finding indicates that the kinase inhibition data gained in the SAR study correlates with the activities in Ba/F3 cells transformed with the NRAS mutation and human OCI-AML3 cell line expressing the NRAS mutation.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Induction of Apoptosis and Cell Cycle Arrest in NRAS Mutant Cell Lines</h3><div class="NLM_p">To determine if the antiproliferative effect of the new GNF-7 analogues is mainly responsible for apoptosis and cell cycle arrest, we examined the level of pro-apoptotic markers (cleaved PARP and cleaved caspase 3) and antiapoptotic markers (bcl-2 and MCL1) by using Western blot analysis. Analogues <b>10d</b> and <b>10k</b> were explored to assess their ability to induce apoptosis in both Ba/F3-NRAS-G12D and OCI-AML3 cells. For this purpose, cells were treated for 24 h with indicated concentrations of compounds (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a). In both Ba/F3-NRAS-G12D and OCI-AML3 cells, <b>10d</b> at 1 μM was found to dramatically increase the levels of both cleaved PARP and cleaved caspase 3 and diminished bcl-2 and MCL1 in a similar manner as does GNF-7. Compound <b>10k</b> increased apoptotic markers in OCI-AML3 at 1 μM and significantly increases the level of apoptotic markers in Ba/F3-NRAS-G12D cells at 5 μM (Supporting Information, <a class="ref internalNav" href="#notes1" aria-label="Figure S2b">Figure S2b</a>). Flow cytometry analysis was carried out next using 1 μM of each analogue and by staining apoptotic cells with annexin V and propidium iodide (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>b and Supporting Information, <a class="ref internalNav" href="#notes1" aria-label="Figure S3">Figure S3</a>). Treatment with <b>10d</b> led to a noticeable increase of apoptotic cells, while treatment with <b>10k</b> slightly increases the number of apoptotic cells in Ba/F3-NRAS-G12D cells, a finding that is consistent with the Western blot results. In OCI-AML3, apoptotic cells were increased up to 15–30% by treatment with <b>10k</b> and <b>10d</b>. It is noteworthy that <b>10d</b> displays better or similar apoptotic induction effect in Ba/F3-NRAS-G12D and OCI-AML3 cells compared to GNF-7. We also observed dose-dependent apoptosis occurs by treatment with <b>10k</b> in both cell lines (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>c and Supporting Information, <a class="ref internalNav" href="#notes1" aria-label="Figure S2a">Figure S2a</a>).</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0006.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effect on the cell apoptosis. (a) Western blot for apoptotic molecules in Ba/F3-NRAS-G12D (upper panel) and OCI-AML3 (low panel) treated with indicated compounds for 24 h. Cleaved PARP form was induced by each compound at 1 μM in OCI-AML3. Cleaved caspase 3 was increased by 1 μM of <b>10d</b> and GNF-7 in Ba/F3-NRAS-G12D cells (upper panel). Actin was used for loading control. (b) Percent of apoptotic cells detected by FACS analysis in Ba/F3-NRAS-G12D (upper panel) and OCI-AML3 (low panel). Apoptotic cells were determined via dual-staining of FITC-conjugated annexin V and propidium iodide after 24 h treatment of indicated compounds at 1 μM. All experiments were performed three times, and the bar graph represents the average (<i>n</i> = 3) and SD. One-Way ANOVA; ** <i>P</i> < 0.05. (c) Dose dependent increase of apoptotic cells by compound <b>10k</b> in Ba/F3-NRAS-G12D (upper panel) and OCI-AML3 (low panel). Each cell line was treated with indicated concentrations of <b>10k</b> for 24 h and subjected to flow cytometry analysis. All experiments were performed in three times, and bar graph represents the average (<i>n</i> = 3) and SD. One-Way ANOVA; ** <i>P</i> < 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, we analyzed cell cycle phase after treatment of each compounds (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). G0–G1 arrest was mainly induced by <b>10d</b> at 1 μM. It was compatible with that of GNF-7. <b>10k</b> at 1 μM also increased G0–G1 population. Taken together, these compounds suppressed cell proliferation via apoptosis and cell cycle arrest.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0007.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Induction of G0–G1 arrest after compound treatment. (a,b) OCI-AML3 were treated with indicated concentration of each compound for 24 h, and the percentage of each cell cycle phase were analyzed by flow cytometry after propidium iodide staining; 1 μM of each compound significantly increases population of G0–G1 phase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Suppression of Anchorage Independent Growth</h3><div class="NLM_p">To investigate if <b>10d</b>, <b>10k</b>, and <b>11i</b> block tumorigenesis of NRAS mutated AML cell line, we carried out soft agar assay in OCI-AML3 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Incubation with each compound at two different concentrations (0.1 and 1 μM) for 14 days suppressed anchorage-independent growth in terms of both colony number and colony size of OCI-AML3 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>b,c). Especially, it is noteworthy that 1 μM of <b>10d</b> completely reduced both colony number and colony size compared to the DMSO treated cells. Furthermore, the effect caused by 1 μM of <b>10d</b> is superior to that promoted by GNF-7, indicating that <b>10d</b> is more effective than GNF-7 in inhibiting anchorage-independent growth of OCI-AML3. <b>10k</b> and <b>11i</b> also diminished colony number and size at 1 μM while they moderately decreased colony formation at 0.1 μM concentration, indicating that blockade of ACK1 and GCK activity prevents tumorigenesis of NRAS mutant driven AML cell line.</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0008.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Anchorage independent growth inhibition of <b>10d</b>, <b>10k</b>, and <b>11i</b> in OCI-AML3. (a) Cells embedded in 0.7% low melting agar were incubated with the indicated concentrations of compounds for 2 weeks, and colonies were observed (<i>n</i> = 3 experiment per condition). (b) Average number of colonies per well was automatically counted using ImageJ software and shown in the bar graph (± SD, One-Way ANOVA; **** <i>p</i> < 0.0001, *** <i>p</i> < 0.0005, ** <i>p</i> < 0.05). (c) Average size of colonies per well was automatically measured using ImageJ software and shown in the bar graph (± SD, One-Way ANOVA; **** <i>p</i> < 0.0001, *** <i>p</i> < 0.0005, ** <i>p</i> < 0.05).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> In Vivo Efficacy Study</h3><div class="NLM_p">The antileukemic efficacies of <b>10k</b> (15 mg/kg/day) and GNF-7 (8 mg/kg/day) compared with a vehicle control were evaluated using the Ba/F3-NRAS-G12D/luciferase-bearing blood circulating mouse model. Analogue <b>10k</b> was found to display a desirable mouse pharmacokinetic profile (data not shown) for oral administration. Differences in tumor engraftment and progression among the different treatment groups (po, qd) were monitored by using bioluminescence imaging (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>a) and quantitative biophotonic imaging analysis (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>b). Derivative <b>10k</b> (15 mg/kg/day) diminished more than 50% of leukemic cells at day 20, which is comparable to the efficacy of GNF-7 (8 mg/kg/day).</div><figure id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0009.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Antileukemic efficacy of vehicle alone, GNF-7, and <b>10k</b> in Ba/F3-NRAS-G12D blood circulating model and OCI-AML3 xenograft model. (a) Bioluminescence images of mice administered with vehicle only, GNF-7, or <b>10k</b> once daily (<i>n</i> = 4 per cohort). Immunodeficient mice were tail intravenously injected with Ba/F3-NRAS-G12D/Luc cells and treated with vehicle, GNF-7 (8 mg/kg/day, po, qd), or <b>10k</b> (15 mg/kg/day, po, qd) for 3 weeks. Bioluminescence images were obtained once every 2 days using IVIS spectrum (PerkinElmer) after administration of luciferin (150 mg/kg). (b) Ba/F3-NRAS-G12D/Luc cell progression was monitored by quantitative biophotonic imaging analysis of control and compound-treatment groups. Quantitation from the in vivo imaging using Opti-view software (version 2.02, ART Inc.). Results represent mean ± SEM, <i>n</i> = 4 per group, **<i>p</i> < 0.05. The mean values and their 95% confidence intervals (error bars) are given. (c) Comparison of lifespan of mice orally administered with vehicle, GNF-7, and <b>10k</b> in AML mouse model bearing Ba/F3-NRAS-G12D. Immunodeficient mice were injected with BaF3-NRAS-G12D cells via the lateral tail vein, and compound administration was initiated 6 d after implantation. Mice were treated with vehicle, GNF-7 (8 mg/kg/day, qd), or <b>10k</b> (15 or 25 mg/kg/day, qd) for 8 weeks. Survival of the mice is represented by a Kaplan–Meier plot. <i>P</i> = 0.05 for mice treated <b>10k</b> oral administrated group with the vehicle control mice. (d) Body weight change during the lifespan measurement. (e) Mouse xenograft study. Immuno-deficient mice were subcutaneously injected with OCI-AML3 cells with 50% Matrigel and treated with vehicle, GNF-7, or <b>10k</b> (15 or 25 mg/kg/day, po, qd) for 3 w (<i>n</i> = 5 per group). Mouse tumor size was measured once every 2 days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The incidence of death due to leukemia progression was also evaluated following administration of <b>10k</b> (po, qd) (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>c). Similar to the results arising from the blood circulating model, <b>10k</b> (15 mg/kg/day) has a level of lifespan extension that is similar to that of GNF-7 (8 mg/kg/day). Moreover, the <b>10k</b> (25 mg/kg/day)-treated group shows a median survival of 35 days, which is almost 50% longer compared with the vehicle control group. In the GNF-7 (8 mg/kg/day)-treated group, noticeable body weight loss (>15%) was observed, which is a common symptom of in vivo toxicity. However, the <b>10k</b> (15 mg/kg/day)-treated group exhibited a very small weight change (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>d). It should be noted that <b>10k</b> is superior to GNF-7 as prominent toxicity was found in mice treated with GNF-7.</div><div class="NLM_p last">The antileukemic efficacy of <b>10k</b> was also assessed in AML xenograft model of OCI-AML3 cells. The tumor volumes of the group treated with vehicle, GNF-7 (8 mg/kg/day), <b>10k</b> (15 mg/kg/day), and <b>10k</b> (25 mg/kg/day) were 100%, 53.8%, 41.9%, and 14.9%, respectively. Overall, the dose-dependent antileukemia effect of <b>10k</b> has been demonstrated using lifespan extension and OCI-AML3 xenograft AML models.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03802" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03802" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Hyperactive RAS is one of most attractive cancer therapeutic targets. As part of a study aimed at developing a novel strategy to target mutant NRAS expressing AML, we recently reported that dual inhibition of the kinases ACK1 and GCK by GNF-7 effectively suppresses proliferation of NRAS mutant driven AML cells. A SAR study was carried out to identify GNF-7 analogues that display superior inhibitory effects against ACK1 and GCK. To the best of our knowledge, this is the first SAR study for targeting NRAS mutant driven AML cell lines.</div><div class="NLM_p">In these current effort, we synthesized 29 derivatives of GNF-7 and investigated their inhibition capabilities of both kinase activities of GCK and ACK1 and cellular proliferation against AML cells bearing NRAS mutation. Analogue <b>10d</b> was found to exhibit exceptional kinase inhibitory activities against both ACK1 (IC<sub>50</sub> of 8 nM) and GCK (IC<sub>50</sub> of 1 nM). We solved the X-ray cocrystal structure of ACK1 complexed with <b>10d</b>, enabling an accurate determination of the binding mode of <b>10d</b> on ACK1. Compound <b>10d</b> binds to the kinase domain of ACK1 as a typical type II inhibitor, and there are unexpected interactions mediated by water molecules, which contributes to stronger activity of <b>10d</b> compared with GNF-7.</div><div class="NLM_p">The results of docking study with <b>10d</b>, which possesses a piperazinylethanone moiety in the head group, led to the suggestion that an additional binding site exists in GCK, in which Glu100-GCK participates in hydrogen bonding interactions with <b>10d</b>, contributing to an improved affinity. Thus, knowledge about the existence of these residues could aid the rationale design of substances that have improved selectivities and activities against ACK1 and GCK. Compared with GNF-7, <b>11i</b> possesses higher kinase inhibitory activity against both ACK (IC<sub>50</sub> = 6 nM) and GCK1 (IC<sub>50</sub> = 2 nM) and more significantly blocks proliferation of both Ba/F3-NRAS-G12D (GI<sub>50</sub> 23 nM) and OCI-AML3 (GI<sub>50</sub> 37 nM) cells. Furthermore, <b>11i</b> possesses a higher differential cytotoxicity than GNF-7 on Ba/F3-NRAS-G12D cells (28-fold) relative to parental Ba/F3 and on OCI-AML3 (53-fold) relative to U937. Thus, <b>11i</b> is obviously superior to GNF-7 in terms of enzymatic activity inhibition and cellular selectivity as well as cellular potency. The results of Western blot analysis showed that this series of compounds dose-dependently attenuates phosphorylation of p70S6K1, AKT, and p38 in OCI-AML3. It was also revealed that they exert their antiproliferative effects by inducing apoptosis and G0–G1 arrest and significantly induce apoptotic markers (cleave PARP and caspase3) in both Ba/F3-NRAS-G12D and OCI-AML3 cells. We also observed that this series of compounds suppressed anchorage independent growth of OCI-AML3 in soft agar assay. Analogue <b>10k</b> having a desirable mouse PK profile exhibited a significant efficacy in a Ba/F3-NRAS-G12D/Luc-bearing blood circulating mouse model, remarkably prolonging the lifespan of Ba/F3-NRAS-G12D injected mice and significantly delaying tumor growth of OCI-AML3 xenograft model without prominent toxicity found in mice treated with GNF-7, which makes <b>10k</b> superior to GNF-7. It is worth recalling that <b>10k</b> displayed more favorable profiles with respect to CYPs inhibition and especially induced evident improvement on CYP2C9 compared with GNF-7.</div><div class="NLM_p last">Overall, in this investigation, we have established structure–activity relationship of GNF-7 derivatives against AML expressing NRAS mutation, which is the first SAR study for overcoming AML caused by NRAS mutation. Therefore, this study has, for the first time, provided insight into the design of novel and potent inhibitors that operate by ACK1 and GCK dual inhibition and, as a result, approaches for overriding NRAS mutant driven AML.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Experimental Procedures</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62763" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62763" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> General Information</h4><div class="NLM_p last">Unless otherwise described, all commercial reagents and solvents were purchased from commercial suppliers and used without further purification. All reactions were performed under N<sub>2</sub> atmosphere in flame-dried glassware. Reactions were monitored by TLC with 0.25 mm E. Merck precoated silica gel plates (60 F254). Reaction progress was monitored by TLC analysis using a UV lamp, ninhydrin, or <i>p</i>-anisaldehyde stain for detection purposes. All solvents were purified by standard techniques. Purification of reaction products was carried out by silica gel column chromatography using Kieselgel 60 Art. 9385 (230–400 mesh). The purity and of all compounds was over 95%, and mass spectra and purity of all compounds were analyzed by using a Waters LCMS system (Waters 2998 photodiode array detector, a Waters 3100 mass detector, a Waters SFO system fluidics organizer, a Water 2545 binary gradient module, a Waters reagent manager, and a Waters 2767 sample manager) using a SunFire C18 column (4.6 mm × 50 mm, 5 μm particle size): solvent gradient = 60% (or 95%) A at 0 min, 1% A at 5 min. Solvent A = 0.035% TFA in H<sub>2</sub>O; solvent B = 0.035% TFA in MeOH; flow rate 3.0 (or 2.5) mL/min. <sup>1</sup>H and <sup>13</sup>C NMR spectra were obtained by using a Bruker 400 MHz FT-NMR (400 MHz for <sup>1</sup>H, and 100 MHz for <sup>13</sup>C) spectrometer. Standard abbreviations are used for denoting the signal multiplicities.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 2,4-Dichloro-5-(chloromethyl)pyrimidine (<b>2</b>)</h4><div class="NLM_p last">To a solution of 5-(hydroxymethyl)pyrimidine-2,4-diol (3.0 g, 21.1 mmol) in toluene was added DIPEA (11 mL, 63.3 mmol) and equipped with nitrogen-inlet bubbler. POCl<sub>3</sub> (9.8 mL, 105.5 mmol) was added dropwise at 0 °C. The mixture was stirred at 110 °C for 1 h and then concentrated. The resulting residue was purified by silica gel column chromatography (15% EtOAc/hexane) to obtain the title compound (3.20 g, 77%) as colorless liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.66 (s, 1H), 4.64 (s, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.62, 160.03, 128.37, 38.66. LRMS (ESI) <i>m</i>/<i>z</i> 196 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>-((2,4-Dichloropyrimidin-5-yl)methyl)-2-methyl-5-nitroaniline (<b>3</b>)</h4><div class="NLM_p last">To a solution of 2,4-dichloro-5-(chloromethyl)pyrimidine (2.4 g, 12.2 mmol) and 2-methyl-5-nitroaniline (1.48 g, 9.8 mmol) in acetone (12 mL) was added NaI (2.2 g, 14.6 mmol) and K<sub>2</sub>CO<sub>3</sub> (2.5 g, 18.3 mmol). The mixture was stirred at 50 °C for 10 h. The reaction was cooled to rt, filtered, and extracted with DCM. The organic layers were dried over magnesium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (20% EtOAc/hexane) to afford the title compound as a yellow solid (2.83 g, 74%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.50 (s, 1H), 7.61 (dd, <i>J</i> = 8.0 Hz, 2.0 Hz, 1H), 7.29 (d, <i>J</i> = 2.0 Hz, 1H), 7.23 (dd, <i>J</i> = 8.0 Hz, 0.4 Hz, 1H), 4.57 (d, <i>J</i> = 6.0 Hz), 4.29 (t, <i>J</i> = 6.0 Hz), 2.29 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.06, 160.50, 157.63, 147.10, 146.16, 130.80, 130.42, 130.13, 111.42, 102.51, 41.31, 17.92. LRMS (ESI) <i>m</i>/<i>z</i> 313 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 2-Chloro-<i>N</i>-methyl-5-(((2-methyl-5-nitrophenyl)amino)methyl)pyrimidin-4-amine (<b>4</b>)</h4><div class="NLM_p last"><i>N</i>-((2,4-Dichloropyrimidin-5-yl)methyl)-2-methyl-5-nitroaniline (2.83 g, 9.0 mmol) is dissolved in 1,4-dioxane (30 mL). The solution was treated with methylamine (2 M in MeOH solution, 4.52 mL, 18.1 mmol) and DIPEA (4.7 mL, 27.1 mmol). The mixture was stirred at 60 °C for 1.5 h, then cooled to room temperature, quenched with water, and extracted with DCM. The organic layers were dried over magnesium sulfate, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (35% EtOAc/hexane) to afford the title compound as a yellow solid (2.15 g, 77%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.90 (s, 1H), 7.54–7.53 (m, 1H), 7.39 (dd, <i>J</i> = 8.0 Hz, <i>J</i> = 2.0 Hz, 1H), 7.24 (s, 1H), 7.22 (s, 1H), 7.18 (d, <i>J</i> = 2.0 Hz, 1H), 6.00 (t, <i>J</i> = 5.6 Hz, 1H), 4.21 (d, <i>J</i> = 5.6 Hz, 2H), 2.89 (d, <i>J</i> = 4.4 Hz, 3H), 2.22 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.88, 158.57, 153.79, 146.95, 146.54, 130.73, 130.24 112.99, 110.97, 102.76, 27.64, 17.91. LRMS (ESI) <i>m</i>/<i>z</i> 308 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 7-Chloro-1-methyl-3-(2-methyl-5-nitrophenyl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>5</b>)</h4><div class="NLM_p last">To a solution of 2-chloro-<i>N</i>-methyl-5-(((2-methyl-5-nitrophenyl)amino)methyl)pyrimidin-4-amine (5.12 g, 16.6 mmol) in THF (50 mL) was slowly added triphosgene (2.5 g, 8.2 mmol) at 0 °C under nitrogen atmosphere. The mixture was slowly treated with TEA (12 mL, 83.0 mmol) and stirred at 70 °C for 1 h. The reaction mixture was quenched with water and extracted with DCM. The organic phase was washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (30% EtOAc/hexane) to get the title compound (3.46 g, 63%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.35 (d, <i>J</i> = 2.4 Hz, 1H), 8.31 (t, <i>J</i> = 0.08 Hz, 1H), 8.15 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 2.8 Hz, 1H), 7.62 (d, <i>J</i> = 8.4 Hz, 1H), 4.94 (d, <i>J</i> = 15.2 Hz, 1H), 4.65 (d, <i>J</i> = 15.2, 1H), 3.28 (s, 3H), 2.27 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.39, 158.16, 154.07, 151.28, 146.33, 144.58, 141.44, 131.85, 122.77, 122.52, 111.64, 46.03, 28.36, 17.43. LRMS (ESI) <i>m</i>/<i>z</i> 334 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 3-(5-Amino-2-methylphenyl)-7-chloro-1-methyl-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>6</b>)</h4><div class="NLM_p last">A mixture of 7-chloro-1-methyl-3-(2-methyl-5-nitrophenyl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (1.4 g, 4.2 mmol), Fe powder (2.3 g, 42 mmol), and NH<sub>4</sub>Cl (4.5 g, 84 mmol) in THF (10 mL), MeOH (5 mL), and H<sub>2</sub>O (2.5 mL) was stirred at 80 °C for 2 h. TLC showed the reaction was completed. The mixture was cooled to room temperature, and the resulting solid was filtered off. The filtrate was basified with NaHCO<sub>3</sub> and extracted by DCM. The organic layer dried over MgSO<sub>4</sub>, filtered, and concentrated to afford the title compound as a pale-yellow solid (1.1 g, 87%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.29 (s, 1H), 6.93–6.91 (m, 1H), 6.51–6.48 (m, 2H), 5.04 (bs, 2H), 4.72 (d, <i>J</i> = 15.6 Hz, 1H), 4.55 (d, <i>J</i> = 15.6 Hz, 1H), 3.26 (s, 3H), 1.95 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.51, 158.09, 153.81, 150.83 147.60, 140.90, 130.85, 121.31, 113.66, 112.21, 111.54, 46.14, 28.23, 16.07. LRMS (ESI) <i>m</i>/<i>z</i> 304 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>N</i>-(3-(7-Chloro-1-methyl-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>7</b>)</h4><div class="NLM_p last">To a solution of 3-(5-amino-2-methylphenyl)-7-chloro-1-methyl-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (230 mg, 0.8 mmol) in DCM (2.52 mL) was added K<sub>2</sub>CO<sub>3</sub> (209.3 mg, 1.5 mmol) and 3-(trifluoromethyl)benzoyl chloride (0.12 mL, 0.8 mmol). The reaction mixture was stirred at room temperature for 1 h, quenched with water, and extracted by DCM. The organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (35% EtOAc/hexane) to afford the title compound (262.1 mg, 73%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.54 (s, 1H), 8.33 (s, 1H), 8.30 (s, 1H), 8.26 (d, <i>J</i> = 8.0 Hz, 1H), 7.97 (d, <i>J</i> = 7.6 Hz, 1H), 7.83 (d, <i>J</i> = 2.0 Hz, 1H), 7.79 (t, <i>J</i> = 8.0 Hz, 1H), 7.63 (dd, <i>J</i> = 8.0 Hz, <i>J</i> = 1.6 Hz, 1H), 7.32 (d, <i>J</i> = 8.0 Hz, 1H), 4.83 (d, <i>J</i> = 15.2 Hz, 1H), 4.66 (d, <i>J</i> = 15.2 Hz, 1H), 3.29 (s, 1H), 2.14 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.87, 158.59, 158.20, 154.03, 151.12, 140.60, 137.59, 135.56, 131.79, 130.96, 130.82, 129.76, 129.33, 129.01, 128.19, 128.16, 125.29, 124.14, 124.10, 122.59, 120.07, 119.31, 111.66, 46.23, 28.38, 16.68. LRMS (ESI) <i>m</i>/<i>z</i> 476 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 1-Methyl-3-(2-methyl-5-nitrophenyl)-7-((6-methylpyridin-3-yl)amino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>8</b>)</h4><div class="NLM_p last">A suspension of 7-chloro-1-methyl-3-(2-methyl-5-nitrophenyl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (1.1 g, 3.3 mmol), 6-methylpyridin-3-amine (256.9 mg, 3.3 mmol), K<sub>2</sub>CO<sub>3</sub> (2.2 g, 6.6 mmol), Xphos (314.6 mg, 0.66 mmol), and Pd<sub>2</sub>(dba)<sub>3</sub> (604.3 mg, 0.66 mmol) in 2-butanol (16.5 mL) was stirred at 100 °C for 2 h. The reaction mixture was cooled to room temperature, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (5–10% MeOH/DCM) to afford the title compound (863.8 mg, 65%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.65 (s, 1H), 8.79 (d, <i>J</i> = 2.4 Hz, 1H), 8.34 (d, <i>J</i> = 2.4 Hz), 8.16–8.13 (m, 2H), 8.05 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 2.8 Hz, 1H), 7.62 (d, <i>J</i> = 8.4 Hz, 1H), 7.18 (d, <i>J</i> = 8.4 Hz, 1H), 4.86 (d, <i>J</i> = 13.6 Hz, 1H), 4.51 (d, <i>J</i> = 13.6 Hz, 1H), 3.34 (s, 3H), 2.40 (s, 3H), 2.28 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.90, 156.82, 153.29, 152.24, 150.25, 146.38, 144.50, 142.03, 140.03, 134.63, 131.81, 126.25, 122.66, 122.43, 122.31, 102.94, 46.37, 28.22, 23.20, 17.55. LRMS (ESI) <i>m</i>/<i>z</i> 406 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 3-(5-Amino-2-methylphenyl)-1-methyl-7-((6-methylpyridin-3-yl)amino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>9</b>)</h4><div class="NLM_p last">A mixture of methyl-5-nitrophenyl-7-((6-methylpyridin-3-yl)amino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (215.2 mg, 0.53 mmol), Fe powder (296 mg, 5.3 mmol), and NH<sub>4</sub>Cl (567 mg, 10.6 mmol) in THF (10 mL), MeOH (5 mL), and H<sub>2</sub>O (2.5 mL) was stirred at 80 °C for 2 h. TLC showed the reaction was completed. The reaction mixture was cooled to room temperature and filtered. The filtrate was basified with NaHCO<sub>3</sub> and extracted by DCM. The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated to afford the title compound as a pale-yellow solid (161.4 mg, 81%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.60 (s, 1H), 8.78 (s, 1H), 8.12 (s, 1H), 8.04 (dd, <i>J</i> = 2.8 Hz, <i>J</i> = 8.4 Hz, 1H), 7.16 (d, <i>J</i> = 8.4 Hz, 1H), 6.92 (d, <i>J</i> = 8.8 Hz, 1H), 6.46 (m, 2H), 4.99 (s, 2H), 4.60 (d, <i>J</i> = 14.4 Hz, 1H), 4.42 (d, <i>J</i> = 14.4 Hz, 1H), 3.30 (s, 3H), 2.40 (s, 3H), 1.95 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.74, 156.92, 152.93, 151.77, 149.98, 147.56, 141.39, 139.83, 134.56, 130.70, 126.02, 122.27, 121.22, 113.31, 112.26, 102.85, 46.47, 28.01, 23.05, 16.10. LRMS (ESI) <i>m</i>/<i>z</i> 376 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> General Procedure A for the Synthesis of Compounds GNF-7 and <b>10a</b>–<b>10k</b></h4><div class="NLM_p">To a solution of <b>7</b> (1 equiv) in 2-butanol (0.15 M) was added various amines (1.1 equiv), K<sub>2</sub>CO<sub>3</sub> (5 equiv), Xphos (0.2 equiv), and Pd<sub>2</sub>(dba)<sub>3</sub> (0.2 equiv) at room temperature. The reaction mixture was then stirred for 1 h at 100 °C, cooled to room temperature, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography.</div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> <i>N</i>-(4-Methyl-3-(1-methyl-7-((6-methylpyridin-3-yl)amino)-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)phenyl)-3-(trifluoromethyl)benzamide (GNF-7)</h5><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.2 mmol) was converted to the target compound using general procedure A. The resulting crude product was purified by flash column chromatography on silica gel (5–10% MeOH/DCM) to afford GNF-7 (66.2 mg, 61%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.54 (s, 1H), 9.65 (s, 1H), 8.79 (d, <i>J</i> = 2.4 Hz, 1H), 8.31 (s, 1H), 8.27 (d, <i>J</i> = 7.6 Hz, 1H), 8.16 (s, 1H), 8.05 (dd, <i>J</i> = 8.4, <i>J</i> = 2.4, 1H), 7.98 (d, <i>J</i> = 8.0 Hz, 1H), 7.81–7.78 (m, 2H), 7.64 (dd, <i>J</i> = 8.0 Hz, <i>J</i> = 2.4 Hz, 1H), 7.32 (d, <i>J</i> = 8.4 Hz, 1H), 7.18 (d, <i>J</i> = 8.4 Hz, 1H), 4.71 (d, <i>J</i> = 14.4 Hz, 1H), 4.53 (d, <i>J</i> = 14.4 Hz, 1H), 3.34 (s, 3H), 2.41 (s, 3H), 2.14 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.65, 158.74, 156.81, 153.01, 151.91, 149.99, 140.96, 139.82, 137.40, 135.41, 134.50, 131.60, 130.73, 130.55, 129.55, 129.47, 129.15, 128.83, 128.52, 127.98, 127.94, 127.83, 126.01, 125.12, 123.98, 123.94, 123.90, 122.42, 122.23, 119.71, 119.62, 119.15, 102.73, 46.44, 28.02, 23.00, 16.58. LRMS (ESI) <i>m</i>/<i>z</i> 548 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>28</sub>H<sub>25</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 548.20, found 548.2014.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> <i>N</i>-(4-Methyl-3-(1-methyl-2-oxo-7-(phenylamino)-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)phenyl)-3-(trifluoromethyl)benzamide (<b>10a</b>)</h5><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.2 mmol) was converted to the target compound using general procedure A. The resulting crude product was purified by flash column chromatography on silica gel (40% EtOAc/hexane) to afford <b>10a</b> (22.9 mg, 22%) as a brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.52 (s, 1H), 9.56 (s, 1H), 8.30 (s, 1H), 8.26 (d, <i>J</i> = 7.6 Hz, 1H), 8.15 (s, 1H), 7.97 (d, <i>J</i> = 8.0 Hz, 1H), 7.80–7.75 (m, 4H), 7.64 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 2.0 Hz, 1H), 7.32–7.26 (m, 3H), 6.93 (t, <i>J</i> = 7.6, 1H), 4.70 (d, <i>J</i> = 14.4 Hz, 1H), 4.52 (d, <i>J</i> = 14.4 Hz, 1H), 3.35 (s, 3H), 2.13 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.65, 158.81, 156.73, 152.97, 151.98, 141.01, 140.36, 137.39, 135.42, 131.61, 130.75, 130.54, 129.56, 129.47, 129.15, 128.83, 128.52, 128.27, 127.99, 127.95, 127.84, 125.13, 123.98, 123.94, 123.90, 122.42, 121.07, 119.71, 119.60, 119.16, 118.60, 102.45, 46.47, 28.02, 16.59. LRMS (ESI) <i>m</i>/<i>z</i> 533 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>28</sub>H<sub>23</sub>F<sub>3</sub>N<sub>6</sub>NaO<sub>2</sub><sup>+</sup> [M + Na]<sup>+</sup> 555.17, found 555.1729.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> <i>N</i>-(3-(7-((4-(4-Ethylpiperazin-1-yl)phenyl)amino)-1-methyl-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>10b</b>)</h5><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.2 mmol) was converted to the target compound using general procedure A. The resulting crude product was purified by flash column chromatography on silica gel (5–10% MeOH/DCM) to afford <b>10b</b> (53.9 mg, 42%) as a gray solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.51 (s, 1H), 9.29 (s, 1H), 8.29 (s, 1H), 8.25 (d, <i>J</i> = 8.0 Hz, 1H), 8.08 (s, 1H), 7.96 (d, <i>J</i> = 7.6 Hz, 1H), 7.80–7.77 (m, 2H), 7.63 (d, <i>J</i> = 8.0 Hz, 1H), 7.57 (d, <i>J</i> = 8.8 Hz, 2 H), 7.30 (d, <i>J</i> = 8.4 Hz, 1H), 6.87 (d, <i>J</i> = 8.8 Hz, 2 H), 4.66 (d, <i>J</i> = 14.0 Hz, 1H), 4.48 (d, <i>J</i> = 14.0 Hz, 1H), 3.04 (s, 4H), 2.34 (q, <i>J</i> = 7.2 Hz, 2H), 2.12 (s, 3H), 1.01 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.63, 158.96, 156.64, 152.99, 152.05, 145.91, 141.05, 137.39, 135.41, 132.42, 131.61, 130.73, 130.53, 129.56, 129.46, 129.14, 128.83, 128.51, 127.96, 127.84, 125.13, 123.98, 123.94, 122.42, 119.92, 119.55, 119.13, 115.59, 101.56, 52.23, 51.44, 48.76, 46.48, 27.95, 16.60, 11.78. LRMS (ESI) <i>m</i>/<i>z</i> 645 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>34</sub>H<sub>36</sub>F<sub>3</sub>N<sub>8</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 645.29, found 645.2903.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> <i>N</i>-(3-(7-((6-(4-Ethylpiperazin-1-yl)pyridin-3-yl)amino)-1-methyl-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>10c</b>)</h5><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.2 mmol) was converted to the target compound using general procedure A. The resulting crude product was purified by flash column chromatography on silica gel (5–10% MeOH/DCM) to afford <b>10c</b> (77.4 mg, 60%) as a brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.53 (s, 1H), 9.32 (s, 1H), 8.46 (d, <i>J</i> = 2.4 Hz, 1H), 8.30 (s, 1H), 8.26 (d, <i>J</i> = 8.0 Hz, 1H), 8.09 (s, 1H), 7.97 (d, <i>J</i> = 7.6 Hz, 1H), 7.88 (dd, <i>J</i> = 8.8 Hz, <i>J</i> = 2.4 Hz, 1H), 7.81–7.78 (m, 2H), 7.64 (dd, <i>J</i> = 8.0 Hz, <i>J</i> = 2.0 Hz, 1H), 7.31 (d, <i>J</i> = 8.8 H, 1H), 6.82 (d, <i>J</i> = 9.2 Hz, 1H), 4.68 (d, <i>J</i> = 14.0, 1H), 4.50 (d, <i>J</i> = 14.0, 1H), 3.39 (s, 4H), 3.33 (s, 3H), 2.45 (s, 4H), 2.36 (q, <i>J</i> = 7.2 Hz, 2H), 2.13 (s, 3H), 1.03 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.64, 159.08, 156.74, 154.83, 153.05, 152.00, 141.02, 138.95, 137.39, 135.41, 131.60, 130.72, 130.53, 129.80, 129.55, 129.15, 128.83, 128.51, 128.04, 125.12, 123.98, 123.94, 122.42, 119.57, 119.13, 106.60, 101.83, 51.99, 51.50, 46.46, 45.17, 27.94, 16.58, 11.75. LRMS (ESI) <i>m</i>/<i>z</i> 646. [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>33</sub>H<sub>35</sub>F<sub>3</sub>N<sub>9</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 646.29, found 646.2876.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> <i>N</i>-(3-(7-((6-(4-Acetylpiperazin-1-yl)pyridin-3-yl)amino)-1-methyl-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>10d</b>)</h5><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.2 mmol) was converted to the target compound using general procedure A. The resulting crude product was purified by flash column chromatography on silica gel (5–10% MeOH/DCM) to afford <b>10d</b> (25.0 mg, 36%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.53 (s, 1H), 9.35 (s, 1H), 8.48 (d, <i>J</i> = 2.4 Hz, 1H), 8.30 (s, 1H), 8.26 (d, <i>J</i> = 8.0 Hz, 1H), 8.10 (s, 1H), 7.97 (d, <i>J</i> = 8.0 Hz, 1H), 7.92 (dd, <i>J</i> = 9.2 Hz, <i>J</i> = 2.8 Hz, 1H), 7.81–1.77 (m, 2H), 7.64 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 2.0 Hz, 1H), 7.31 (d, <i>J</i> = 8.4 Hz, 1H), 6.87 (d, <i>J</i> = 9.2 Hz, 1H), 4.68 (d, <i>J</i> = 13.6 Hz, 1H), 4.50 (d, <i>J</i> = 13.6 Hz, 1H), 3.54–3.53 (m, 4H), 3.46–3.45 (m, 2H), 3.39–3.38 (m, 2H), 3.32 (s, 3H), 2.13 (s, 3H), 2.04 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.23, 163.75, 159.15, 156.86, 154.49, 153.15, 152.09, 141.12, 138.97, 137.48, 135.51, 131.71, 130.83, 130.64, 129.95, 129.66, 129.57, 129.25, 128.93, 128.50, 128.09, 128.05, 125.22, 124.07, 124.03, 122.52, 119.68, 119.24, 107.05, 102.02, 46.55, 45.45, 45.19, 45.13, 28.05, 21.14, 16.68. LRMS (ESI) <i>m</i>/<i>z</i> 660 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>33</sub>H<sub>32</sub>F<sub>3</sub>N<sub>9</sub>NaO<sub>3</sub><sup>+</sup> [M + Na]<sup>+</sup> 682.25, found 682.2476.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> <i>N</i>-(3-(7-((6-(4-Ethylpiperazine-1-carbonyl)pyridin-3-yl)amino)-1-methyl-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>10e</b>)</h5><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.2 mmol) was converted to the target compound using general procedure A. The resulting crude product was purified by flash column chromatography on silica gel (5–10% MeOH/DCM) to afford <b>10e</b> (18.0 mg, 13%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.53 (s, 1H), 10.02 (s, 1H), 8.89 (d, <i>J</i> = 1.6 Hz, 1H), 8.34 (dd, <i>J</i> = 8.8 Hz, <i>J</i> = 2.4 Hz, 1H), 8.29 (s, 1H), 8.25 (d, <i>J</i> = 7.6 Hz, 1H), 8.21 (s, 1H), 7.96 (d, <i>J</i> = 8.0 Hz, 1H), 7.80–7.76 (m, 2H), 7.63 (dd, <i>J</i> = 8.4 Hz, 1H), 7.57 (d, <i>J</i> = 8.8 Hz, 1H), 7.31 (d, <i>J</i> = 8.4 Hz, 1H), 4.73 (d, <i>J</i> = 14.4 Hz, 1H), 4.55 (d, <i>J</i> = 14.4 Hz, 1H), 3.61–3.54 (m, 4H), 3.35 (s, 3H), 2.40 (s, 2H), 2.36–2.31 (m, 4H), 2.13 (s. 3H), 0.99 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.32, 163.73, 158.44, 157.02, 153.01, 151.88, 145.86, 140.96, 138.19, 137.86, 137.46, 135.47, 131.69, 130.80, 130.64, 129.65, 129.20, 128.88, 128.05, 125.16, 124.04, 124.00, 123.78, 122.48, 119.71, 119.20, 103.79, 52.64, 51.98, 51.38, 46.60, 46.47, 41.65, 28.21, 16.66, 11.73. LRMS (ESI) <i>m</i>/<i>z</i> 674 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>34</sub>H<sub>34</sub>F<sub>3</sub>N<sub>9</sub>NaO<sub>3</sub><sup>+</sup> [M + Na]<sup>+</sup> 696.26, found 696.2632.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> <i>N</i>-(4-Methyl-3-(1-methyl-7-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)phenyl)-3-(trifluoromethyl)benzamide (<b>10f</b>)</h5><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.2 mmol) was converted to the target compound using general procedure A. The resulting crude product was purified by flash column chromatography on silica gel (5–10% MeOH/DCM) to afford <b>10f</b> (20.0 mg, 14%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.51 (s, 1H), 9.40 (s, 1H), 8.29 (s, 1H), 8.25 (d, <i>J</i> = 8.4 Hz, 1H), 8.08 (s, 1H), 7.96 (d, <i>J</i> = 7.6 Hz, 1H), 7.83–7.77 (m, 3 H), 7.63 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 2.0 Hz, 1H), 7.50 (s, 1H), 7.30 (d, <i>J</i> = 8.4 Hz, 1H), 4.66 (d, <i>J</i> = 14.0 Hz, 1H), 4.48 (d, <i>J</i> = 14.0 Hz, 1H), 3.80 (s, 3H), 3.34 (s, 3H), 2.12 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.87, 158.65, 157.16, 152.30, 141.28, 137.58, 135.63, 131.84, 130.94, 130.75, 129.80, 129.35, 129.03, 128.19, 125.34, 124.15, 123.29, 122.64, 120.24, 119.76, 119.34, 46.65, 28.32, 16.82. LRMS (ESI) <i>m</i>/<i>z</i> 537 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>26</sub>H<sub>23</sub>F<sub>3</sub>N<sub>8</sub>NaO<sub>2</sub><sup>+</sup> [M + Na]<sup>+</sup> 559.18, found 559.1793.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> <i>N</i>-(3-(7-((1,3-Dimethyl-1<i>H</i>-pyrazol-5-yl)amino)-1-methyl-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>10g</b>)</h5><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.2 mmol) was converted to the target compound using general procedure A. The resulting crude product was purified by flash column chromatography on silica gel (5–10% MeOH/DCM) to afford <b>10g</b> (55.5 mg, 51%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.52 (s, 1H), 9.30 (s, 1H), 8.30 (s, 1H), 8.26 (d, <i>J</i> = 8.0 Hz, 1H), 8.10 (s, 1H), 7.97 (d, <i>J</i> = 7.6 Hz, 1H), 7.81–7.77 (m, 2H), 7.63 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 2.0 Hz, 1H), 7.31 (d, <i>J</i> = 8.4 Hz, 1H), 6.02 (s, 1H), 4.68 (d, <i>J</i> = 14.4 Hz, 1H), 4.51 (d, <i>J</i> = 14.4 Hz, 1H), 3.59 (s, 3H), 3.27 (s, 3H), 2.13 (s, 3H), 2.10 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.85, 159.26, 157.26, 153.33, 152.10, 145.06, 141.15, 138.35, 137.58, 135.61, 131.81, 130.93, 130.74, 129.76, 129.34, 129.02, 128.19, 125.32, 124.17, 124.13, 122.62, 119.81, 119.34, 103.09, 98.01, 46.56, 35.07, 28.04, 16.77, 13.78. LRMS (ESI) <i>m</i>/<i>z</i> 551 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated C<sub>27</sub>H<sub>25</sub>F<sub>3</sub>N<sub>8</sub>NaO<sub>2</sub><sup>+</sup> [M + Na]<sup>+</sup> 573.19, found 573.1942.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> <i>N</i>-(3-(7-(Cyclopropylamino)-1-methyl-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>10h</b>)</h5><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.2 mmol) was converted to the target compound using general procedure A. The resulting crude product was purified by flash column chromatography on silica gel (10% MeOH/DCM) to afford <b>10h</b> (74.2 mg, 75%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.52 (s, 1H), 8.31 (s, 1H), 8.27 (d, <i>J</i> = 7.6 Hz, 1H), 8.00–7.97 (m, 2H), 7.82–7.77 (m, 2H), 7.65 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 2.0 Hz, 1H), 7.32 (s, 1H), 7.31 (d, <i>J</i> = 4.8 Hz, 1H), 4.63 (d, <i>J</i> = 14.0 Hz, 1H), 4.44 (d, <i>J</i> = 13.6 Hz, 1H), 3.29 (s, 3H), 2.76–2.70 (m, 1H), 2.13 (s, 3H), 0.69–0.65 (m, 2H), 0.50–0.47 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.63, 162.33, 156.59, 153.01, 152.22, 141.14, 137.35, 135.42, 131.61, 130.71, 130.49, 130.20, 129.56, 129.14, 128.83, 127.98, 125.12, 123.97, 123.93, 122.42, 119.49, 119.12, 66.93, 46.44, 31.49, 30.47, 27.58, 23.66, 22.87, 16.59, 9.85, 6.11. LRMS (ESI) <i>m</i>/<i>z</i> 497 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>25</sub>H<sub>23</sub>F<sub>3</sub>N<sub>6</sub>NaO<sub>2</sub><sup>+</sup> [M + Na]<sup>+</sup>, 519.17, found 519.17.32.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> <i>N</i>-(3-(7-(Cyclohexylamino)-1-methyl-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>10i</b>)</h5><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.2 mmol) was converted to the target compound using general procedure A. The resulting crude product was purified by flash column chromatography on silica gel (5–10% MeOH/DCM) to afford <b>10i</b> (89.6 mg, 83%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.51 (s, 1H), 8.30 (s, 1H), 8.26 (d, <i>J</i> = 8.0 Hz, 1H), 7.97–7.95 (m, 2H), 7.81–7.75 (m, 2H), 7.64 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 2.0 Hz, 1H), 7.29 (d, <i>J</i> = 8.4 Hz, 1H), 6.94 (s, 1H), 4.60 (d, <i>J</i> = 14.0 Hz, 1H), 4.41 (d, <i>J</i> = 14.0 Hz, 1H), 3.70 (s, 1H), 3.3 (s, 3H), 2.12 (s, 3H), 1.90–1.57 (m, 5H), 1.34–1.09 (m, 5H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.78, 160.80, 156.81, 152.39, 141.32, 137.50, 135.58, 131.75, 130.85, 130.64, 129.71, 129.30, 128.98, 128.13, 125.28, 124.12, 124.09, 122.57, 119.62, 119.27, 49.38, 46.60, 32.40, 27.69, 25.37, 24.82, 16.74. LRMS (ESI) <i>m</i>/<i>z</i> 539 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>28</sub>H<sub>29</sub>F<sub>3</sub>N<sub>6</sub>NaO<sub>2</sub><sup>+</sup> [M + Na]<sup>+</sup> 561.22, found 561.2189.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> <i>N</i>-(3-(7-((2-Hydroxyethyl)amino)-1-methyl-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>10j</b>)</h5><div class="NLM_p last">Compound <b>7</b> (100 mg, 0.2 mmol) was converted to the target compound using general procedure A. The resulting crude product was purified by flash column chromatography on silica gel (5–10% MeOH/DCM) to afford <b>10j</b> (83.8 mg, 84%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.50 (s, 1H), 8.30 (s, 1H), 8.26 (d, <i>J</i> = 7.6 Hz, 1H), 7.97–7.96 (m, 2H), 7.78 (t, <i>J</i> = 8.0 Hz, 1H), 7.75 (d, <i>J</i> = 2.0, 1H), 7.63 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 2.4 Hz, 1H), 7.30 (d, <i>J</i> = 8.4 Hz, 1H), 6.96 (t, <i>J</i> = 5.6 Hz, 1 H), 4.66 (t, <i>J</i> = 5.6, 1H), 4.61 (d, <i>J</i> = 13.6 Hz, 1H), 4.42 (d, <i>J</i> = 13.6 Hz, 1H), 3.53 (q, <i>J</i> = 6.0 Hz, 2H), 3.38–3.35 (m, 2H), 3.26 (s, 3H), 2.11 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.82, 161.56, 156.84, 152.38, 141.30, 137.51, 135.58, 131.77, 130.88, 130.67, 129.74, 129.31, 128.99, 128.12, 125.29, 124.14, 124.10, 122.59, 119.66, 119.29, 59.76, 46.58, 43.52, 27.75, 16.76. LRMS (ESI) <i>m</i>/<i>z</i> 501 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>24</sub>H<sub>24</sub>F<sub>3</sub>N<sub>6</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup> 501.19, found 501.1863.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> <i>N</i>-(3-(7-Amino-1-methyl-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>10k</b>)</h5><div class="NLM_p last">To a solution of compound <b>7</b> (100 mg, 0.2 mmol) in DMSO (5 mL) was added ammonia solution (28.0∼30.0%, 5 mL) at room temperature. The mixture was stirred at 150 °C for 15 h. The reaction mixture was cooled to room temperature, diluted with EtOAc, and quenched with H<sub>2</sub>O. The organic layer was washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (5–10% MeOH/DCM) to afford the title compound (25.8 mg, 28%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.51 (s, 1H), 8.30 (s, 1H), 8.26 (d, <i>J</i> = 7.6 Hz, 1H), 7.97 (d, <i>J</i> = 8.0 Hz, 1H), 7.93 (s, 1H), 7.79 (t, <i>J</i> = 8.0 Hz, 1H), 7.75 (d, <i>J</i> = 2.0 Hz, 1H), 7.64 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 2.0 Hz, 1H), 7.30 (d, <i>J</i> = 8.4 Hz, 1H), 6.58 (s, 2H), 4.60 (d, <i>J</i> = 14.0 Hz, 1H), 4.41 (d, <i>J</i> = 14.0 Hz, 1H), 3.25 (s, 3H), 2.12 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.81, 162.72, 157.00, 153.42, 152.40, 141.30, 137.50, 135.58, 131.76, 130.88, 130.66, 129.73, 129.30, 128.99, 128.11, 125.28, 124.13, 124.09, 119.66, 119.31, 100.36, 46.58, 27.83, 16.75. LRMS (ESI) <i>m</i>/<i>z</i> 457 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>22</sub>H<sub>20</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 457.16, found 457.1590.</div></div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> General Procedure B for the Synthesis of Compounda <b>11a</b>–<b>11i</b></h4><div class="NLM_p">To a solution of <b>9</b> (1 equiv) in DMF (0.1 M) was added different carboxylic acids (1.5 equiv), HATU (2 equiv), and DIPEA (3 equiv). The reaction mixture was then stirred for 1 h at room temperature, quenched with water, and diluted with EtOAc. The organic layer was washed with H<sub>2</sub>O, dried over MgSO<sub>4</sub>, filtered, and concentrated. The residue was purified by flash column chromatography on silica gel.</div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> <i>N</i>-(4-Methyl-3-(1-methyl-7-((6-methylpyridin-3-yl)amino)-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)phenyl)benzamide (<b>11a</b>)</h5><div class="NLM_p last">Compound <b>9</b> (200 mg, 0.5 mmol) was converted to the target compound using general procedure B. The resulting crude product was purified by flash column chromatography on silica gel (5–10% MeOH/DCM) to afford <b>11a</b> (112.8 mg, 33%) as a pale-brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.30 (s, 1H), 9.63 (s, 1H), 8.79 (d, <i>J</i> = 2.8 Hz, 1H), 8.15 (s, 1H), 8.05 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 2.8 Hz, 1H), 7.96–7.94 (m, 2H), 7.82 (d, <i>J</i> = 2.0 Hz, 1H), 7.63–7.51 (m, 4H), 7.28 (d, <i>J</i> = 8.4 Hz, 1H), 7.17 (d, <i>J</i> = 8.4 Hz, 1H), 4.70 (d, <i>J</i> = 14.4 Hz, 1H), 4.52 (d, <i>J</i> = 14.4 Hz, 1H), 3.33 (s, 3H), 2.40 (s, 3H), 2.12 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.21, 158.74, 156.79, 152.99, 151.89, 149.96, 140.90, 139.81, 137.82, 134.61, 134.52, 131.36, 130.45, 130.27, 128.18, 127.40, 125.97, 122.22, 119.42, 118.86, 102.71, 54.69, 46.45, 28.02, 23.01, 16.57. LRMS (ESI) <i>m</i>/<i>z</i> 480 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>27</sub>H<sub>26</sub>N<sub>7</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 480.21, found 480.2145.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> 4-Methyl-<i>N</i>-(4-methyl-3-(1-methyl-7-((6-methylpyridin-3-yl)amino)-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)phenyl)-3-(trifluoromethyl)benzamide (<b>11b</b>)</h5><div class="NLM_p last">Compound <b>9</b> (200 mg, 0.5 mmol) was converted to the target compound using general procedure B. The resulting crude product was purified by flash column chromatography on silica gel (5–10% MeOH/DCM) to afford <b>11b</b> (114.5 mg, 48%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.46 (s, 1H), 9.63 (s, 1H), 8.79 (d, <i>J</i> = 2.4 Hz, 1H) 8.25 (s, 1H), 8.16–8.15 (m. 2H), 8.05 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 2.4 Hz, 1H), 7.78 (d, <i>J</i> = 2.0 Hz, 1H), 7–65–7.62 (m, 2H), 7.31 (d, <i>J</i> = 8.4 Hz, 1H), 7.18 (d, <i>J</i> = 8.4 Hz, 1H), 4.70 (d, <i>J</i> = 14.0, 1H), 4.52 (d, <i>J</i> = 14.0, 1H),3.34 (s, 3H), 2.53 (s, 3H), 2.40 (s, 3H), 2.13 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.79, 158.93, 157.01, 153.20, 152.09, 150.18, 141.13, 140.01, 139.90, 137.65, 134.68, 132.68, 132.48, 131.48, 130.78, 130.71, 128.35, 127.88, 127.59, 127.29, 126.99, 126.20, 125.62, 124.86, 124.81, 124.75, 122.90, 122.42, 120.18, 119.77, 119.30, 102.94, 64.89, 46.62, 28.21, 23.20, 18.79, 18.77, 16.76. LRMS (ESI) <i>m</i>/<i>z</i> 562 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>29</sub>H<sub>26</sub>F<sub>3</sub>N<sub>7</sub>NaO<sub>2</sub><sup>+</sup> [M + Na]<sup>+</sup> 584.20, found 584.1993.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> <i>N</i>-(4-Methyl-3-(1-methyl-7-((6-methylpyridin-3-yl)amino)-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)phenyl)-3-morpholino-5-(trifluoromethyl)benzamide (<b>11c</b>)</h5><div class="NLM_p last">Compound <b>9</b> (200 mg, 0.5 mmol) was converted to the target compound using general procedure B. The resulting crude product was purified by flash column chromatography on silica gel (5–10% MeOH/DCM) to afford <b>11c</b> (97.9 mg, 30%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.40 (s, 1H), 9.64 (s, 1H), 8.79 (d, <i>J</i> = 2.4 Hz, 1H), 8.16 (s, 1H), 8.05 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 2.4 Hz, 1H), 7.75 (d, <i>J</i> = 2.0 Hz, 1H), 7.72 (s, 1H), 7.65 (s, 1H), 7.63 (d, <i>J</i> = 2.4 Hz, 1H), 7.39 (s, 1H), 7.31 (d, <i>J</i> = 8.4 Hz, 1H), 7.18 (d, <i>J</i> = 8.4 Hz, 1H), 4.70 (d, <i>J</i> = 14.0 Hz, 1H), 4.53 (d, <i>J</i> = 14.4 Hz, 1H), 3.78–3.76 (m, 4H), 3.34 (s, 3H), 3.31–3.28 (m, 4H), 2.40 (s, 3H), 2.14 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.14, 158.83, 156.91, 153.11, 152.00, 151.33, 150.09, 141.02, 139.91, 137.48, 136.37, 134.57, 130.74, 130.60, 130.20, 129.88, 126.11, 125.35, 122.64, 122.33, 119.80, 119.36, 117.00, 113.73, 113.69, 113.32, 102.83, 65.76, 47.55, 46.51, 28.11, 23.10, 16.66. LRMS (ESI) <i>m</i>/<i>z</i> 633 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>32</sub>H<sub>31</sub>F<sub>3</sub>N<sub>8</sub>NaO<sub>3</sub><sup>+</sup> [M + Na]<sup>+</sup> 655.24, found 655.2336.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> 3-(4-Hydroxypiperidin-1-yl)-<i>N</i>-(4-methyl-3-(1-methyl-7-((6-methylpyridin-3-yl)amino)-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)phenyl)-5-(trifluoromethyl)benzamide (<b>11d</b>)</h5><div class="NLM_p last">Compound <b>9</b> (200 mg, 0.5 mmol) was converted to the target compound using general procedure B. The resulting crude product was purified by flash column chromatography on silica gel (5–10% MeOH/DCM) to afford <b>11d</b> (116.1 mg, 36%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.38 (s, 1H), 9.63 (s, 1H), 8.79 (d, <i>J</i> = 2.4 Hz, 1H), 8.16 (s, 1H), 8.05 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 2.4 Hz, 1H), 7.75 (s, 1H), 7.70 (s, 1H), 7.65 (dd, <i>J</i> = 8.0 Hz, <i>J</i> = 1.2 Hz, 1H), 7.57 (s, 1H), 7.35 (s, 1H), 7.31 (d, <i>J</i> = 8.8 Hz, 1H), 7.17 (d, <i>J</i> = 8.4 Hz, 1H), 4.73 (d, <i>J</i> = 4.4 Hz, 1H), 4.70 (d, <i>J</i> = 14.4 Hz, 1H), 4.53 (d, <i>J</i> = 14.0 Hz, 1H), 3.72–3.69 (m, 4H), 3.04 (t, <i>J</i> = 10.0 Hz, 2H), 2.40 (s, 3H), 2.14 (s, 3H), 1.85–1.83 (m, 2H), 1.51–1.43 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.23, 158.80, 156.88, 153.08, 151.97, 150.99, 150.06, 140.98, 139.88, 137.49, 136.34, 134.55, 130.68, 130.56, 130.20, 129.89, 126.08, 125.38, 122.67, 122.31, 119.79, 119.35, 117.30, 113.41, 112.70, 102.81, 65.50, 46.48, 45.52, 33.31, 28.09, 23.08, 16.63. LRMS (ESI) <i>m</i>/<i>z</i> 647 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>33</sub>H<sub>34</sub>F<sub>3</sub>N<sub>8</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup> 647.27, found 647.2714.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> 3-(4-Methyl-1<i>H</i>-imidazol-1-yl)-<i>N</i>-(4-methyl-3-(1-methyl-7-((6-methylpyridin-3-yl)amino)-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)phenyl)-5-(trifluoromethyl)benzamide (<b>11d</b>)</h5><div class="NLM_p last">Compound <b>9</b> (200 mg, 0.5 mmol) was converted to the target compound using general procedure B. The resulting crude product was purified by flash column chromatography on silica gel (5–10% MeOH/DCM) to afford <b>11e</b> (191.5 mg, 61%) as a pale-brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.56 (s, 1H), 9.64 (s, 1H), 8.79 (m, 1H), 8.45 (s, 1H), 8.40 (s, 1H), 8.24 (s, 1H), 8.16 (s, 2H), 8.05 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 2.0 Hz, 1H), 7.77 (s, 1H), 7.71 (s, 1H), 7.66 (d, <i>J</i> = 8.4 Hz, 1H), 7.34 (d, <i>J</i> = 8.4 Hz, 1H), 7.17 (d, <i>J</i> = 8.4 Hz, 1H), 4.70 (d, <i>J</i> = 14.0 Hz, 1H), 4.54 (d, <i>J</i> = 14.0 Hz, 1H), 3.34 (s, 3H), 2.40 (s, 3H), 2.19 (s, 3H), 2.15 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.06, 158.95, 157.02, 153.24, 152.13, 150.21, 141.22, 140.03, 138.97, 137.76, 137.42, 137.37, 135.25, 134.69, 131.34, 131.17, 131.01, 130.84, 130.68, 126.23, 124.80, 122.58, 122.45, 122.08, 121.78, 119.85, 119.43, 119.16, 114.24, 102.94, 46.63, 28.22, 23.22, 16.80, 13.57. LRMS (ESI) <i>m</i>/<i>z</i> 628 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>32</sub>H<sub>28</sub>F<sub>3</sub>N<sub>9</sub>NaO<sub>2</sub><sup>+</sup> [M + Na]<sup>+</sup> 650.22, found 650.2266.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> <i>N</i>-(4-Methyl-3-(1-methyl-7-((6-methylpyridin-3-yl)amino)-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)phenyl)-4-(1<i>H</i>-pyrrol-1-yl)-3-(trifluoromethyl)benzamide (<b>11f</b>)</h5><div class="NLM_p last">Compound <b>9</b> (200 mg, 0.5 mmol) was converted to the target compound using general procedure B. The resulting crude product was purified by flash column chromatography on silica gel (5–10% MeOH/DCM) to afford <b>11f</b> (138.3 mg, 45%) as pale-gray solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.62 (s, 1H), 9.64 (s, 1H), 8.79 (d, <i>J</i> = 2.0 Hz, 1H), 8.44 (d, <i>J</i> = 1.2 Hz, 1H), 8.35 (d, <i>J</i> = 8.4 Hz, 1H), 8.16 (s, 1H), 8.05 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 2.4 Hz, 1H), 7.81 (d, <i>J</i> = 1.6 Hz, 1H), 7.69 (d, <i>J</i> = 8.4 Hz, 1H), 7.66 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 2.0 Hz, 1H), 7.33 (d, <i>J</i> = 8.4 Hz, 1H), 7.17 (d, <i>J</i> = 8.4 Hz, 1H), 7.01 (s, 2H), 6.29 (t, <i>J</i> = 2.0 Hz, 2H), 4.71 (d, <i>J</i> = 14.0 Hz, 1H), 4.53 (d, <i>J</i> = 14.0 Hz, 1H), 3.34 (s, 3H), 2.40 (s, 3H), 2.14 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.04, 158.85, 156.93, 153.14, 152.03, 150.11, 141.19, 141.09, 139.94, 137.42, 134.60, 134.12, 132.70, 130.96, 130.69, 129.85, 127.01, 126.42, 126.37, 126.13, 124.53, 124.29, 124.23, 123.13, 122.35, 121.57, 119.74, 119.30, 109.67, 102.86, 46.54, 28.14, 23.12, 16.70. LRMS (ESI) <i>m</i>/<i>z</i> 613 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>32</sub>H<sub>27</sub>F<sub>3</sub>N<sub>8</sub>NaO<sub>2</sub><sup>+</sup> [M + Na]<sup>+</sup> 635.21, found 635.2090.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> <i>N</i>-(4-Methyl-3-(1-methyl-7-((6-methylpyridin-3-yl)amino)-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)phenyl)-4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)benzamide (<b>11g</b>)</h5><div class="NLM_p last">Compound <b>9</b> (200 mg, 0.5 mmol) was converted to the target compound using general procedure B. The resulting crude product was purified by flash column chromatography on silica gel (5–10% MeOH/DCM) to afford <b>11g</b> (187.7 mg, 58%) as a pale-brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.41 (s, 1H), 9.65 (s, 1H), 8.79 (s, 1H), 8.24 (s, 1H), 8.21 (d, <i>J</i> = 8.4 Hz, 1H), 8.16 (s, 1H), 8.05 (dd, <i>J</i> = 8.8 Hz, <i>J</i> = 2.4 Hz, 1H), 7.78 (s, 1H), 7.63–7.60 (m, 2H), 7.30 (d, <i>J</i> = 8.4 Hz, 1H), 7.18 (d, <i>J</i> = 8.8 Hz, 1H), 4.70 (d, <i>J</i> = 14.0 Hz, 1H), 4.52 (d, <i>J</i> = 14.0 Hz, 1H), 2.96 (t, <i>J</i> = 4.0 Hz, 4H), 2.47 (m, 4H), 2.40 (s, 3H), 2.23 (s, 3H), 2.13 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.69, 158.93, 157.02, 154.83, 153.22, 152.09, 150.19, 141.12, 140.02, 137.73, 134.68, 132.76, 130.69, 130.07, 126.88, 126.22, 123.62, 122.44, 119.72, 119.25, 102.95, 54.82, 52.68, 46.61, 45.75, 28.22, 23.21, 16.76. LRMS (ESI) <i>m</i>/<i>z</i> 646 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>33</sub>H<sub>35</sub>F<sub>3</sub>N<sub>9</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 646.29, found 646.2866.</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> <i>N</i>-(4-Methyl-3-(1-methyl-7-((6-methylpyridin-3-yl)amino)-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>11h</b>)</h5><div class="NLM_p last">Compound <b>9</b> (200 mg, 0.5 mmol) was converted to the target compound using general procedure B. The resulting crude product was purified by flash column chromatography on silica gel (10% MeOH/DCM) to afford <b>11h</b> (122.8 mg, 37%) as a gray solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.71 (d, <i>J</i> = 1.6 Hz, 1H), 8.38 (s, 1H), 8.11 (s, 1H), 8.03–7.92 (m, 4H), 7.75 (s, 1H), 7.33 (d, <i>J</i> = 8.8 Hz, 1H), 7.18–7.15 (m, 2H), 7.07 (s, 1H), 4.70 (d, <i>J</i> = 14.4 Hz, 1H), 4.46 (d, <i>J</i> = 14.0 Hz, 1H), 3.70 (s, 2H), 3.48 (s, 3H), 2.54 (m, 11H), 2.32 (s, 3H), 1.99 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 164.30, 159.24, 157.59, 153.18, 152.93, 152.30, 141.89, 140.48, 137.29, 133.61, 133.50, 131.29, 130.70, 128.73, 127.11, 124.83, 122.99, 120.36, 119.64, 102.92, 57.94, 55.10, 53.03, 47.37, 45.92, 28.72, 23.69, 16.74. LRMS (ESI) <i>m</i>/<i>z</i> 660 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>34</sub>H<sub>37</sub>F<sub>3</sub>N<sub>9</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 660.30, found 660.3019.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> 4-((3-(Dimethylamino)pyrrolidin-1-yl)methyl)-<i>N</i>-(4-methyl-3-(1-methyl-7-((6-methylpyridin-3-yl)amino)-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)phenyl)-3-(trifluoromethyl)benzamide (<b>11i</b>)</h5><div class="NLM_p last">Compound <b>9</b> (200 mg, 0.5 mmol) was converted to the target compound using general procedure B. The resulting crude product was purified by flash column chromatography on silica gel (10% MeOH/DCM) to afford <b>11i</b> (138.9 mg, 41%) as a pale-gray solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD-<i>d</i><sub>4</sub>) δ 8.78 (d, <i>J</i> = 2.4 Hz, 1H), 8.27 (s, 1H), 8.18 (d, <i>J</i> = 8.4 Hz, 1H), 8.12–8.09 (m, 2H), 7.92 (d, <i>J</i> = 8.0 Hz, 1H), 7.77 (d, <i>J</i> = 2.0 Hz, 1H), 7.60 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 2.0 Hz, 1H), 7.34 (d, <i>J</i> = 8.4 Hz, 1H), 7.25 (d, <i>J</i> = 8.4 Hz, 1H), 4.78 (d, <i>J</i> = 14.4 Hz, 1H), 4.59 (d, <i>J</i> = 14.4 Hz, 1H), 3.95–3.86 (m, 2H), 3.76 (s, 1H), 3.44 (s, 3H), 2.97–2.90 (m, 2H), 2.81–2.76 (m, 8H), 2.49 (s, 3H), 2.34–2.27 (m, 1H), 2.23 (s, 3H), 2.07–1.95 (m, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD-<i>d</i><sub>4</sub>) δ 209.98, 166.69, 160.64, 158.75, 154.78, 154.26, 151.97, 142.47, 142.24, 140.60, 138.78, 136.56, 135.40, 133.28, 132.30, 132.15, 129.14, 126.34, 124.49, 121.82, 120.96, 104.53, 66.62, 56.57, 56.07, 53.56, 41.75, 30.57, 28.94, 27.64, 22.82, 17.11. LRMS (ESI) <i>m</i>/<i>z</i> 674 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>35</sub>H<sub>39</sub>F<sub>3</sub>N<sub>9</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 674.32, found 674.3172.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> <i>N</i>-(3-(((2,4-Dichloropyrimidin-5-yl)methyl)amino)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>12</b>)</h5><div class="NLM_p last">To a solution of 2,4-dichloro-5-(chloromethyl)pyrimidine (5.0 g, 25.6 mmol) and <i>N</i>-(3-amino-4-methylphenyl)-3-(trifluoromethyl)benzamide (7.5 g, 25.6 mmol) in acetone (30 mL) was added NaI (4.6 g, 30.72 mmol), K<sub>2</sub>CO<sub>3</sub> (5.3 g, 38.40 mmol). The mixture was stirred at 50 °C for 14 h. The reaction was cooled to rt, filtered, and extracted with DCM. The organic layers were dried over magnesium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (70% EtOAc/hexane) to afford the title compound as a brown solid (8.0 g, 69%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.13 (s, 1H), 8.58 (s, 1H), 8.19–8.17 (m, 2H), 7.92 (d, <i>J</i> = 7.6 Hz, 1H), 7.74 (t, <i>J</i> = 7.6 Hz, 1H), 7.06 (d, <i>J</i> = 7.6 Hz, 1H), 7.00 (d, <i>J</i> = 8.4 Hz, 1H), 6.82 (s, 1H), 5.72 (t, <i>J</i> = 6.0 Hz, 1H), 4.40 (d, <i>J</i> = 5.2 Hz, 2H), 2.15 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.75, 160.85, 160.26, 157.43, 145.21, 137.75, 136.13, 131.67, 130.68, 129.93, 129.60, 129.24, 128.92, 127.82, 125.31, 124.15, 124.11, 122.61, 118.35, 109.12, 102.12, 41.77, 17.21. LRMS (ESI) <i>m</i>/<i>z</i> 455 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> General Procedure C for the Synthesis of Compounds <b>15a</b>–<b>c</b>, <b>15e</b></h4><div class="NLM_p">To a solution of <b>12</b> (1 equiv) in THF (0.1 M) was added different amine (1 equiv) at room temperature. The mixture was stirred at 60 °C for 2 h, then cooled to room temperature, quenched with water, and extracted with DCM. The organic layers were dried over magnesium sulfate, filtered, and concentrated. The residue was diluted with dry THF (5 mL) and treated slowly with triphosgene (0.5 equiv) at 0 °C under nitrogen atmosphere. The mixture was slowly treated with TEA (5 equiv) and stirred at 70 °C for 1 h. The mixture was quenched with water and extracted with DCM. The organic phase was washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The resulting residue was diluted with 2-butanol (0.15 M), treated with 6-methylpyridin-3-amine (1.2 equiv), K<sub>2</sub>CO<sub>3</sub> (5 equiv), Xphos (0.2 equiv), and Pd<sub>2</sub>(dba)<sub>3</sub> (0.2 equiv) at room temperature. The mixture was stirred at 100 °C for 2 h, then cooled to room temperature, filtered, and concentrated. The residue was purified by flash column chromatography on silica gel.</div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> <i>N</i>-(3-(1-Ethyl-7-((6-methylpyridin-3-yl)amino)-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>15a</b>)</h5><div class="NLM_p last">Compound <b>12</b> (0.5 g, 1.10 mmol) was converted to the target compound using general procedure C. The resulting crude product was purified by flash column chromatography on silica gel (5–10% MeOH/DCM) to afford <b>15a</b> (130.2 mg, 21%) as a pale-gray solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.52 (s, 1H), 9.62 (s, 1H), 8.79 (d, <i>J</i> = 2.4 Hz, 1H), 8.31 (s, 1H), 8.27 (d, <i>J</i> = 7.6 Hz, 1H), 8.15 (s, 1H), 8.04 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 2.4 Hz, 1H), 7.97 (d, <i>J</i> = 8.0 Hz, 1H), 7.79 (t, <i>J</i> = 7.6 Hz, 2H), 7.65 (dd, <i>J</i> = 8.0 Hz, <i>J</i> = 2.0 Hz, 1H), 7.31 (d, <i>J</i> = 8.4 Hz, 1H), 7.17 (d, <i>J</i> = 8.4 Hz, 1H), 4.72 (d, <i>J</i> = 14.0 Hz, 1H), 4.51 (d, <i>J</i> = 14.0 Hz, 1H), 4.02 (q, <i>J</i> = 6.8 Hz, 2H), 2.40 (s, 3H), 2.13 (s, 3H), 1.22 (t, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.70, 158.85, 156.12, 153.41, 151.33, 150.09, 141.04, 139.81, 137.44, 135.47, 134.56, 131.67, 130.77, 130.60, 129.64, 129.21, 128.89, 128.06, 125.99, 125.19, 124.03, 123.99, 122.48, 122.27, 119.62, 119.05, 102.63, 46.47, 35.78, 23.07, 16.63, 13.16. LRMS (ESI) <i>m</i>/<i>z</i> 562 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>29</sub>H<sub>26</sub>F<sub>3</sub>N<sub>7</sub>NaO<sub>2</sub><sup>+</sup> [M + Na]<sup>+</sup> 584.20, found 584.1996.</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> <i>N</i>-(3-(1-Cyclopropyl-7-((6-methylpyridin-3-yl)amino)-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>15b</b>)</h5><div class="NLM_p last">Compound <b>12</b> (0.5 g, 1.10 mmol) was converted to the target compound using general procedure C. The resulting crude product was purified by flash column chromatography on silica gel (5–10% MeOH/DCM) to afford <b>15b</b> (123.5 mg, 20%) as a pale-gray solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.52 (s, 1H), 9.66 (s, 1H), 8.88 (s,1H), 8.31 (s, 1H), 8.27 (d, <i>J</i> = 8.0 Hz, 1H), 8.21–8.18 (m, 2H), 7.97 (d, <i>J</i> = 7.6 Hz, 1H), 7.79 (d, <i>J</i> = 7.6 Hz, 1H), 7.74 (s, 1H), 7.65 (d, <i>J</i> = 8.0 Hz, 1H), 7.31 (d, <i>J</i> = 8.0 Hz, 1H), 7.18 (d, <i>J</i> = 8.4 Hz, 1H), 4.59 (d, <i>J</i> = 14.0 Hz, 1H), 4.44 (d, <i>J</i> = 14.0 Hz, 1H), 2.77–2.76 (m, 1H), 2.40 (s, 3H), 2.12 (s, 3H), 1.08–1.06 (m, 2H), 0.75–0.69 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.81, 159.03, 158.73, 153.07, 152.99, 149.98, 141.14, 139.84, 137.46, 135.56, 134.80, 131.78, 130.86, 130.67, 129.31, 128.99, 128.17, 125.29, 124.14, 124.10, 122.59, 122.35, 119.71, 119.38, 104.11, 46.39, 24.67, 23.18, 16.92, 9.14, 8.90. LRMS (ESI) <i>m</i>/<i>z</i> 574 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>30</sub>H<sub>26</sub>F<sub>3</sub>N<sub>7</sub>NaO<sub>2</sub><sup>+</sup> [M + Na]<sup>+</sup> 596.20, found 596.1996.</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> <i>N</i>-(3-(1-Cyclohexyl-7-((6-methylpyridin-3-yl)amino)-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>15c</b>)</h5><div class="NLM_p last">Compound <b>12</b> (0.5 g, 1.10 mmol) was converted to the target compound using general procedure C. The resulting crude product was purified by flash column chromatography on silica gel (5–10% MeOH/DCM) to afford <b>15c</b> (109.1 mg, 16%) as a gray solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.50 (s, 1H), 9.57 (s, 1H), 8.74 (d, <i>J</i> = 2.0 Hz, 1H), 8.29 (s, 1H), 8.25 (d, <i>J</i> = 8.0 Hz, 1H), 8.16 (s, H), 8.03 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 2.0 Hz, 1H), 7.96 (d, <i>J</i> = 8.0 Hz, 1H), 7.78 (t, <i>J</i> = 8.0 Hz, 1H), 7.74 (s, 1H), 7.63 (d, <i>J</i> = 8.0 Hz, 1H), 7.28 (d, <i>J</i> = 8.4 Hz, 1H), 7.16 (d, <i>J</i> = 8.4 Hz, 1H), 4.66–4.55 (m, 2H), 4.44 (d, <i>J</i> = 14.0 Hz, 1H), 2.40 (s, 3H), 2.09 (s, 3H), 1.82–1.63 (m, 6H), 1.36–1.14 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.81, 158.88, 157.42, 153.62, 151.98, 150.46, 141.29, 140.34, 137.48, 135.57, 134.56, 131.78, 130.85, 130.62, 129.77, 129.33, 129.01, 128.16, 126.44, 125.31, 124.15, 124.11, 122.60, 122.32, 119.54, 119.03, 103.80, 54.44, 46.34, 29.19, 28.90, 26.29, 26.19, 25.07, 23.24, 16.86. LRMS (ESI) <i>m</i>/<i>z</i> 616 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>33</sub>H<sub>32</sub>F<sub>3</sub>N<sub>7</sub>NaO<sub>2</sub><sup>+</sup> [M + Na]<sup>+</sup> 638.25, found 638.2465.</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> <i>N</i>-(4-Methyl-3-(7-((6-methylpyridin-3-yl)amino)-2-oxo-1-phenyl-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)phenyl)-3-(trifluoromethyl)benzamide (<b>15d</b>)</h5><div class="NLM_p last">To a solution of <b>12</b> (0.5 g, 1.10 mmol) in <i>n</i>-butanol (10 mL) was added aniline (0.1 mL, 1.10 mmol) and TEA (0.32 mL, 2.20 mmol) at room temperature. The mixture was stirred at 120 °C for 3 h, then cooled to room temperature, quenched with water, and extracted with DCM. The organic layers were dried over magnesium sulfate, filtered, and concentrated. The residue was dissolved in dry THF (5 mL) and treated slowly with triphosgene (162.8 mg, 0.55 mmol) at 0 °C under nitrogen atmosphere. The mixture was slowly treated with TEA (0.79 mL, 5.50 mmol) and stirred at 70 °C for 1 h. The mixture was quenched with water and extracted with DCM. The organic phase was washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The resulting residue was dissolved in 2-butanol (8 mL) and treated with 6-methylpyridin-3-amine (142.6 mg, 1.32 mmol), K<sub>2</sub>CO<sub>3</sub> (760 mg, 5.50 mmol), Xphos (104.8 mg, 0.22 mmol), and Pd<sub>2</sub>(dba)<sub>3</sub> (101.4 mg, 0.22 mmol) at room temperature. The mixture was stirred at 100 °C for 2 h, then cooled to room temperature, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (5–10% MeOH/DCM) to afford the title compound (183.6 mg, 27%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.53 (s, 1H), 9.55 (s, 1H), 8.32–8.31 (m, 2H), 8.28–8.25 (m, 2H), 7.97 (d, <i>J</i> = 7.6 Hz, 1H), 7.89 (s, 1H), 7.79 (t, <i>J</i> = 8 Hz, 1H), 7.64 (d, <i>J</i> = 8.4 Hz, 1H), 7.55–7.47 (m, 4H), 7.37 (d, <i>J</i> = 7.6 Hz, 2H), 7.32 (d, <i>J</i> = 8.4 Hz, 1H), 6.72(d, <i>J</i> = 8.4 Hz, 1H), 4.90 (d, <i>J</i> = 14.0 Hz, 1H), 4.67 (d, <i>J</i> = 14.0 Hz, 1H), 2.31 (s, 3H), 2.22 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.85, 158.51, 157.56, 154.20, 151.37, 149.57, 140.95, 139.37, 137.59, 136.97, 135.60, 134.58, 131.81, 130.99, 130.77, 130.01, 129.77, 129.34, 129.02, 128.87, 128.19, 125.32, 124.98, 124.16, 124.12, 122.61, 121.84, 119.82, 119.23, 102.30, 47.05, 23.09, 16.80. LRMS (ESI) <i>m</i>/<i>z</i> 610 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>33</sub>H<sub>26</sub>F<sub>3</sub>N<sub>7</sub>NaO<sub>2</sub><sup>+</sup> [M + Na]<sup>+</sup> 632.20, found 632.1997.</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> <i>N</i>-(3-(1-Benzyl-7-((6-methylpyridin-3-yl)amino)-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>15e</b>)</h5><div class="NLM_p last">Compound <b>12</b> (0.5 g, 1.10 mmol) was converted to the target compound using general procedure C. The resulting crude product was purified by flash column chromatography on silica gel (5–10% MeOH/DCM) to afford <b>15e</b> (80.9 mg, 12%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.52 (s, 1H), 9.58 (s, 1H), 8.59 (d, <i>J</i> = 2.4 Hz, 1H), 8.30 (s, 1H), 8.26 (d, <i>J</i> = 8.0 Hz, 1H), 8.19 (s, 1H), 7.97 (d, <i>J</i> = 8 Hz, 1H), 7.83–7.77 (m, 3H), 7.66 (dd, <i>J</i> = 8.4 Hz, <i>J</i> = 2.0 Hz, 1H), 7.32–7.31 (m, 5H), 7.25–7.19 (m, 1H), 7.04 (d, <i>J</i> = 8.8 Hz, 1H), 5.26–5.18 (m, 2H), 4.82 (d, <i>J</i> = 14.4 Hz, 1H), 4.60 (d, <i>J</i> = 14.4 Hz, 1H), 2.38 (s, 3H), 2.15 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.84, 158.89, 156.21, 153.94, 151.71, 150.30, 141.06, 140.13, 138.09, 137.61, 135.59, 134.40, 131.81, 130.89, 130.79, 129.77, 129.65, 129.34, 129.02, 128.27, 128.16, 126.69, 126.59, 126.20, 125.32, 124.17, 124.13, 122.61, 122.29, 119.91, 119.28, 102.56, 46.74, 43.42, 23.21, 16.76. LRMS (ESI) <i>m</i>/<i>z</i> 624 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>34</sub>H<sub>28</sub>F<sub>3</sub>N<sub>7</sub>NaO<sub>2</sub><sup>+</sup> [M + Na]<sup>+</sup> 646.22, found 646.2159.</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> <i>N</i>-(3-(7-Chloro-1-methyl-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)-4-methylphenyl)-4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>16</b>)</h5><div class="NLM_p last">To a solution of <b>6</b> (2.0 g, 6.60 mmol) in DMF (13 mL) was added 4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)benzoic acid (3.2 g, 9.90 mmol), HATU (5.0 g, 13.20 mmol), and DIPEA (3.4 mL, 19.80 mmol). The mixture was then stirred for 1 h at room temperature, quenched with water, and diluted with EtOAc. The organic layer was washed with H<sub>2</sub>O, dried over MgSO<sub>4</sub>, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (5–10% MeOH/DCM) to afford the title compound (2.6 g, 65%) as a brown solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.03 (s, 1H), 8.10 (s, 1H), 8.06 (s, 1H), 8.03 (d, <i>J</i> = 8.0 Hz, 1H), 7.82 (d, <i>J</i> = 8.4 Hz, 1H), 7.76 (dd, <i>J</i> = 6.4 Hz, <i>J</i> = 2.0 Hz, 1H), 7.23–7.19 (m,1H), 7.01 (d, <i>J</i> = 8.4 Hz, 1H), 4.71 (d, <i>J</i> = 15.6 Hz, 1H), 4.48 (d, <i>J</i> = 15.2 Hz, 1H), 3.77 (q, <i>J</i> = 15.2 Hz, 1H), 3.47 (s, 1H), 2.95–2.92 (m, 1H), 2.72–2.55 (m, 4H), 2.26 (s, 6H), 2.04–1.93 (m. 1H), 1.83–1.76 (m, 1H), 1.73 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 164.46, 160.21, 158.64, 153.61, 152.56, 142.14, 139.61, 137.79, 133.39, 131.18, 131.11, 130.75, 130.55, 128.38, 128.07, 125.49, 125.09, 125.03, 122.76, 120.87, 119.74, 110.24, 65.36, 55.73, 53.51, 53.47, 46.95, 28.94, 28.67, 16.50. LRMS (ESI) <i>m</i>/<i>z</i> 602 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> <i>N</i>-(3-(7-((6-(4-Acetylpiperazin-1-yl)pyridin-3-yl)amino)-1-methyl-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)-4-methylphenyl)-4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>17a</b>)</h5><div class="NLM_p last">Compound <b>16</b> (100 mg, 0.17 mmol) was converted to the target compound using general procedure A. The resulting crude product was purified by flash column chromatography on silica gel (10% MeOH/DCM) to afford <b>17a</b> (74.6 mg, 56%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.49 (s, 1H), 9.35 (s, 1H), 8.48 (d, <i>J</i> = 2.4 Hz, 1H), 8.24–8.21 (d, <i>J</i> = 12 Hz, 2H), 8.09 (s, 1H), 7.93–7.89 (m, 2H), 7.78 (s, 1H), 7.63 (d, <i>J</i> = 8.4 Hz, 1H), 7.30 (d, <i>J</i> = 8.4 Hz, 1H), 6.86 (d, <i>J</i> = 9.2 Hz, 1H), 4.68 (d, <i>J</i> = 14.0 Hz, 1H), 4.50 (d, <i>J</i> = 14.0 Hz, 1H), 3.84–3.73 (m, 2H), 3.54 (m, 4H), 3.46–3.45 (m, 2H), 3.37 (t, <i>J</i> = 5.2 Hz, 2H), 3.32 (s, 3H), 2.79–2.72 (m, 1H), 2.68–2.59 (m, 1H), 2.39–2.36 (m, 1H), 2.13 (s, 3H), 2.08 (s, 6H), 2.04 (s, 3H), 1.92–1.84 (m, 1H), 1.68–1.57 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.28, 163.83, 159.20, 156.92, 154.54, 153.22, 152.14, 141.65, 141.16, 139.02, 137.61, 133.50, 131.55, 130.78, 130.68, 130.54, 130.01, 128.55, 126.86, 126.56, 124.93, 124.87, 119.69, 119.22, 107.12, 64.82, 57.62, 55.36, 53.09, 46.60, 45.51, 45.24, 45.19, 43.19, 28.34, 28.11, 21.22, 16.74. LRMS (ESI) <i>m</i>/<i>z</i> 786 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>40</sub>H<sub>46</sub>F<sub>3</sub>N<sub>11</sub>NaO<sub>3</sub><sup>+</sup> [M + Na]<sup>+</sup> 808.36, found 808.3635.</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> 4-((3-(Dimethylamino)pyrrolidin-1-yl)methyl)-<i>N</i>-(3-(7-((6-(4-ethylpiperazine-1-carbonyl)pyridin-3-yl)amino)-1-methyl-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>17b</b>)</h5><div class="NLM_p last">Compound <b>16</b> (100 mg, 0.17 mmol) was converted to the target compound using general procedure A. The resulting crude product was purified by flash column chromatography on silica gel (10% MeOH/DCM) to afford <b>17b</b> (46.5 mg, 34%) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.49 (s, 1H), 10.02 (s, 1H), 8.90 (d, <i>J</i> = 2.4 Hz, 1H), 8.35 (dd, <i>J</i> = 8.8 Hz, <i>J</i> = 2.0 Hz, 1H), 8.25–8.21 (m, 3H), 7.90 (d, <i>J</i> = 8.4 Hz, 1H), 7.80 (s, 1H), 7.63 (d, <i>J</i> = 6.8 Hz, 1H), 7.58 (d, <i>J</i> = 8.8 Hz, 1H), 7.31 (d, <i>J</i> = 8.4 Hz, 1H), 4.73 (d, <i>J</i> = 14.4 Hz, 1H), 4.56 (d, <i>J</i> = 14.0 Hz, 1H), 3.79 (q, <i>J</i> = 15.2, 2H), 3.62–3.55 (m, 4H), 3.36 (s, 1H), 2.80–2.79 (m, 1H), 2.68–2.64 (m, 1H), 2.61–2.58 (m, 1H), 2.42–2.34 (m, 2H), 2.37–2.34 (m, 4H), 2.14 (s, 3H), 2.11 (s, 6H), 1.93–1.85 (m, 1H), 1.70–1.62 (m, 1H), 1.00 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.36, 163.78, 158.48, 157.05, 153.06, 151.91, 145.90, 141.58, 140.99, 138.23, 137.89, 137.56, 133.45, 131.51, 130.74, 130.66, 130.50, 126.51, 125.21, 123.81, 119.71, 119.18, 103.83, 64.74, 57.47, 55.29, 53.00, 52.68, 52.02, 51.41, 46.63, 46.50, 43.05, 28.24, 16.69, 11.76. LRMS (ESI) <i>m</i>/<i>z</i> 800 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>42</sub>H<sub>49</sub>F<sub>3</sub>N<sub>10</sub>NaO<sub>3</sub><sup>+</sup> [M + Na]<sup>+</sup> 822.38, found 822.4006.</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> 4-((3-(Dimethylamino)pyrrolidin-1-yl)methyl)-<i>N</i>-(4-methyl-3-(1-methyl-7-((1-methyl-<i>1H</i>-pyrazol-4-yl)amino)-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)phenyl)-3-(trifluoromethyl)benzamide (<b>17c</b>)</h5><div class="NLM_p last">Compound <b>16</b> (100 mg, 0.17 mmol) was converted to the target compound using general procedure A. The resulting crude product was purified by flash column chromatography on silica gel (10% MeOH/DCM) to afford <b>17c</b> (55.3 mg, 49%) as a pale-gray solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.48 (s, 1H), 9.41 (s, 1H), 8.25–8.21 (m, 2H), 8.09 (s, 1H), 7.90 (d, <i>J</i> = 8 Hz, 1H), 7.84 (s, 1H), 7.77 (s, 1H), 7.63 (d, <i>J</i> = 7.6 Hz, 1H), 7.50 (s, 1H), 7.30 (d, <i>J</i> = 8 Hz, 1H), 4.67 (d, <i>J</i> = 13.6 Hz, 1H), 4.49 (d, <i>J</i> = 14.0 Hz, 1H), 3.84–3.73 (m, 5H), 3.33 (d, <i>J</i> = 7.6 Hz, 3H), 2.80–2.73 (m, 1H), 2.68–2.64 (m, 1H), 2.62–2.58 (m, 1H), 2.40–2.36 (m, 1H), 2.13 (s, 3H), 2.09 (s, 6H), 1.92–1.84 (m, 1H), 1.69–1.61 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.82, 158.60, 157.09, 152.23, 141.64, 141.21, 137.60, 133.51, 131.55, 130.77, 130.67, 130.54, 129.72, 126.87, 126.57, 125.49, 124.93, 123.23, 122.76, 120.18, 119.65, 119.21, 64.82, 57.59, 55.36, 53.08, 46.60, 43.17, 28.31, 16.75. LRMS (ESI) <i>m</i>/<i>z</i> 663 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>33</sub>H<sub>37</sub>F<sub>3</sub>N<sub>10</sub>NaO<sub>2</sub><sup>+</sup> [M + Na]<sup>+</sup> 685.30, found 685.2955.</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> <i>N</i>-(3-(7-((1,3-Dimethyl-<i>1H</i>-pyrazol-5-yl)amino)-1-methyl-2-oxo-1,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-3(2<i>H</i>)-yl)-4-methylphenyl)-4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)benzamide (<b>17d</b>)</h5><div class="NLM_p last">Compound <b>16</b> (100 mg, 0.17 mmol) was converted to the target compound using general procedure A. The resulting crude product was purified by flash column chromatography on silica gel (10% MeOH/DCM) to afford <b>17d</b> (71.0 mg, 62%) as a pale-gray solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.47 (s, 1H), 9.28 (s, 1H), 8.25 (s, 1H), 8.23 (d, <i>J</i> = 8.4 Hz, 1H), 8.10 (s, 1H), 7.90 (d, <i>J</i> = 8.4 Hz, 1H), 7.78 (s, 1H), 7.63 (d, <i>J</i> = 8.4 Hz, 1H), 7.30 (d, <i>J</i> = 8.4 Hz, 1H), 6.02 (s, 1H), 4.68 (d, <i>J</i> = 14.0 Hz, 1H), 4.51 (d, <i>J</i> = 14.0 Hz, 1H), 3.79 (q, <i>J</i> = 14.8 Hz, 2H), 3.60 (s, 3H), 3.28 (s, 3H), 2.84–2.81 (m, 1H), 2.69–2.54 (m, 3H), 2.43–2.40 (m, 1H), 2.13 (s, 9H), 2.11 (s, 3H), 1.94–1.85 (m, 1H), 1.71–1.63 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.86, 159.25, 157.24, 153.32, 152.08, 145.05, 141.63, 141.12, 138.34, 137.63, 133.54, 131.58, 130.83, 130.72, 130.59, 126.90, 126.60, 125.51, 124.96, 124.91, 122.78, 119.75, 119.26, 103.08, 98.01, 64.81, 57.50, 55.35, 53.07, 46.54, 43.07, 35.06, 28.22, 28.03, 16.76, 13.77. LRMS (ESI) <i>m</i>/<i>z</i> 677 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>34</sub>H<sub>39</sub>F<sub>3</sub>N<sub>10</sub>NaO<sub>2</sub><sup>+</sup> [M + Na]<sup>+</sup> 699.31, found 699.3107.</div></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Cell Culture</h3><div class="NLM_p last">OCI-AML3 and U937 cells were purchased from DSMZ (Braunschweig, Germany) and Korean Cell Line Bank (Seoul, Korea), respectively. All cells used in this study were grown in RPMI media supplemented with 10% FBS and 1% antibiotics (Welgene, Korea). Parental Ba/F3 cells were cultured in the presence of 1 ng/mL of IL-3 as an extra supplement. Ba/F3-NRAS-G12D cells were established following by previously described procedure.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Antiproliferation Assay</h3><div class="NLM_p">In the case of suspension cells, 1 × 10<sup>4</sup> cells per well were seeded in a 96-well plate. After 4 h stabilization of cells, compound was treated to the cells with 1:3 serial dilution in DMSO. After 72 h, the viability of cells was determined by CellTiter-Glo reagent (G7572, Promega, USA). Dose–response curve was fitted and GI<sub>50</sub> values were calculated using Graphpad prism 5.0 software. All assays were performed in duplicate, and standard deviation (SD) was determined from three independent experiments.</div><div class="NLM_p last">ACK1/GCK siRNA (200 nM of each) or 400 nM scramble siRNA (AccuTarget, Bioneer, Korea) were transfected into 5  ×  10<sup>6</sup> OCI-AML3 cells using Amaxa Nucleofector (Lonza, USA) following manufacturer’s instruction. After 10 h transfection, the cells were seeded in 96-well plates and treated with indicated compounds for 36 h. Cell proliferation was measured using CellTiter-Glo Reagent (Promega, USA).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Molecular Docking Atudy</h3><div class="NLM_p last">To establish the homology model, the type II structure of ABL1 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IK3">3IK3</a>) was adopted for GCK modeling<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and ABL2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GVU">3GVU</a>) was utilized for ACK1 using BIOVIA Discovery Studio 4.5.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The protein structures were minimized using the Protein Preparation Wizard by applying an OPLS force field. For the grid generation, the binding site of inhibitor was defined as the centroid of the ATP binding site. Docking study of a compound onto the ATP-binding site of the kinases was carried out using the Schrödinger docking program, Glide. The best-docked poses were selected as the lowest Glide score.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Protein Expression and Purification</h3><div class="NLM_p">The ACK1 kinase domain encompassing residues 115–389 with an N-terminal tabacco etch virus cleavable His6 tag was subcloned into pFastBac1 vector. Recombinant baculoviruses were prepared by using the Bac-to-Bac system protocol (Invitrogen). The ACK1 viruses were coinfected in Sf9 cells with a baculovirus expressing PTPN1 tyrosine phosphatase in order to generate the nonphosphorylated protein. Infected cells were harvested 72 h postinfection by centrifugation and pellets were stored at −80 °C until purification.</div><div class="NLM_p last">Purification was conducted at 4 °C. Cell pellets were lysed by resuspension in buffer containing 25 mM Hepes, pH 7.5, 300 mM NaCl, 0.5 mM TCEP, 10% glycerol, 20 mM imidazole, and EDTA-free complete protease inhibitor tablet (Roche) followed by centrifugation at 35000<i>g</i> for 1 h. The supernatant was loaded with 5 mL of Ni-NTA resin. The resin was washed with lysis buffer and the bound protein eluted using elution buffer (25 mM HEPES, pH 7.5, 300 mM NaCl, 0.5 mM TCEP, 10% glycerol, 250 mM imidazole). The eluted protein was treated with TEV protease during overnight dialysis against lysis buffer. The cleaved protein was passed through the Ni-NTA resin again, and the flow-through fraction was collected. ACK1 protein was further purified on a Superdex200 size exclusion column equilibrated with 25 mM HEPES, pH 7.7, 300 mM NaCl, 20 mM MgCl<sub>2</sub>, 0.5 mM TCEP, and 10% glycerol. Fraction containing ACK1 protein was concentrated to 5–6 mg/mL for crystallization.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Crystallization, <b>10d</b> Soaking, and Data Collection</h3><div class="NLM_p last">Crystallization was accomplished by the hanging-drop vapor diffusion method at 18 °C. Apo crystals of human ACK1 were obtained from a 4 μL drop consisting of 2 μL of well solution [24–30% (w/v) PEG 3350, 100 mM Bis-tris propane, pH 6.1–6.7, 200 mM ammonium sulfate, and 10 mM DTT] and 2 μL of protein. The crystals grew within 2–3 days. A cocrystal in complex with <b>10d</b> was obtained by soaking the apo crystal in 125 μM <b>10d</b> for 24 h in the presence of 28% PEG 3350, 100 mM Bis-tris propane, pH 6.1, 200 mM ammonium sulfate, and 10 mM DTT. Crystals were cryoprotected by dipping them into a solution of mother liquid and 20% glycerol (v/v). Diffraction data was collected on the 5C beamline at the Pohang Accelerator Laboratory (Pohang, South Korea). Date processing and scaling were performed using HKL2000 (HKL Research, Inc., Charlottesville, VA).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Structure Determination and Refinement</h3><div class="NLM_p last">Molecular replacement was used to determine the structure of ACK1 in complex with <b>10d</b> using a previously solved structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EWH">4EWH</a>) as a search model with water and ligand removed. Rigid body refinement, followed by simulated annealing at 5000 K, was conducted using PHENIX (Python-Based Hierachical Environment for Integrated Xtallography).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Subsequently, refinement was conducted in alternating cycles of manual model building in COOT (Crystallographic Object Oriented Toolkit),<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> followed by refinement in PHENIX until the R factors converged. Data collection and refinement statistics are shown in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>. The coordinate and structural factors of the complex structure have been deposited in the Protein Data Bank (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZXB">5ZXB</a>). Molecular structure images were generated using the PyMOL Molecular Graphics System.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Western Blot</h3><div class="NLM_p last">Cells (2 × 10<sup>6</sup> cells) were treated with indicated compounds for 2 h and briefly washed with ice-cold PBS once. Thereafter, cells were subjected to lysis in a NP40 buffer (50 mM Tris-HCl pH7.5, 1% NP40, 1 mM EDTA, 150 mM NaCl, 5 mM Na<sub>3</sub>VO<sub>4</sub> and 2.5 mM NaF) containing 1× protease inhibitor cocktail (Roche). The equal amount of lysate was separated by SDS-PAGE gel and transferred to PVDF membrane. All primary antibodies were uniformly prediluted in TBS-T at 1:1000 (v/v) except for actin (1:5000), while all secondary antibodies were prediluted in 5% skim milk (in TBS-T) at 1:5000. All primary antibody used for phospho-form of p70S6K1 (Thr421/Ser424, no. 9204), AKT (S473, no. 9171), pJNK (T183/Y185 no. 9251) p-p38 (Thr180/Tyr182 no. 9216), and cleaved caspase-3 (no. 9661) were purchased from Cell Signaling Technologies (Massachusetts, USA). Antibodies for β-actin (SC-47778), cleaved PARP (SC-7150), and HRP-conjugated secondary antibodies for rabbit and mouse (SC-2305, SC-2318) were products of Santa Cruz Biotech (California, USA).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Flow Cytometric Analysis</h3><div class="NLM_p last">Cells (2 × 10<sup>6</sup> cells per vial) were prepared and incubated for 24 h with test compounds. For harvesting, cells were centrifuged at 1000 rpm for 2 min. After brief ice-cold PBS washing, the cells were stained with Alexafluor488 conjugated annexin V (A13201) and propidium iodide (P3560) according to the manufacturer’s instruction (Thermo Fisher Scientific, USA). Thereafter, apoptotic cells were determined by FACS Canto II (BD Biosciences, USA).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Apoptosis and Cell-Cycle Analysis</h3><div class="NLM_p last">For apoptosis assay, cells (2 × 10<sup>6</sup> cells per vial) were prepared and incubated for 24 h with test compounds. Cells were centrifuged at 1000 rpm for 2 min. After ice-cold DPBS washing, the cells were stained with Alexafluor488 conjugated annexin V (A13201) and propidium iodide (P3560) according to the manufacturer’s instruction (Thermo Fisher Scientific, USA). Thereafter, apoptotic cells were determined by FACS Canto II (BD Biosciences, USA). For cell-cycle analysis, cells were treated with compounds for 24 h and then fixed in 70% ethanol at −20 °C overnight. Cells were harvested by centrifugation at 500<i>g</i>, washed with ice-cold DPBS, and then suspended in propidium iodide/RNase solution (Cell Signaling Technology, no. 4087) and incubated for 30 min in a dark condition before flow cytometer analysis (Accuri C6, BD Biosciences).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Anchorage Independent Assay</h3><div class="NLM_p last">On the 1.5% bottom agar, cells in the complete media containing 0.7% agar was plated at a density of 5000 cells in 6-well plates. The cells were incubated with indicated compounds for 2 w at 37 °C and 5% CO<sub>2</sub>. Spheroids were stained using iodonitrotetrazolium chloride (Sigma-Aldrich) for 24 h. The entire area of each well was photographed without magnification, and the average number and size of colonies in each well were counted using ImageJ software.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> In Vivo Efficacy Study</h3><div class="NLM_p last">All animal procedures were approved by the KIST Laboratory Animal Facilities and Use Committee and carried out in AAALAC-accredited facilities. Female immunodeficient mice (<i>n</i> = 4 per cohort) aged 6 weeks (Orientbio Inc., Korea) received 3 × 10<sup>6</sup> Ba/F3-NRAS-G12D cells by lateral tail vein injection. Following treatments were administered for each cohort: vehicle alone, 15 or 25 mg/kg/day <b>10k</b>, and 8 mg/kg/day GNF-7. Oral administration was initiated on day 6 for Ba/F3-NRAS-G12D cells. <b>10k</b> formulated in 5% NMP, 30% PEG E400, 15% solutol, and 50% 0.05 M citric acid was administered for 8 weeks (po, qd). Actuarial survival was analyzed by the Kaplan–Meier methodology. For xenograft mouse model, OCI-AML3 cell line (1 × 10<sup>6</sup> cells) was subcutaneously injected into right flanks of mice. At day 21, OCI-AML-3 (<i>n</i> = 5 per cohort) implanted mice received 15 or 25 mg/kg/day <b>10k</b>, GNF7 (8 mg/kg/day), or vehicle alone for 3 weeks (po, qd). Mouse weight and tumor size were measured once every 2 days. To determine tumor volume by external caliper, the greatest longitudinal diameter (length) and the greatest transverse diameter (width) were determined. Tumor volumes were calculated by the modified ellipsoidal formula. Significant differences between values were determined using the Log-rank (Mantel-Cox) test for trend. <i>P</i> values 0.05 were assigned to be significant.<span class="NLM_disp-formula"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_m001.gif" alt="" id="_i82" /></img></span></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i83"><a href="/doi/suppl/10.1021/acs.jmedchem.8b00882" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13333" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13333" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b00882" class="ext-link">10.1021/acs.jmedchem.8b00882</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">In vitro selectivity profiling of <b>10k</b> at 1 μΜ against 351 human kinases, antiproliferative activity of selected compounds in ACK1/GCK double knockdown OCI-AML3 cells, dose-dependent induction of apoptosis by compound <b>10k</b>, FACS analysis for the selected compounds in Ba/F3-NRAS-G12D and OCI-AML3 cell lines (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00882/suppl_file/jm8b00882_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">PDB-formatted coordinates for computational models (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00882/suppl_file/jm8b00882_si_002.zip" class="ext-link">ZIP</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00882/suppl_file/jm8b00882_si_003.xlsx" class="ext-link">XLSX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00882/suppl_file/jm8b00882_si_001.pdf">jm8b00882_si_001.pdf (793.77 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00882/suppl_file/jm8b00882_si_002.zip">jm8b00882_si_002.zip (331.39 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00882/suppl_file/jm8b00882_si_003.xlsx">jm8b00882_si_003.xlsx (11.42 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB ID code for ACK1-<b>10d</b> complex is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZXB">5ZXB</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.8b00882" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25504" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25504" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Taebo Sim</span> - <span class="hlFld-Affiliation affiliation">KU-KIST
Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea</span>; 
    <span class="hlFld-Affiliation affiliation">Chemical
Kinomics Research Center, Korea Institute
of Science and Technology (KIST), 5 Hwarangro 14-gil, Seongbuk-gu, Seoul 02792, Republic
of Korea</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3015-2059" title="Orcid link">http://orcid.org/0000-0003-3015-2059</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7e0a1c0d17133e15170d0a500c1b50150c5e0a1c0d17133e15110c1b1f501f1d50150c"><span class="__cf_email__" data-cfemail="c4b0a6b7ada984afadb7b0eab6a1eaafb6">[email protected]</span> <span class="__cf_email__" data-cfemail="94e0f6e7fdf9d4fffbe6f1f5baf5f7baffe6">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hanna Cho</span> - <span class="hlFld-Affiliation affiliation">KU-KIST
Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Injae Shin</span> - <span class="hlFld-Affiliation affiliation">KU-KIST
Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eunhye Ju</span> - <span class="hlFld-Affiliation affiliation">KU-KIST
Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Seunghye Choi</span> - <span class="hlFld-Affiliation affiliation">KU-KIST
Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wooyoung Hur</span> - <span class="hlFld-Affiliation affiliation">Chemical
Kinomics Research Center, Korea Institute
of Science and Technology (KIST), 5 Hwarangro 14-gil, Seongbuk-gu, Seoul 02792, Republic
of Korea</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8034-0501" title="Orcid link">http://orcid.org/0000-0002-8034-0501</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haelee Kim</span> - <span class="hlFld-Affiliation affiliation">Daegu-Gyeongbuk
Medical Innovation Foundation, 2387 dalgubeol-daero, Suseong-gu, Daegu 42019, Republic
of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eunmi Hong</span> - <span class="hlFld-Affiliation affiliation">Daegu-Gyeongbuk
Medical Innovation Foundation, 2387 dalgubeol-daero, Suseong-gu, Daegu 42019, Republic
of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nam Doo Kim</span> - <span class="hlFld-Affiliation affiliation">Daegu-Gyeongbuk
Medical Innovation Foundation, 2387 dalgubeol-daero, Suseong-gu, Daegu 42019, Republic
of Korea</span>; 
    <span class="hlFld-Affiliation affiliation">NDBio
Therapeutics Inc., 32
Songdogwahak-ro, Yeonsu-gu, Incheon 21984, Republic of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hwan Geun Choi</span> - <span class="hlFld-Affiliation affiliation">Daegu-Gyeongbuk
Medical Innovation Foundation, 2387 dalgubeol-daero, Suseong-gu, Daegu 42019, Republic
of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nathanael S. Gray</span> - <span class="hlFld-Affiliation affiliation">Department
of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5354-7403" title="Orcid link">http://orcid.org/0000-0001-5354-7403</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Hanna Cho and Injae Shin contributed equally to this work. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i86">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68764" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68764" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by Korea Institute of Science and Technology (KIST), the KU-KIST Graduate School of Converging Science and Technology Program, a grant (D33400) from the Korea Basic Science Institute, Support for Candidate Development Program (NRF-2016M3A9B5940991), and Pioneer Research Center Program (NRF-2014M3C1A3051476) of the National Research Foundation of Korea funded by the Ministry of Science and ICT.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ACK1</td><td class="NLM_def"><p class="first last">activated Cdc42-associated tyrosine kinase 1</p></td></tr><tr><td class="NLM_term">GCK</td><td class="NLM_def"><p class="first last">germinal center kinase</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly(ADP-ribose) polymerase</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin complex</p></td></tr><tr><td class="NLM_term">Xphos</td><td class="NLM_def"><p class="first last">2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl</p></td></tr><tr><td class="NLM_term">Pd<sub>2</sub>(dba)<sub>3</sub></td><td class="NLM_def"><p class="first last">tris(dibenzylideneacetone)dipalladium(0)</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[Bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate</p></td></tr><tr><td class="NLM_term">PTPN1</td><td class="NLM_def"><p class="first last">tyrosine-protein phosphatase nonreceptor type 1</p></td></tr><tr><td class="NLM_term">TCEP</td><td class="NLM_def"><p class="first last">tris(2-carboxyethyl)phosphine hydrochloride</p></td></tr><tr><td class="NLM_term">TEV</td><td class="NLM_def"><p class="first last">tabacco etch virus</p></td></tr><tr><td class="NLM_term">HEPES</td><td class="NLM_def"><p class="first last">4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i88">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15114" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15114" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 32 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolias, P.</span></span> <span> </span><span class="NLM_article-title">Recent advances in cancer drug discovery targeting RAS</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1915</span>– <span class="NLM_lpage">1919</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1016%2Fj.drudis.2016.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=27506872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlaiu73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=1915-1919&author=C.+Y.+Wilsonauthor=P.+Tolias&title=Recent+advances+in+cancer+drug+discovery+targeting+RAS&doi=10.1016%2Fj.drudis.2016.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in cancer drug discovery targeting RAS</span></div><div class="casAuthors">Wilson, Candice Y.; Tolias, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1915-1919</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Mutated RAS is present in 30% of human tumors, appearing in 90% of pancreatic, 45% of colon and 35% of lung cancers.  These high occurrences make RAS one of the most important drug targets in oncol.  Three decades of effort to target RAS have been unsuccessful in generating drug therapies suggesting that it might represent an 'undruggable' target.  However, recent reports highlighting new approaches for targeting RAS have uncovered more information on protein structure and identified new binding pockets.  Efforts to target the KRAS G12C mutation specifically have shown promising results whereas other approaches have targeted various protein complexes.  These advances could lead to development of new effective cancer drugs targeting RAS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJnoLMitHbsrVg90H21EOLACvtfcHk0liI_lmbNZcdmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlaiu73P&md5=5bcad00948b76112248f9ebc332a8d73</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DC.%2BY.%26aulast%3DTolias%26aufirst%3DP.%26atitle%3DRecent%2520advances%2520in%2520cancer%2520drug%2520discovery%2520targeting%2520RAS%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D1915%26epage%3D1919%26doi%3D10.1016%2Fj.drudis.2016.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span> <span> </span><span class="NLM_article-title">Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4186</span>– <span class="NLM_lpage">4192</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-3270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1158%2F1078-0432.CCR-13-3270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=24895460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCltr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=4186-4192&author=D.+B.+Johnsonauthor=K.+S.+Smalleyauthor=J.+A.+Sosman&title=Molecular+pathways%3A+targeting+NRAS+in+melanoma+and+acute+myelogenous+leukemia&doi=10.1158%2F1078-0432.CCR-13-3270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous Leukemia</span></div><div class="casAuthors">Johnson, Douglas B.; Smalley, Keiran S. M.; Sosman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4186-4192</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Successful targeting of specific oncogenic "driver" mutations with small-mol. inhibitors has represented a major advance in cancer therapeutics over the past 10 to 15 years.  The most common activating oncogene in human malignancy, RAS (rat sarcoma), has proved to be an elusive target.  Activating mutations in RAS induce mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase-AKT pathway signaling and drive malignant progression in up to 30% of cancers.  Oncogenic NRAS mutations occur in several cancer types, notably melanoma, acute myelogenous leukemia (AML), and less commonly, colon adenocarcinoma, thyroid carcinoma, and other hematol. malignancies.  Although NRAS-mutant tumors have been recalcitrant to targeted therapeutic strategies historically, newer agents targeting MAP/ERK kinase 1 (MEK1)/2 have recently shown signs of clin. efficacy as monotherapy.  Combination strategies of MEK inhibitors with other targeted agents have strong preclin. support and are being evaluated in clin. trials.  This review discusses the recent preclin. and clin. studies about the role of NRAS in cancer, with a focus on melanoma and AML.  Clin Cancer Res; 20(16); 4186-92. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHb9TN00_uU7Vg90H21EOLACvtfcHk0ljKBoGuvOdlug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCltr%252FK&md5=4656a7aa671cfa3989c09d93f4d60226</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-3270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-3270%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BB.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26atitle%3DMolecular%2520pathways%253A%2520targeting%2520NRAS%2520in%2520melanoma%2520and%2520acute%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D4186%26epage%3D4192%26doi%3D10.1158%2F1078-0432.CCR-13-3270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowens, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1038/leu.2014.149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2Fleu.2014.149" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=27-37&author=E.+Weisbergauthor=A.+Nonamiauthor=Z.+Chenauthor=F.+Liuauthor=J.+Zhangauthor=M.+Sattlerauthor=E.+Nelsonauthor=K.+Cowensauthor=A.+L.+Christieauthor=C.+Mitsiadesauthor=K.-K.+Wongauthor=Q.+Liuauthor=N.+Grayauthor=J.+D.+Griffin&title=Identification+of+Wee1+as+a+novel+therapeutic+target+for+mutant+RAS-driven+acute+leukemia+and+other+malignancies&doi=10.1038%2Fleu.2014.149"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1038%2Fleu.2014.149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2014.149%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DNonami%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DNelson%26aufirst%3DE.%26aulast%3DCowens%26aufirst%3DK.%26aulast%3DChristie%26aufirst%3DA.%2BL.%26aulast%3DMitsiades%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DIdentification%2520of%2520Wee1%2520as%2520a%2520novel%2520therapeutic%2520target%2520for%2520mutant%2520RAS-driven%2520acute%2520leukemia%2520and%2520other%2520malignancies%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26spage%3D27%26epage%3D37%26doi%3D10.1038%2Fleu.2014.149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sachs, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaRue, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, N. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz-Flores, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathe, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarver, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendall, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, N. GA.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diers, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">NOlan, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Largaespada, D. A.</span></span> <span> </span><span class="NLM_article-title">NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">3274</span>– <span class="NLM_lpage">3283</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-08-521708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1182%2Fblood-2013-08-521708" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=3274-3283&author=Z.+Sachsauthor=R.+S.+LaRueauthor=H.+T.+Nguyenauthor=K.+Sachsauthor=K.+E.+Nobleauthor=N.+A.+M.+Hassanauthor=E.+Diaz-Floresauthor=S.+K.+Ratheauthor=A.+L.+Sarverauthor=S.+C.+Bendallauthor=N.+GA.+Haauthor=M.+D.+Diersauthor=G.+D.+NOlanauthor=K.+M.+Shannonauthor=D.+A.+Largaespada&title=NRASG12V+oncogene+facilitates+self-renewal+in+a+murine+model+of+acute+myelogenous+leukemia&doi=10.1182%2Fblood-2013-08-521708"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-08-521708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-08-521708%26sid%3Dliteratum%253Aachs%26aulast%3DSachs%26aufirst%3DZ.%26aulast%3DLaRue%26aufirst%3DR.%2BS.%26aulast%3DNguyen%26aufirst%3DH.%2BT.%26aulast%3DSachs%26aufirst%3DK.%26aulast%3DNoble%26aufirst%3DK.%2BE.%26aulast%3DHassan%26aufirst%3DN.%2BA.%2BM.%26aulast%3DDiaz-Flores%26aufirst%3DE.%26aulast%3DRathe%26aufirst%3DS.%2BK.%26aulast%3DSarver%26aufirst%3DA.%2BL.%26aulast%3DBendall%26aufirst%3DS.%2BC.%26aulast%3DHa%26aufirst%3DN.%2BGA.%26aulast%3DDiers%26aufirst%3DM.%2BD.%26aulast%3DNOlan%26aufirst%3DG.%2BD.%26aulast%3DShannon%26aufirst%3DK.%2BM.%26aulast%3DLargaespada%26aufirst%3DD.%2BA.%26atitle%3DNRASG12V%2520oncogene%2520facilitates%2520self-renewal%2520in%2520a%2520murine%2520model%2520of%2520acute%2520myelogenous%2520leukemia%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D3274%26epage%3D3283%26doi%3D10.1182%2Fblood-2013-08-521708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haigis, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDaniel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding-Theobald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogan, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akagi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacks, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, K.</span></span> <span> </span><span class="NLM_article-title">Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">2022</span>– <span class="NLM_lpage">2032</span>, <span class="refDoi"> DOI: 10.1182/blood-2010-04-280750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1182%2Fblood-2010-04-280750" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=2022-2032&author=Q.+Liauthor=K.+M.+Haigisauthor=A.+McDanielauthor=E.+Harding-Theobaldauthor=S.+C.+Koganauthor=K.+Akagiauthor=J.+C.+Wongauthor=B.+S.+Braunauthor=L.+Wolffauthor=T.+Jacksauthor=K.+Shannon&title=Hematopoiesis+and+leukemogenesis+in+mice+expressing+oncogenic+NrasG12D+from+the+endogenous+locus&doi=10.1182%2Fblood-2010-04-280750"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-04-280750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-04-280750%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DHaigis%26aufirst%3DK.%2BM.%26aulast%3DMcDaniel%26aufirst%3DA.%26aulast%3DHarding-Theobald%26aufirst%3DE.%26aulast%3DKogan%26aufirst%3DS.%2BC.%26aulast%3DAkagi%26aufirst%3DK.%26aulast%3DWong%26aufirst%3DJ.%2BC.%26aulast%3DBraun%26aufirst%3DB.%2BS.%26aulast%3DWolff%26aufirst%3DL.%26aulast%3DJacks%26aufirst%3DT.%26aulast%3DShannon%26aufirst%3DK.%26atitle%3DHematopoiesis%2520and%2520leukemogenesis%2520in%2520mice%2520expressing%2520oncogenic%2520NrasG12D%2520from%2520the%2520endogenous%2520locus%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3D2022%26epage%3D2032%26doi%3D10.1182%2Fblood-2010-04-280750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, S. J.</span></span> <span> </span><span class="NLM_article-title">Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>504</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">147</span>, <span class="refDoi"> DOI: 10.1038/nature12830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2Fnature12830" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=504&publication_year=2013&pages=143-147&author=Q.+Liauthor=N.+Bohinauthor=T.+Wenauthor=V.+Ngauthor=J.+Mageeauthor=S.+C.+Chenauthor=K.+Shannonauthor=S.+J.+Morrison&title=Oncogenic+Nras+has+bimodal+effects+on+stem+cells+that+sustainably+increase+competitiveness&doi=10.1038%2Fnature12830"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2e&amp;dbid=16384&amp;doi=10.1038%2Fnature12830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12830%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DBohin%26aufirst%3DN.%26aulast%3DWen%26aufirst%3DT.%26aulast%3DNg%26aufirst%3DV.%26aulast%3DMagee%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%2BC.%26aulast%3DShannon%26aufirst%3DK.%26aulast%3DMorrison%26aufirst%3DS.%2BJ.%26atitle%3DOncogenic%2520Nras%2520has%2520bimodal%2520effects%2520on%2520stem%2520cells%2520that%2520sustainably%2520increase%2520competitiveness%26jtitle%3DNature%26date%3D2013%26volume%3D504%26spage%3D143%26epage%3D147%26doi%3D10.1038%2Fnature12830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nonami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patricelli, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saur, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">3133</span>– <span class="NLM_lpage">3143</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-12-615906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1182%2Fblood-2014-12-615906" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=3133-3143&author=A.+Nonamiauthor=M.+Sattlerauthor=E.+Weisbergauthor=Q.+Liuauthor=J.+Zhangauthor=M.+P.+Patricelliauthor=A.+L.+Christieauthor=A.+M.+Saurauthor=N.+E.+Kohlauthor=A.+L.+Kungauthor=H.+Yoonauthor=T.+Simauthor=N.+S.+Grayauthor=J.+D.+Griffin&title=Identification+of+novel+therapeutic+targets+in+acute+leukemias+with+NRAS+mutations+using+a+pharmacologic+approach&doi=10.1182%2Fblood-2014-12-615906"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-12-615906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-12-615906%26sid%3Dliteratum%253Aachs%26aulast%3DNonami%26aufirst%3DA.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPatricelli%26aufirst%3DM.%2BP.%26aulast%3DChristie%26aufirst%3DA.%2BL.%26aulast%3DSaur%26aufirst%3DA.%2BM.%26aulast%3DKohl%26aufirst%3DN.%2BE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DYoon%26aufirst%3DH.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DIdentification%2520of%2520novel%2520therapeutic%2520targets%2520in%2520acute%2520leukemias%2520with%2520NRAS%2520mutations%2520using%2520a%2520pharmacologic%2520approach%26jtitle%3DBlood%26date%3D2015%26volume%3D125%26spage%3D3133%26epage%3D3143%26doi%3D10.1182%2Fblood-2014-12-615906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, T. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björkholm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, P. C.</span></span> <span> </span><span class="NLM_article-title">Survival and cure of acute myeloid leukaemia in England, 1971–2006: a population–based study</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1111/bjh.12425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1111%2Fbjh.12425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=23786647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A280%3ADC%252BC3sjks1eqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2013&pages=509-516&author=A.+Shahauthor=T.+M.+L.+Anderssonauthor=B.+Rachetauthor=M.+Bj%C3%B6rkholmauthor=P.+C.+Lambert&title=Survival+and+cure+of+acute+myeloid+leukaemia+in+England%2C+1971%E2%80%932006%3A+a+population%E2%80%93based+study&doi=10.1111%2Fbjh.12425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study</span></div><div class="casAuthors">Shah Anjali; Andersson Therese M-L; Rachet Bernard; Bjorkholm Magnus; Lambert Paul C</div><div class="citationInfo"><span class="NLM_cas:title">British journal of haematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">509-16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The 5-year relative survival of adults diagnosed with acute myeloid leukaemia (AML) was less than 10% during the 1970s and 1980s in England.  This population-based study estimated the 5-year relative survival and 'cure' for 48 380 adult patients diagnosed with AML in England during 1971-2006.  Relative survival and cure mixture models were used to produce estimates of 5-year relative survival and the percentage 'cured'. 'Cure' was defined as the proportion of a group of survivors for whom there is no excess mortality compared with the general population.  The 5-year relative survival and the percentage 'cured' increased for patients aged under 70 years at diagnosis during 1971-2006, but advancing age was associated with poorer outcome.  During the study period a dramatic increase in 5-year relative survival occurred in those aged 15-24 years, from 7% to 53%.  The percentage 'cured' was less than 10% for all ages in 1975, but increased to 45% for those aged 15-24 years in 2000.  Cure could not be estimated for patients over 70 years, because survival was consistently low (<5%).  The long-term outcome of patients with AML has improved substantially, particularly in younger patients.  The potential exists for further increasing levels of 'cure'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRGi030miilreWhZTslLrfffW6udTcc2eZ--0yclq_7CLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjks1eqsA%253D%253D&md5=513555d4c7e42dd36720d51691222734</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fbjh.12425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.12425%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DA.%26aulast%3DAndersson%26aufirst%3DT.%2BM.%2BL.%26aulast%3DRachet%26aufirst%3DB.%26aulast%3DBj%25C3%25B6rkholm%26aufirst%3DM.%26aulast%3DLambert%26aufirst%3DP.%2BC.%26atitle%3DSurvival%2520and%2520cure%2520of%2520acute%2520myeloid%2520leukaemia%2520in%2520England%252C%25201971%25E2%2580%25932006%253A%2520a%2520population%25E2%2580%2593based%2520study%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2013%26volume%3D162%26spage%3D509%26epage%3D516%26doi%3D10.1111%2Fbjh.12425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Podoltsev, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeidan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gore, S. D.</span></span> <span> </span><span class="NLM_article-title">Selecting initial treatment of acute myeloid leukaemia in older adults</span>. <i>Blood Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1016/j.blre.2016.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1016%2Fj.blre.2016.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=27745715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A280%3ADC%252BC2srgvV2gtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=43-62&author=N.+A.+Podoltsevauthor=M.+Stahlauthor=A.+M.+Zeidanauthor=S.+D.+Gore&title=Selecting+initial+treatment+of+acute+myeloid+leukaemia+in+older+adults&doi=10.1016%2Fj.blre.2016.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Selecting initial treatment of acute myeloid leukaemia in older adults</span></div><div class="casAuthors">Podoltsev Nikolai A; Zeidan Amer M; Gore Steven D; Stahl Maximilian</div><div class="citationInfo"><span class="NLM_cas:title">Blood reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">43-62</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">More than half of the patients with acute myeloid leukaemia (AML) are older than 60years.  The treatment outcomes in this group remain poor with a median overall survival of <1year.  Selecting initial treatment for these patients involves an assessment of 'fitness' for induction chemotherapy.  This is done based on patient and disease-related characteristics which help to estimate treatment-related mortality and chance of complete remission with induction chemotherapy.  If the risk of treatment-related mortality is high and/or the likelihood of a patient achieving a complete remission is low, lower-intensity treatment (low-dose cytarabine, decitabine and azacitidine) should be discussed.  As outcomes in both groups of patients remain poor, enrolment into clinical trials of novel agents with varying mechanisms of action should be considered for all older adults with AML.  Novel agents in Phase III development include CPX-351, guadecitabine (SGI-110), quizartinib, crenolanib, sapacitabine, vosaroxin and volasertib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSOTEk4l7FYFxKDYG3bNImrfW6udTcc2eZ--0yclq_7CLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srgvV2gtw%253D%253D&md5=0b21bc450b84f8107469ec038be759f9</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.blre.2016.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.blre.2016.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DPodoltsev%26aufirst%3DN.%2BA.%26aulast%3DStahl%26aufirst%3DM.%26aulast%3DZeidan%26aufirst%3DA.%2BM.%26aulast%3DGore%26aufirst%3DS.%2BD.%26atitle%3DSelecting%2520initial%2520treatment%2520of%2520acute%2520myeloid%2520leukaemia%2520in%2520older%2520adults%26jtitle%3DBlood%2520Rev.%26date%3D2017%26volume%3D31%26spage%3D43%26epage%3D62%26doi%3D10.1016%2Fj.blre.2016.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Saygin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carraway, H. E.</span></span> <span> </span><span class="NLM_article-title">Emerging therapies for acute myeloid leukemia</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">93</span>, <span class="refDoi"> DOI: 10.1186/s13045-017-0463-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1186%2Fs13045-017-0463-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=28420416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A280%3ADC%252BC1cvovFWhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=93&author=C.+Sayginauthor=H.+E.+Carraway&title=Emerging+therapies+for+acute+myeloid+leukemia&doi=10.1186%2Fs13045-017-0463-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging therapies for acute myeloid leukemia</span></div><div class="casAuthors">Saygin Caner; Carraway Hetty E; Carraway Hetty E</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">93</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity.  Despite the advances in our understanding of its pathobiology, the chemotherapy-directed management has remained largely unchanged in the past 40 years.  However, various novel agents have demonstrated clinical activity, either as single agents (e.g., isocitrate dehydrogenase (IDH) inhibitors, vadastuximab) or in combination with standard induction/consolidation at diagnosis and with salvage regimens at relapse.  The classes of agents described in this review include novel cytotoxic chemotherapies (CPX-351 and vosaroxin), epigenetic modifiers (guadecitabine, IDH inhibitors, histone deacetylase (HDAC) inhibitors, bromodomain and extraterminal (BET) inhibitors), FMS-like tyrosine kinase receptor 3 (FLT3) inhibitors, and antibody-drug conjugates (vadastuximab), as well as cell cycle inhibitors (volasertib), B-cell lymphoma 2 (BCL-2) inhibitors, and aminopeptidase inhibitors.  These agents are actively undergoing clinical investigation alone or in combination with available chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_EeV9zuCZfTdblLE_E9PWfW6udTcc2eZ--0yclq_7CLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvovFWhuw%253D%253D&md5=3c1c9d98886f14e32c9e8d9e1d47823a</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1186%2Fs13045-017-0463-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-017-0463-6%26sid%3Dliteratum%253Aachs%26aulast%3DSaygin%26aufirst%3DC.%26aulast%3DCarraway%26aufirst%3DH.%2BE.%26atitle%3DEmerging%2520therapies%2520for%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2017%26volume%3D10%26spage%3D93%26doi%3D10.1186%2Fs13045-017-0463-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubielecka, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghunathan, V. M.</span></span> <span> </span><span class="NLM_article-title">Molecular targeting in acute myeloid leukemia</span>. <i>J. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1186/s12967-017-1281-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1186%2Fs12967-017-1281-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=28851395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A280%3ADC%252BC1cbis1Omtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=183-196&author=S.+H.+Limauthor=P.+M.+Dubieleckaauthor=V.+M.+Raghunathan&title=Molecular+targeting+in+acute+myeloid+leukemia&doi=10.1186%2Fs12967-017-1281-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular targeting in acute myeloid leukemia</span></div><div class="casAuthors">Lim Seah H; Dubielecka Patrycja M; Raghunathan Vikram M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of translational medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">183</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acute myeloid leukemia (AML) is a heterogenous disease associated with distinct genetic and molecular abnormalities.  Somatic mutations result in dysregulation of intracellular signaling pathways, epigenetics, and apoptosis of the leukemia cells.  Understanding the basis for the dysregulated processes provides the platform for the design of novel targeted therapy for AML patients.  The effort to devise new targeted therapy has been helped by recent advances in methods for high-throughput genomic screening and the availability of computer-assisted techniques for the design of novel agents that are predicted to specifically inhibit the mutant molecules involved in these intracellular events.  In this review, we will provide the scientific basis for targeting the dysregulated molecular mechanisms and discuss the agents currently being investigated, alone or in combination with chemotherapy, for treating patients with AML.  Successes in molecular targeting will ultimately change the treatment paradigm for the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ8xkAkzMDBjHqj_yg7twvpfW6udTcc2eaE5tHbO8kvN7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbis1Omtg%253D%253D&md5=d646ab2d344c55fc913fc87aedbdb673</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1186%2Fs12967-017-1281-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12967-017-1281-x%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DS.%2BH.%26aulast%3DDubielecka%26aufirst%3DP.%2BM.%26aulast%3DRaghunathan%26aufirst%3DV.%2BM.%26atitle%3DMolecular%2520targeting%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Transl.%2520Med.%26date%3D2017%26volume%3D15%26spage%3D183%26epage%3D196%26doi%3D10.1186%2Fs12967-017-1281-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">De Kouchkovsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul-Hay, M.</span></span> <span> </span><span class="NLM_article-title">Acute myeloid leukemia: a comprehensive review and 2016 update</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">e441</span>, <span class="refDoi"> DOI: 10.1038/bcj.2016.50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2Fbcj.2016.50" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=27367478" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=e441&author=I.+De+Kouchkovskyauthor=M.+Abdul-Hay&title=Acute+myeloid+leukemia%3A+a+comprehensive+review+and+2016+update&doi=10.1038%2Fbcj.2016.50"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2016.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2016.50%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BKouchkovsky%26aufirst%3DI.%26aulast%3DAbdul-Hay%26aufirst%3DM.%26atitle%3DAcute%2520myeloid%2520leukemia%253A%2520a%2520comprehensive%2520review%2520and%25202016%2520update%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2016%26volume%3D6%26spage%3De441%26doi%3D10.1038%2Fbcj.2016.50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Baines, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Ras for cancer treatment: the search continues</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1787</span>– <span class="NLM_lpage">1808</span>, <span class="refDoi"> DOI: 10.4155/fmc.11.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.4155%2Ffmc.11.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=22004085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlertbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1787-1808&author=A.+T.+Bainesauthor=D.+Xuauthor=C.+J.+Der&title=Inhibition+of+Ras+for+cancer+treatment%3A+the+search+continues&doi=10.4155%2Ffmc.11.121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Ras for cancer treatment: the search continues</span></div><div class="casAuthors">Baines, Antonio T.; Xu, Dapeng; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1787-1808</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The RAS oncogenes (HRAS, NRAS and KRAS) comprise the most frequently mutated class of oncogenes in human cancers (33%), thus stimulating intensive effort in developing anti-Ras inhibitors for cancer treatment.  Despite intensive effort, to date, no effective anti-Ras strategies have successfully made it to the clinic.  We present an overview of past and ongoing strategies to inhibit oncogenic Ras in cancer.  Since approaches to directly target mutant Ras have not been successful, most efforts have focused on indirect approaches to block Ras membrane assocn. or downstream effector signaling.  While inhibitors of effector signaling are currently under clin. evaluation, genome-wide unbiased genetic screens have identified novel directions for future anti-Ras drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGSljlfnR2TbVg90H21EOLACvtfcHk0lj0vQDEP1Zrpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlertbjJ&md5=bb810b0cf2b8dc975d5a476907f5c2ec</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.121%26sid%3Dliteratum%253Aachs%26aulast%3DBaines%26aufirst%3DA.%2BT.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DInhibition%2520of%2520Ras%2520for%2520cancer%2520treatment%253A%2520the%2520search%2520continues%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D1787%26epage%3D1808%26doi%3D10.4155%2Ffmc.11.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieu, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messersmith, W. A.</span></span> <span> </span><span class="NLM_article-title">Therapeutic approaches to RAS mutation</span>. <i>Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1097/PPO.0000000000000187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1097%2FPPO.0000000000000187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=27341593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCltLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=165-174&author=A.+J.+Scottauthor=C.+H.+Lieuauthor=W.+A.+Messersmith&title=Therapeutic+approaches+to+RAS+mutation&doi=10.1097%2FPPO.0000000000000187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Approaches to RAS Mutation</span></div><div class="casAuthors">Scott, Aaron J.; Lieu, Christopher H.; Messersmith, Wells A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Journal (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">165-174</span>CODEN:
                <span class="NLM_cas:coden">CAJOCB</span>;
        ISSN:<span class="NLM_cas:issn">1528-9117</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The study of oncogenic RAS mutations has led to crucial discoveries regarding cancer mol. biol. and behavior and has been integral in shaping the era of targeted cancer therapy.  RAS mutations are one of the most common oncogenic drivers in human cancer, and intense efforts to find a clin. effective inhibitor are ongoing.  Despite these efforts, targeting RAS mutations has remained elusive, so much so that some have termed oncogenic RAS mutations as "undruggable.  " In this review, we will summarize current understanding of RAS biol., explore strategies to inhibit RAS oncoproteins and its downstream effectors, and discuss recently described complexities that have shed new light on this pursuit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokgFYmAV2BQLVg90H21EOLACvtfcHk0lj0vQDEP1Zrpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCltLjF&md5=eaa1ed8b15c77758cb9f174acc0f99c8</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1097%2FPPO.0000000000000187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FPPO.0000000000000187%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DA.%2BJ.%26aulast%3DLieu%26aufirst%3DC.%2BH.%26aulast%3DMessersmith%26aufirst%3DW.%2BA.%26atitle%3DTherapeutic%2520approaches%2520to%2520RAS%2520mutation%26jtitle%3DCancer%2520J.%26date%3D2016%26volume%3D22%26spage%3D165%26epage%3D174%26doi%3D10.1097%2FPPO.0000000000000187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Athuluri-Divakar, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasquez-Del Carpio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosenza, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogt, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulholland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span> <span> </span><span class="NLM_article-title">A small molecule RAS-mimetic disrupts RAS association with effector proteins to block signaling</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">655</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2016.03.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1016%2Fj.cell.2016.03.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=27104980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslShtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=643-655&author=S.+K.+Athuluri-Divakarauthor=R.+Vasquez-Del+Carpioauthor=K.+Duttaauthor=S.+J.+Bakerauthor=S.+C.+Cosenzaauthor=I.+Basuauthor=Y.+K.+Guptaauthor=M.+R.+Reddyauthor=L.+Uenoauthor=J.+R.+Hartauthor=P.+K.+Vogtauthor=D.+Mulhollandauthor=C.+Guhaauthor=A.+K.+Aggarwalauthor=E.+P.+Reddy&title=A+small+molecule+RAS-mimetic+disrupts+RAS+association+with+effector+proteins+to+block+signaling&doi=10.1016%2Fj.cell.2016.03.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling</span></div><div class="casAuthors">Athuluri-Divakar, Sai Krishna; Vasquez-Del Carpio, Rodrigo; Dutta, Kaushik; Baker, Stacey J.; Cosenza, Stephen C.; Basu, Indranil; Gupta, Yogesh K.; Reddy, M. V. Ramana; Ueno, Lynn; Hart, Jonathan R.; Vogt, Peter K.; Mulholland, David; Guha, Chandan; Aggarwal, Aneel K.; Reddy, E. Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">643-655</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Oncogenic activation of RAS genes via point mutations occurs in 20%-30% of human cancers.  The development of effective RAS inhibitors has been challenging, necessitating new approaches to inhibit this oncogenic protein.  Functional studies have shown that the switch region of RAS interacts with a large no. of effector proteins contg. a common RAS-binding domain (RBD).  Because RBD-mediated interactions are essential for RAS signaling, blocking RBD assocn. with small mols. constitutes an attractive therapeutic approach.  Here, the authors present evidence that rigosertib, a styryl-benzyl sulfone, acts as a RAS-mimetic and interacts with the RBDs of RAF kinases, resulting in their inability to bind to RAS, disruption of RAF activation, and inhibition of the RAS-RAF-MEK pathway.  The authors also find that ribosertib binds to the RBDs of Ral-GDS and PI3Ks.  These results suggest that targeting of RBDs across multiple signaling pathways by rigosertib may represent an effective strategy for inactivation of RAS signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa5skbfbqCQrVg90H21EOLACvtfcHk0lgZvDAfEqWhlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslShtbs%253D&md5=c79482e4a9cc6819034dd9117348b8bc</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.03.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.03.045%26sid%3Dliteratum%253Aachs%26aulast%3DAthuluri-Divakar%26aufirst%3DS.%2BK.%26aulast%3DVasquez-Del%2BCarpio%26aufirst%3DR.%26aulast%3DDutta%26aufirst%3DK.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DBasu%26aufirst%3DI.%26aulast%3DGupta%26aufirst%3DY.%2BK.%26aulast%3DReddy%26aufirst%3DM.%2BR.%26aulast%3DUeno%26aufirst%3DL.%26aulast%3DHart%26aufirst%3DJ.%2BR.%26aulast%3DVogt%26aufirst%3DP.%2BK.%26aulast%3DMulholland%26aufirst%3DD.%26aulast%3DGuha%26aufirst%3DC.%26aulast%3DAggarwal%26aufirst%3DA.%2BK.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DA%2520small%2520molecule%2520RAS-mimetic%2520disrupts%2520RAS%2520association%2520with%2520effector%2520proteins%2520to%2520block%2520signaling%26jtitle%3DCell%26date%3D2016%26volume%3D165%26spage%3D643%26epage%3D655%26doi%3D10.1016%2Fj.cell.2016.03.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ledford, H.</span></span> <span> </span><span class="NLM_article-title">The ras renaissance</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>520</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1038/520278a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2F520278a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=520&publication_year=2015&pages=278-280&author=H.+Ledford&title=The+ras+renaissance&doi=10.1038%2F520278a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2F520278a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F520278a%26sid%3Dliteratum%253Aachs%26aulast%3DLedford%26aufirst%3DH.%26atitle%3DThe%2520ras%2520renaissance%26jtitle%3DNature%26date%3D2015%26volume%3D520%26spage%3D278%26epage%3D280%26doi%3D10.1038%2F520278a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesik, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimmelman, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">Drugging the undruggable RAS: mission possible?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">828</span>– <span class="NLM_lpage">851</span>, <span class="refDoi"> DOI: 10.1038/nrd4389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2Fnrd4389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=25323927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslKmu7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=828-851&author=A.+D.+Coxauthor=S.+W.+Fesikauthor=A.+C.+Kimmelmanauthor=J.+Luoauthor=C.+J.+Der&title=Drugging+the+undruggable+RAS%3A+mission+possible%3F&doi=10.1038%2Fnrd4389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging the undruggable RAS: Mission Possible?</span></div><div class="casAuthors">Cox, Adrienne D.; Fesik, Stephen W.; Kimmelman, Alec C.; Luo, Ji; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">828-851</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite more than three decades of intensive effort, no effective pharmacol. inhibitors of the RAS oncoproteins have reached the clinic, prompting the widely held perception that RAS proteins are 'undruggable'.  However, recent data from the lab. and the clinic have renewed our hope for the development of RAS-inhibitory mols.  In this Review, we summarize the progress and the promise of five key approaches.  Firstly, we focus on the prospects of using direct inhibitors of RAS.  Secondly, we address the issue of whether blocking RAS membrane assocn. is a viable approach.  Thirdly, we assess the status of targeting RAS downstream effector signalling, which is arguably the most favorable current approach.  Fourthly, we address whether the search for synthetic lethal interactors of mutant RAS still holds promise.  Finally, RAS-mediated changes in cell metab. have recently been described and we discuss whether these changes could be exploited for new therapeutic directions.  We conclude with perspectives on how addnl. complexities, which are not yet fully understood, may affect each of these approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvWzW1JqxN4LVg90H21EOLACvtfcHk0lgZvDAfEqWhlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslKmu7zE&md5=6c8645293b079023de7d31011ae1a192</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1038%2Fnrd4389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4389%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DA.%2BD.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26aulast%3DKimmelman%26aufirst%3DA.%2BC.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DDrugging%2520the%2520undruggable%2520RAS%253A%2520mission%2520possible%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D828%26epage%3D851%26doi%3D10.1038%2Fnrd4389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cromm, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossmann, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldmann, H.</span></span> <span> </span><span class="NLM_article-title">Small-molecule modulation of Ras signaling</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">613</span>– <span class="NLM_lpage">622</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2Fnchembio.1560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=24929527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslGisbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=613-622&author=J.+Spiegelauthor=P.+M.+Crommauthor=G.+Zimmermannauthor=T.+N.+Grossmannauthor=H.+Waldmann&title=Small-molecule+modulation+of+Ras+signaling&doi=10.1038%2Fnchembio.1560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule modulation of Ras signaling</span></div><div class="casAuthors">Spiegel, Jochen; Cromm, Philipp M.; Zimmermann, Gunther; Grossmann, Tom N.; Waldmann, Herbert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">613-622</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite intense efforts in pharmaceutical industry and academia, a therapeutic grip on oncogenic Ras proteins has remained elusive.  Mutated Ras is assocd. with ∼20-30% of all human cancers often not responsive to established therapies.  In particular, K-Ras, the most frequently mutated Ras isoform, is considered one of the most important but 'undruggable' targets in cancer research.  Recently, new cavities on Ras for small-mol. ligands were identified, and selective direct targeting of mutated K-RasG12C has become possible for what is to our knowledge the first time.  In addn., impairment of Ras spatial organization, in particular via targeting the prenyl-binding Ras chaperone PDEδ, has opened a fresh perspective in anticancer research.  These recent advances fuel hopes for the development of new drugs targeting Ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTcp4dzeVKK7Vg90H21EOLACvtfcHk0lj5E9VDucZYpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslGisbw%253D&md5=f8d84f054e1b392cf6bfe55d5e235c28</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1560%26sid%3Dliteratum%253Aachs%26aulast%3DSpiegel%26aufirst%3DJ.%26aulast%3DCromm%26aufirst%3DP.%2BM.%26aulast%3DZimmermann%26aufirst%3DG.%26aulast%3DGrossmann%26aufirst%3DT.%2BN.%26aulast%3DWaldmann%26aufirst%3DH.%26atitle%3DSmall-molecule%2520modulation%2520of%2520Ras%2520signaling%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D613%26epage%3D622%26doi%3D10.1038%2Fnchembio.1560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pratilas, C.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span> <span> </span><span class="NLM_article-title">Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3329</span>– <span class="NLM_lpage">3334</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-3064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1158%2F1078-0432.CCR-09-3064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=20472680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1Wlsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=3329-3334&author=C.%0AA.+Pratilasauthor=D.+B.+Solit&title=Targeting+the+mitogen-activated+protein+kinase+pathway%3A+physiological+feedback+and+drug+response&doi=10.1158%2F1078-0432.CCR-09-3064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response</span></div><div class="casAuthors">Pratilas, Christine A.; Solit, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3329-3334</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Mitogen-activated protein kinase (MAPK) pathway activation is a frequent event in human cancer and is often the result of activating mutations in the BRAF and RAS oncogenes.  Targeted inhibitors of BRAF and its downstream effectors are in various stages of preclin. and clin. development.  These agents offer the possibility of greater efficacy and less toxicity than current therapies for tumors driven by oncogenic mutations in the MAPK pathway.  Early clin. results with the BRAF-selective inhibitor PLX4032 suggest that this strategy will prove successful in a select group of patients whose tumors are driven by V600E BRAF.  Relief of physiol. feedback upon pathway inhibition may, however, attenuate drug response and contribute to the development of acquired resistance.  An improved understanding of the adaptive response of cancer cells to MAPK pathway inhibition may thus aid in the identification of those patients most likely to respond to targeted pathway inhibitors and provide a rational basis for tailored combination strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg94UtFJDa8rVg90H21EOLACvtfcHk0lj5E9VDucZYpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1Wlsbw%253D&md5=afdeddfefff1ac57f16556753541f3be</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-3064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-3064%26sid%3Dliteratum%253Aachs%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DTargeting%2520the%2520mitogen-activated%2520protein%2520kinase%2520pathway%253A%2520physiological%2520feedback%2520and%2520drug%2520response%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D3329%26epage%3D3334%26doi%3D10.1158%2F1078-0432.CCR-09-3064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Durrant, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D. K.</span></span> <span> </span><span class="NLM_article-title">Targeting the Raf kinases in human cancer: the Raf dimer dilemma</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1038/bjc.2017.399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2Fbjc.2017.399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=29235562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFKhu7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2018&pages=3-8&author=D.+E.+Durrantauthor=D.+K.+Morrison&title=Targeting+the+Raf+kinases+in+human+cancer%3A+the+Raf+dimer+dilemma&doi=10.1038%2Fbjc.2017.399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Raf kinases in human cancer: the Raf dimer dilemma</span></div><div class="casAuthors">Durrant, David E.; Morrison, Deborah K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-8</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The Raf protein kinases are key intermediates in cellular signal transduction, functioning as direct effectors of the Ras GTPases and as the initiating kinases in the ERK cascade.  In human cancer, Raf activity is frequently dysregulated due to mutations in the Raf family member B-Raf or to alterations in upstream Raf regulators, including Ras and receptor tyrosine kinases.  First-generation Raf inhibitors, such as vemurafenib and dabrafenib, have yielded dramatic responses in malignant melanomas contg. B-Raf mutations; however, their overall usefulness has been limited by both intrinsic and acquired drug resistance.  In particular, issues related to the dimerization of the Raf kinases can impact the efficacy of these compds. and are a primary cause of drug resistance.  Here, we will review the importance of Raf dimerization in cell signalling as well as its effects on Raf inhibitor therapy, and we will present the new strategies that are being pursued to overcome the 'Raf Dimer Dilemma'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHTShTLpMLiLVg90H21EOLACvtfcHk0lj5E9VDucZYpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFKhu7vL&md5=186dbe3ee9006a384d9b50831000e144</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2017.399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2017.399%26sid%3Dliteratum%253Aachs%26aulast%3DDurrant%26aufirst%3DD.%2BE.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26atitle%3DTargeting%2520the%2520Raf%2520kinases%2520in%2520human%2520cancer%253A%2520the%2520Raf%2520dimer%2520dilemma%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2018%26volume%3D118%26spage%3D3%26epage%3D8%26doi%3D10.1038%2Fbjc.2017.399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span> <span> </span><span class="NLM_article-title">The clinical development of MEK inhibitors</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">385</span>– <span class="NLM_lpage">400</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2014.83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2Fnrclinonc.2014.83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=24840079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVyqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=385-400&author=Y.+Zhaoauthor=A.+A.+Adjei&title=The+clinical+development+of+MEK+inhibitors&doi=10.1038%2Fnrclinonc.2014.83"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical development of MEK inhibitors</span></div><div class="casAuthors">Zhao, Yujie; Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">385-400</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Aberrant activation of the RAS-RAF-MEK-ERK1/2 pathway occurs in more than 30% of human cancers.  As part of this pathway, MEK1 and MEK2 have crucial roles in tumorigenesis, cell proliferation and inhibition of apoptosis and, therefore, MEK1/2 inhibition is an attractive therapeutic strategy in a no. of cancers.  Highly selective and potent non-ATP-competitive allosteric MEK1/2 inhibitors have been developed and assessed in numerous clin. studies over the past decade.  These agents are not efficacious in a broad range of unselected cancers, although single-agent antitumor activity has been detected mainly in tumors that harbor mutations in genes encoding the members of the RAS and RAF protein families, such as certain melanomas.  Combinations of MEK1/2 inhibitors and cytotoxic chemotherapy, and/or other targeted agents are being studied to expand the efficacy of this class of agents.  Identifying predictive biomarkers, and delineating de novo and acquired resistance mechanisms are essential for the future clin. development of MEK inhibitors.  We discuss the clin. experience with MEK inhibitors to date, and consider the novel approaches to MEK-inhibitor therapy that might improve outcomes and lead to the wider use of such treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjbK3B6OzVbVg90H21EOLACvtfcHk0lj5E9VDucZYpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVyqtbo%253D&md5=c81e0a5f52a8d4d482b7d617901d67eb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2014.83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2014.83%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DThe%2520clinical%2520development%2520of%2520MEK%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D11%26spage%3D385%26epage%3D400%26doi%3D10.1038%2Fnrclinonc.2014.83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Restaino, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayananth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNunzio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windsor, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angagaw, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinheiro, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipps, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paliwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daublain, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutterbach, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philippar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siliphaivanh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschmeier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicklin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samatar, A. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1158%2F2159-8290.CD-13-0070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=23614898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=742-750&author=E.+J.+Morrisauthor=S.+Jhaauthor=C.+R.+Restainoauthor=P.+Dayananthauthor=H.+Zhuauthor=A.+Cooperauthor=D.+Carrauthor=Y.+Dengauthor=W.+Jinauthor=S.+Blackauthor=B.+Longauthor=J.+Liuauthor=E.+DiNunzioauthor=W.+Windsorauthor=R.+Zhangauthor=S.+Zhaoauthor=M.+H.+Angagawauthor=E.+M.+Pinheiroauthor=J.+Desaiauthor=L.+Xiaoauthor=G.+Shippsauthor=A.+Hruzaauthor=J.+Wangauthor=J.+Kellyauthor=S.+Paliwalauthor=X.+Gaoauthor=B.+S.+Babuauthor=L.+Zhuauthor=P.+Daublainauthor=L.+Zhangauthor=B.+A.+Lutterbachauthor=M.+R.+Pelletierauthor=U.+Philipparauthor=P.+Siliphaivanhauthor=D.+Witterauthor=P.+Kirschmeierauthor=W.+R.+Bishopauthor=D.+Hicklinauthor=D.+G.+Gillilandauthor=L.+Jayaramanauthor=L.+Zawelauthor=S.+Fawellauthor=A.+A.+Samatar&title=Discovery+of+a+novel+ERK+inhibitor+with+activity+in+models+of+acquired+resistance+to+BRAF+and+MEK+inhibitors&doi=10.1158%2F2159-8290.CD-13-0070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors</span></div><div class="casAuthors">Morris, Erick J.; Jha, Sharda; Restaino, Clifford R.; Dayananth, Priya; Zhu, Hugh; Cooper, Alan; Carr, Donna; Deng, Yongi; Jin, Weihong; Black, Stuart; Long, Brian; Liu, Jenny; DiNunzio, Edward; Windsor, William; Zhang, Rumin; Zhao, Shuxia; Angagaw, Minilik H.; Pinheiro, Elaine M.; Desai, Jagdish; Xiao, Li; Shipps, Gerald; Hruza, Alan; Wang, James; Kelly, Joe; Paliwal, Sunil; Gao, Xiaolei; Babu, Boga Sobhana; Zhu, Liang; Daublain, Pierre; Zhang, Ling; Lutterbach, Bart A.; Pelletier, Marc R.; Philippar, Ulrike; Siliphaivanh, Phieng; Witter, David; Kirschmeier, Paul; Bishop, W. Robert; Hicklin, Daniel; Gilliland, D. Gary; Jayaraman, Lata; Zawel, Leigh; Fawell, Stephen; Samatar, Ahmed A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">742-750</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The high frequency of activating RAS or BRAF mutations in cancer provides strong rationale for targeting the mitogen-activated protein kinase (MAPK) pathway.  Selective BRAF and MAP-ERK kinase (MEK) inhibitors have shown clin. efficacy in patients with melanoma.  However, the majority of responses are transient, and resistance is often assocd. with pathway reactivation of the extracellular signal-regulated kinase (ERK) signaling pathway.  Here, we describe the identification and characterization of SCH772984, a novel and selective inhibitor of ERK1/2 that displays behaviors of both type I and type II kinase inhibitors.  SCH772984 has nanomolar cellular potency in tumor cells with mutations in BRAF, NRA5, or KRAS and induces tumor regressions in xenograft models at tolerated doses.  Importantly, SCH772984 effectively inhibited MAPK signaling and cell proliferation in BRAF or MEK inhibitor-resistant models as well as in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors.  These data support the clin. development of ERK inhibitors for tumors refractory to MAPK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4HJ4HhYmLL7Vg90H21EOLACvtfcHk0liUfGZZG_23Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE&md5=1f26a4a5bb1fab64bdd6c38c16b3f4e3</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0070%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DE.%2BJ.%26aulast%3DJha%26aufirst%3DS.%26aulast%3DRestaino%26aufirst%3DC.%2BR.%26aulast%3DDayananth%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DW.%26aulast%3DBlack%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDiNunzio%26aufirst%3DE.%26aulast%3DWindsor%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DAngagaw%26aufirst%3DM.%2BH.%26aulast%3DPinheiro%26aufirst%3DE.%2BM.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DShipps%26aufirst%3DG.%26aulast%3DHruza%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DKelly%26aufirst%3DJ.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DBabu%26aufirst%3DB.%2BS.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDaublain%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLutterbach%26aufirst%3DB.%2BA.%26aulast%3DPelletier%26aufirst%3DM.%2BR.%26aulast%3DPhilippar%26aufirst%3DU.%26aulast%3DSiliphaivanh%26aufirst%3DP.%26aulast%3DWitter%26aufirst%3DD.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DBishop%26aufirst%3DW.%2BR.%26aulast%3DHicklin%26aufirst%3DD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DJayaraman%26aufirst%3DL.%26aulast%3DZawel%26aufirst%3DL.%26aulast%3DFawell%26aufirst%3DS.%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520ERK%2520inhibitor%2520with%2520activity%2520in%2520models%2520of%2520acquired%2520resistance%2520to%2520BRAF%2520and%2520MEK%2520inhibitors%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D742%26epage%3D750%26doi%3D10.1158%2F2159-8290.CD-13-0070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Asati, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahapatra, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharti, S. K.</span></span> <span> </span><span class="NLM_article-title">K-ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.09.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1016%2Fj.ejmech.2016.09.049" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2017&pages=299-314&author=V.+Asatiauthor=D.+K.+Mahapatraauthor=S.+K.+Bharti&title=K-ras+and+its+inhibitors+towards+personalized+cancer+treatment%3A+Pharmacological+and+structural+perspectives&doi=10.1016%2Fj.ejmech.2016.09.049"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.09.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.09.049%26sid%3Dliteratum%253Aachs%26aulast%3DAsati%26aufirst%3DV.%26aulast%3DMahapatra%26aufirst%3DD.%2BK.%26aulast%3DBharti%26aufirst%3DS.%2BK.%26atitle%3DK-ras%2520and%2520its%2520inhibitors%2520towards%2520personalized%2520cancer%2520treatment%253A%2520Pharmacological%2520and%2520structural%2520perspectives%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D125%26spage%3D299%26epage%3D314%26doi%3D10.1016%2Fj.ejmech.2016.09.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Samatar, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">Targeting RAS–ERK signalling in cancer: promises and challenges</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">928</span>– <span class="NLM_lpage">942</span>, <span class="refDoi"> DOI: 10.1038/nrd4281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2Fnrd4281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=25435214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2lsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=928-942&author=A.+A.+Samatarauthor=P.+I.+Poulikakos&title=Targeting+RAS%E2%80%93ERK+signalling+in+cancer%3A+promises+and+challenges&doi=10.1038%2Fnrd4281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAS-ERK signalling in cancer: promises and challenges</span></div><div class="casAuthors">Samatar, Ahmed A.; Poulikakos, Poulikos I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">928-942</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumors, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes.  Recently, the use of compds. targeting components of ERK signalling, such as RAF or MEK inhibitors, has led to substantial improvement in clin. outcome in metastatic melanoma and has shown promising clin. activity in addnl. tumor types.  However, response rates are highly variable and the efficacy of these drugs is primarily limited by the development of resistance.  Both intrinsic and acquired resistance to RAF and MEK inhibitors are frequently assocd. with the persistence of ERK signalling in the presence of the drug, implying the need for more innovative approaches to target the pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL4UeXNUJnYbVg90H21EOLACvtfcHk0liUfGZZG_23Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2lsrrI&md5=ab4038893612f438cf4406680ab2e4f4</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1038%2Fnrd4281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4281%26sid%3Dliteratum%253Aachs%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DTargeting%2520RAS%25E2%2580%2593ERK%2520signalling%2520in%2520cancer%253A%2520promises%2520and%2520challenges%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D928%26epage%3D942%26doi%3D10.1038%2Fnrd4281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fruman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rommel, C.</span></span> <span> </span><span class="NLM_article-title">PI3K and cancer: lessons, challenges and opportunities</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1038/nrd4204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2Fnrd4204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=24481312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=140-156&author=D.+A.+Frumanauthor=C.+Rommel&title=PI3K+and+cancer%3A+lessons%2C+challenges+and+opportunities&doi=10.1038%2Fnrd4204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K and cancer: lessons, challenges and opportunities</span></div><div class="casAuthors">Fruman, David A.; Rommel, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-156</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The central role of phosphoinositide 3-kinase (PI3K) activation in tumor cell biol. has prompted a sizeable effort to target PI3K and/or downstream kinases such as AKT and mammalian target of rapamycin (mTOR) in cancer.  However, emerging clin. data show limited single-agent activity of inhibitors targeting PI3K, AKT or mTOR at tolerated doses.  One exception is the response to PI3Kδ inhibitors in chronic lymphocytic leukemia, where a combination of cell-intrinsic and -extrinsic activities drive efficacy.  Here, we review key challenges and opportunities for the clin. development of inhibitors targeting the PI3K-AKT-mTOR pathway.  Through a greater focus on patient selection, increased understanding of immune modulation and strategic application of rational combinations, it should be possible to realize the potential of this promising class of targeted anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlD2rY54m9LbVg90H21EOLACvtfcHk0lhu9_P437J4cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D&md5=c4f6b4b9f9fcacd6ef55eb17d3a4f425</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrd4204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4204%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%2BA.%26aulast%3DRommel%26aufirst%3DC.%26atitle%3DPI3K%2520and%2520cancer%253A%2520lessons%252C%2520challenges%2520and%2520opportunities%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D140%26epage%3D156%26doi%3D10.1038%2Fnrd4204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karoulia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavathiotis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">New perspectives for targeting RAF kinase in human cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">676</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1038/nrc.2017.79</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2Fnrc.2017.79" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=28984291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Sqt7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=676-691&author=Z.+Karouliaauthor=E.+Gavathiotisauthor=P.+I.+Poulikakos&title=New+perspectives+for+targeting+RAF+kinase+in+human+cancer&doi=10.1038%2Fnrc.2017.79"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">New perspectives for targeting RAF kinase in human cancer</span></div><div class="casAuthors">Karoulia, Zoi; Gavathiotis, Evripidis; Poulikakos, Poulikos I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">676-691</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The discovery that a subset of human tumors is dependent on mutationally deregulated BRAF kinase intensified the development of RAF inhibitors to be used as potential therapeutics.  The US Food and Drug Administration (FDA)-approved second-generation RAF inhibitors vemurafenib and dabrafenib have elicited remarkable responses and improved survival of patients with BRAF-V600E/K melanoma, but their effectiveness is limited by resistance.  Beyond melanoma, current clin. RAF inhibitors show modest efficacy when used for colorectal and thyroid BRAF-V600E tumors or for tumors harboring BRAF alterations other than the V600 mutation.  Accumulated exptl. and clin. evidence indicates that the complex biochem. mechanisms of RAF kinase signalling account both for the effectiveness of RAF inhibitors and for the various mechanisms of tumor resistance to them.  Recently, a no. of next-generation RAF inhibitors, with diverse structural and biochem. properties, have entered preclin. and clin. development.  In this Review, we discuss the current understanding of RAF kinase regulation, mechanisms of inhibitor action and related clin. resistance to these drugs.  The recent elucidation of crit. structural and biochem. aspects of RAF inhibitor action, combined with the availability of a no. of structurally diverse RAF inhibitors currently in preclin. and clin. development, will enable the design of more effective RAF inhibitors and RAF-inhibitor-based therapeutic strategies, tailored to different clin. contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEUrKAljS7SrVg90H21EOLACvtfcHk0lhu9_P437J4cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Sqt7fN&md5=7e8ee4222467a2d5c12b23ccce99fc62</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2017.79&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2017.79%26sid%3Dliteratum%253Aachs%26aulast%3DKaroulia%26aufirst%3DZ.%26aulast%3DGavathiotis%26aufirst%3DE.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DNew%2520perspectives%2520for%2520targeting%2520RAF%2520kinase%2520in%2520human%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2017%26volume%3D17%26spage%3D676%26epage%3D691%26doi%3D10.1038%2Fnrc.2017.79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klochkov, S. G.</span>; <span class="NLM_string-name">Neganova, M. E.</span>; <span class="NLM_string-name">Yarla, N. S.</span>; <span class="NLM_string-name">Parvathaneni, M.</span>; <span class="NLM_string-name">Sharma, B.</span>; <span class="NLM_string-name">Tarasov, V. V.</span>; <span class="NLM_string-name">Barreto, G.</span>; <span class="NLM_string-name">Bachurin, S. O.</span>; <span class="NLM_string-name">Ashraf, G. M.</span>; <span class="NLM_string-name">Aliev, G.</span></span> <span> </span><span class="NLM_article-title">Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy</span>.  <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span> <span class="refDoi"> DOI: 10.1016/j.semcancer.2017.10.010</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1016%2Fj.semcancer.2017.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=29100957" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=S.+G.+Klochkov&author=M.+E.+Neganova&author=N.+S.+Yarla&author=M.+Parvathaneni&author=B.+Sharma&author=V.+V.+Tarasov&author=G.+Barreto&author=S.+O.+Bachurin&author=G.+M.+Ashraf&author=G.+Aliev&title=Implications+of+farnesyltransferase+and+its+inhibitors+as+a+promising+strategy+for+cancer+therapy&doi=10.1016%2Fj.semcancer.2017.10.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2017.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2017.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DKlochkov%26aufirst%3DS.%2BG.%26atitle%3DImplications%2520of%2520farnesyltransferase%2520and%2520its%2520inhibitors%2520as%2520a%2520promising%2520strategy%2520for%2520cancer%2520therapy%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2017%26doi%3D10.1016%2Fj.semcancer.2017.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scholl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fröhling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinzel, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadlow, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaswamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Root, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacks, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">834</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1016%2Fj.cell.2009.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=19490892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVCltLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2009&pages=821-834&author=C.+Schollauthor=S.+Fr%C3%B6hlingauthor=I.+F.+Dunnauthor=A.+C.+Schinzelauthor=D.+A.+Barbieauthor=S.+Y.+Kimauthor=S.+J.+Silverauthor=P.+Tamayoauthor=R.+C.+Wadlowauthor=S.+Ramaswamyauthor=K.+D%C3%B6hnerauthor=L.+Bullingerauthor=P.+Sandyauthor=J.+S.+Boehmauthor=D.+E.+Rootauthor=T.+Jacksauthor=W.+C.+Hahnauthor=D.+G.+Gilliland&title=Synthetic+lethal+interaction+between+oncogenic+KRAS+dependency+and+STK33+suppression+in+human+cancer+cells&doi=10.1016%2Fj.cell.2009.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells</span></div><div class="casAuthors">Scholl, Claudia; Frohling, Stefan; Dunn, Ian F.; Schinzel, Anna C.; Barbie, David A.; Kim, So Young; Silver, Serena J.; Tamayo, Pablo; Wadlow, Raymond C.; Ramaswamy, Sridhar; Dohner, Konstanze; Bullinger, Lars; Sandy, Peter; Boehm, Jesse S.; Root, David E.; Jacks, Tyler; Hahn, William C.; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">821-834</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">An alternative to therapeutic targeting of oncogenes is to perform "synthetic lethality" screens for genes that are essential only in the context of specific cancer-causing mutations.  We used high-throughput RNA interference (RNAi) to identify synthetic lethal interactions in cancer cells harboring mutant KRAS, the most commonly mutated human oncogene.  We find that cells that are dependent on mutant KRAS exhibit sensitivity to suppression of the serine/threonine kinase STK33 irresp. of tissue origin, whereas STK33 is not required by KRAS-independent cells.  STK33 promotes cancer cell viability in a kinase activity-dependent manner by regulating the suppression of mitochondrial apoptosis mediated through S6K1-induced inactivation of the death agonist BAD selectively in mutant KRAS-dependent cells.  These observations identify STK33 as a target for treatment of mutant KRAS-driven cancers and demonstrate the potential of RNAi screens for discovering functional dependencies created by oncogenic mutations that may enable therapeutic intervention for cancers with "undruggable" genetic alterations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2ijlOPM8WN7Vg90H21EOLACvtfcHk0lhu9_P437J4cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVCltLc%253D&md5=478f083a4815b8d57cee8d3b07042400</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DScholl%26aufirst%3DC.%26aulast%3DFr%25C3%25B6hling%26aufirst%3DS.%26aulast%3DDunn%26aufirst%3DI.%2BF.%26aulast%3DSchinzel%26aufirst%3DA.%2BC.%26aulast%3DBarbie%26aufirst%3DD.%2BA.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DSilver%26aufirst%3DS.%2BJ.%26aulast%3DTamayo%26aufirst%3DP.%26aulast%3DWadlow%26aufirst%3DR.%2BC.%26aulast%3DRamaswamy%26aufirst%3DS.%26aulast%3DD%25C3%25B6hner%26aufirst%3DK.%26aulast%3DBullinger%26aufirst%3DL.%26aulast%3DSandy%26aufirst%3DP.%26aulast%3DBoehm%26aufirst%3DJ.%2BS.%26aulast%3DRoot%26aufirst%3DD.%2BE.%26aulast%3DJacks%26aufirst%3DT.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DSynthetic%2520lethal%2520interaction%2520between%2520oncogenic%2520KRAS%2520dependency%2520and%2520STK33%2520suppression%2520in%2520human%2520cancer%2520cells%26jtitle%3DCell%26date%3D2009%26volume%3D137%26spage%3D821%26epage%3D834%26doi%3D10.1016%2Fj.cell.2009.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, N. P.</span></span> <span> </span><span class="NLM_article-title">ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">4162</span>– <span class="NLM_lpage">4167</span>, <span class="refDoi"> DOI: 10.1038/onc.2014.350</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2Fonc.2014.350" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=25347744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVWmsLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=4162-4167&author=K.+Mahajanauthor=N.+P.+Mahajan&title=ACK1%2FTNK2+tyrosine+kinase%3A+molecular+signaling+and+evolving+role+in+cancers&doi=10.1038%2Fonc.2014.350"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers</span></div><div class="casAuthors">Mahajan, K.; Mahajan, N. P.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">4162-4167</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulated tyrosine kinase signaling alters cellular homeostasis to drive cancer progression.  The emergence of a non-receptor tyrosine kinase (non-RTK), ACK1 (also known as activated Cdc42-assocd. kinase 1 or TNK2) as an oncogenic kinase, has uncovered novel mechanisms by which tyrosine kinase signaling promotes cancer progression.  Although early studies focused on ACK1 as a cytosolic effector of activated transmembrane RTKs, wherein it shuttles between the cytosol and the nucleus to rapidly transduce extracellular signals from the RTKs to the intracellular effectors, recent data unfold a new aspect of its functionality as an epigenetic regulator.  ACK1 interacts with the estrogen receptor (ER)/histone demethylase KDM3A (JHDM2a) complex, which modifies KDM3A by tyrosine phosphorylation to regulate the transcriptional outcome at HOXA1 locus to promote the growth of tamoxifen-resistant breast cancer.  It is also well established that ACK1 regulates the activity of androgen receptor (AR) by tyrosine phosphorylation to fuel the growth of hormone-refractory prostate cancers.  Further, recent explosion in genomic sequencing has revealed recurrent ACK1 gene amplification and somatic mutations in a variety of human malignancies, providing a mol. basis for its role in neoplastic transformation.  In this review, we will discuss the various facets of ACK1 signaling, including its newly uncovered epigenetic regulator function, which enables cells to bypass the blockade to major survival pathways to promote resistance to std. cancer treatments.  Not surprisingly, cancer cells appear to acquire an 'addiction' to ACK1-mediated survival, particularly under stress conditions, such as growth factor deprivation or genotoxic insults or hormone deprivation.  With the accelerated development of potent and selective ACK1 inhibitors, targeted treatment for cancers harboring aberrant ACK1 activity may soon become a clin. reality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQZA9Fv5H3LLVg90H21EOLACvtfcHk0li3rEkwp_h1ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVWmsLjK&md5=b6376cc52eb148e8726197c14279cdf1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fonc.2014.350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2014.350%26sid%3Dliteratum%253Aachs%26aulast%3DMahajan%26aufirst%3DK.%26aulast%3DMahajan%26aufirst%3DN.%2BP.%26atitle%3DACK1%252FTNK2%2520tyrosine%2520kinase%253A%2520molecular%2520signaling%2520and%2520evolving%2520role%2520in%2520cancers%26jtitle%3DOncogene%26date%3D2015%26volume%3D34%26spage%3D4162%26epage%3D4167%26doi%3D10.1038%2Fonc.2014.350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, N. P.</span></span> <span> </span><span class="NLM_article-title">PI3K-independent AKT activation in cancers: A treasure trove for novel therapeutics</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>227</i></span>,  <span class="NLM_fpage">3178</span>– <span class="NLM_lpage">3184</span>, <span class="refDoi"> DOI: 10.1002/jcp.24065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1002%2Fjcp.24065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=22307544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1KntL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=227&publication_year=2012&pages=3178-3184&author=K.+Mahajanauthor=N.+P.+Mahajan&title=PI3K-independent+AKT+activation+in+cancers%3A+A+treasure+trove+for+novel+therapeutics&doi=10.1002%2Fjcp.24065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K-independent AKT activation in cancers: A treasure trove for novel therapeutics</span></div><div class="casAuthors">Mahajan, Kiran; Mahajan, Nupam P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">227</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3178-3184</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  AKT/PKB serine threonine kinase, a crit. signaling mol. promoting cell growth and survival pathways, is frequently dysregulated in many cancers.  Although phosphatidylinositol-3-OH kinase (PI3K), a lipid kinase, is well characterized as a major regulator of AKT activation in response to a variety of ligands, recent studies highlight a diverse group of tyrosine (Ack1/TNK2, Src, PTK6) and serine/threonine (TBK1, IKBKE, DNAPKcs) kinases that activate AKT directly to promote its pro-proliferative signaling functions.  While some of these alternate AKT activating kinases respond to growth factors, others respond to inflammatory and genotoxic stimuli.  A common theme emerging from these studies is that aberrant or hyperactivation of these alternate kinases is often assocd. with malignancy.  Consequently, evaluating the use of small mol. inhibitors against these alternate AKT activating kinases at earlier stages of cancer therapy may overcome the pressing problem of drug resistance surfacing esp. in patients treated with PI3K inhibitors.  J. Cell. Physiol. 227: 3178-3184, 2012. © 2012 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkNt3Lfr5PxrVg90H21EOLACvtfcHk0li3rEkwp_h1ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1KntL4%253D&md5=3e21f9af43df4cf664fa5a5ff60f9eb8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fjcp.24065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.24065%26sid%3Dliteratum%253Aachs%26aulast%3DMahajan%26aufirst%3DK.%26aulast%3DMahajan%26aufirst%3DN.%2BP.%26atitle%3DPI3K-independent%2520AKT%2520activation%2520in%2520cancers%253A%2520A%2520treasure%2520trove%2520for%2520novel%2520therapeutics%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2012%26volume%3D227%26spage%3D3178%26epage%3D3184%26doi%3D10.1002%2Fjcp.24065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pombo, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehrl, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avruch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zon, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodgett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Force, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyriakis, J. M.</span></span> <span> </span><span class="NLM_article-title">Activation of the SAPK pathway by the human STE20 homologue germinal centre kinase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">750</span>– <span class="NLM_lpage">754</span>, <span class="refDoi"> DOI: 10.1038/377750a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2F377750a0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=1995&pages=750-754&author=C.+M.+Pomboauthor=J.+H.+Kehrlauthor=I.+S%C3%A1nchezauthor=P.+Katzauthor=J.+Avruchauthor=L.+I.+Zonauthor=J.+R.+Woodgettauthor=T.+Forceauthor=J.+M.+Kyriakis&title=Activation+of+the+SAPK+pathway+by+the+human+STE20+homologue+germinal+centre+kinase&doi=10.1038%2F377750a0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2F377750a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F377750a0%26sid%3Dliteratum%253Aachs%26aulast%3DPombo%26aufirst%3DC.%2BM.%26aulast%3DKehrl%26aufirst%3DJ.%2BH.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DI.%26aulast%3DKatz%26aufirst%3DP.%26aulast%3DAvruch%26aufirst%3DJ.%26aulast%3DZon%26aufirst%3DL.%2BI.%26aulast%3DWoodgett%26aufirst%3DJ.%2BR.%26aulast%3DForce%26aufirst%3DT.%26aulast%3DKyriakis%26aufirst%3DJ.%2BM.%26atitle%3DActivation%2520of%2520the%2520SAPK%2520pathway%2520by%2520the%2520human%2520STE20%2520homologue%2520germinal%2520centre%2520kinase%26jtitle%3DNature%26date%3D1995%26volume%3D377%26spage%3D750%26epage%3D754%26doi%3D10.1038%2F377750a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span> <span> </span><span class="NLM_article-title">A type-II kinase inhibitor capable of inhibiting the T315I “gatekeeper” mutant of Bcr-Abl</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5439</span>– <span class="NLM_lpage">5448</span>, <span class="refDoi"> DOI: 10.1021/jm901808w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901808w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5439-5448&author=H.+G.+Choiauthor=P.+Renauthor=F.+Adrianauthor=F.+Sunauthor=H.+S.+Leeauthor=X.+Wangauthor=Q.+Dingauthor=G.+Zhangauthor=Y.+Xieauthor=J.+Zhangauthor=Y.+Liuauthor=T.+Tuntlandauthor=M.+Warmuthauthor=P.+W.+Manleyauthor=J.+Mestanauthor=N.+S.+Grayauthor=T.+Sim&title=A+type-II+kinase+inhibitor+capable+of+inhibiting+the+T315I+%E2%80%9Cgatekeeper%E2%80%9D+mutant+of+Bcr-Abl&doi=10.1021%2Fjm901808w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm901808w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901808w%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DAdrian%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSim%26aufirst%3DT.%26atitle%3DA%2520type-II%2520kinase%2520inhibitor%2520capable%2520of%2520inhibiting%2520the%2520T315I%2520%25E2%2580%259Cgatekeeper%25E2%2580%259D%2520mutant%2520of%2520Bcr-Abl%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5439%26epage%3D5448%26doi%3D10.1021%2Fjm901808w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span>; <span class="NLM_string-name">Lee, H.
S.</span>; <span class="NLM_string-name">Ren, P.</span>; <span class="NLM_string-name">Ding, Q.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Uno, T.</span>; <span class="NLM_string-name">Zhang, G.</span>; <span class="NLM_string-name">Liu, Y.</span>; <span class="NLM_string-name">Li, B.</span>; <span class="NLM_string-name">Li, L.</span>; <span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Compounds and Compositions as Protein Kinase Inhibitors</span>. WO Patent <span class="NLM_patent">2005/011597</span>, Feb 10, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=T.+Sim&author=H.%0AS.+Lee&author=P.+Ren&author=Q.+Ding&author=X.+Wang&author=T.+Uno&author=G.+Zhang&author=Y.+Liu&author=B.+Li&author=L.+Li&author=N.+S.+Gray&title=Compounds+and+Compositions+as+Protein+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSim%26aufirst%3DT.%26atitle%3DCompounds%2520and%2520Compositions%2520as%2520Protein%2520Kinase%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xian, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">A structure-guided approach to creating covalent FGFR inhibitors</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1016%2Fj.chembiol.2010.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=20338520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=285-295&author=W.+Zhouauthor=W.+Hurauthor=U.+McDermottauthor=A.+Duttauthor=W.+Xianauthor=S.+B.+Ficarroauthor=J.+Zhangauthor=S.+V.+Sharmaauthor=J.+Bruggeauthor=M.+Meyersonauthor=J.+Settlemanauthor=N.+S.+Gray&title=A+structure-guided+approach+to+creating+covalent+FGFR+inhibitors&doi=10.1016%2Fj.chembiol.2010.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">A Structure-Guided Approach to Creating Covalent FGFR Inhibitors</span></div><div class="casAuthors">Zhou, Wenjun; Hur, Wooyoung; McDermott, Ultan; Dutt, Amit; Xian, Wa; Ficarro, Scott B.; Zhang, Jianming; Sharma, Sreenath V.; Brugge, Joan; Meyerson, Matthew; Settleman, Jeffrey; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-295</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The fibroblast growth factor receptor tyrosine kinases (FGFR1, 2, 3, and 4) represent promising therapeutic targets in a no. of cancers.  We have developed the first potent and selective irreversible inhibitor of FGFR1, 2, 3, and 4, which we named FIIN-1 that forms a covalent bond with cysteine 486 located in the P loop of the FGFR1 ATP binding site.  We demonstrated that the inhibitor potently inhibits Tel-FGFR1-transformed Ba/F3 cells (EC50 = 14 nM) as well as numerous FGFR-dependent cancer cell lines.  A biotin-derivatized version of the inhibitor, FIIN-1-biotin, was shown to covalently label FGFR1 at Cys486.  FIIN-1 is a useful probe of FGFR-dependent cellular phenomena and may provide a starting point of the development of therapeutically relevant irreversible inhibitors of wild-type and drug-resistant forms of FGFR kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqxMZh8QQP47Vg90H21EOLACvtfcHk0lit5RDas2_Pvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D&md5=0b7b084a073b1c6f30f38565a0e4db81</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DDutt%26aufirst%3DA.%26aulast%3DXian%26aufirst%3DW.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBrugge%26aufirst%3DJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520structure-guided%2520approach%2520to%2520creating%2520covalent%2520FGFR%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D285%26epage%3D295%26doi%3D10.1016%2Fj.chembiol.2010.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guagnano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spanka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Douget, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brueggen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wartmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghausen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drueckes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graus Porta, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-(2, 6-dichloro-3, 5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7066</span>– <span class="NLM_lpage">7083</span>, <span class="refDoi"> DOI: 10.1021/jm2006222</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2006222" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7066-7083&author=V.+Guagnanoauthor=P.+Furetauthor=C.+Spankaauthor=V.+Bordasauthor=M.+Le+Dougetauthor=C.+Stammauthor=J.+Brueggenauthor=M.+R.+Jensenauthor=C.+Schnellauthor=H.+Schmidauthor=M.+Wartmannauthor=J.+Berghausenauthor=P.+Drueckesauthor=A.+Zimmerlinauthor=D.+Bussiereauthor=J.+Murrayauthor=D.+Graus+Porta&title=Discovery+of+3-%282%2C+6-dichloro-3%2C+5-dimethoxy-phenyl%29-1-%7B6-%5B4-%284-ethyl-piperazin-1-yl%29-phenylamino%5D-pyrimidin-4-yl%7D-1-methyl-urea+%28NVP-BGJ398%29%2C+a+potent+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+family+of+receptor+tyrosine+kinase&doi=10.1021%2Fjm2006222"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm2006222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2006222%26sid%3Dliteratum%253Aachs%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DSpanka%26aufirst%3DC.%26aulast%3DBordas%26aufirst%3DV.%26aulast%3DLe%2BDouget%26aufirst%3DM.%26aulast%3DStamm%26aufirst%3DC.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DSchmid%26aufirst%3DH.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DBerghausen%26aufirst%3DJ.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DGraus%2BPorta%26aufirst%3DD.%26atitle%3DDiscovery%2520of%25203-%25282%252C%25206-dichloro-3%252C%25205-dimethoxy-phenyl%2529-1-%257B6-%255B4-%25284-ethyl-piperazin-1-yl%2529-phenylamino%255D-pyrimidin-4-yl%257D-1-methyl-urea%2520%2528NVP-BGJ398%2529%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520family%2520of%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7066%26epage%3D7083%26doi%3D10.1021%2Fjm2006222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomanbhoy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurbani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patricelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herhaus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ham, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrlage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapkota, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westover, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1021/jm500480k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500480k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyiurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=183-196&author=L.+Tanauthor=T.+Nomanbhoyauthor=D.+Gurbaniauthor=M.+Patricelliauthor=J.+Hunterauthor=J.+Gengauthor=L.+Herhausauthor=J.+Zhangauthor=E.+Paulsauthor=Y.+Hamauthor=H.+G.+Choiauthor=T.+Xieauthor=X.+Dengauthor=S.+J.+Buhrlageauthor=T.+Simauthor=P.+Cohenauthor=G.+Sapkotaauthor=K.+D.+Westoverauthor=N.+S.+Gray&title=Discovery+of+type+II+inhibitors+of+TGF%CE%B2-activated+kinase+1+%28TAK1%29+and+mitogen-activated+protein+kinase+kinase+kinase+kinase+2+%28MAP4K2%29&doi=10.1021%2Fjm500480k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Type II Inhibitors of TGFβ-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2)</span></div><div class="casAuthors">Tan, Li; Nomanbhoy, Tyzoon; Gurbani, Deepak; Patricelli, Matthew; Hunter, John; Geng, Jiefei; Herhaus, Lina; Zhang, Jianming; Pauls, Eduardo; Ham, Youngjin; Choi, Hwan Geun; Xie, Ting; Deng, Xianming; Buhrlage, Sara J.; Sim, Taebo; Cohen, Philip; Sapkota, Gopal; Westover, Kenneth D.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">183-196</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors developed a pharmacophore model for type II inhibitors that was used to guide the construction of a library of kinase inhibitors.  Kinome-wide selectivity profiling of the library resulted in the identification of a series of 4-substituted 1H-pyrrolo[2,3-b]pyridines that exhibited potent inhibitory activity against two mitogen-activated protein kinases (MAPKs), TAK1 (MAP3K7) and MAP4K2, as well as pharmacol. well interrogated kinases such as p38α (MAPK14) and ABL.  Further investigation of the structure-activity relationship (SAR) resulted in the identification effect two potent dual TAK1 and MAP4K2 inhibitors such as I as well as two MAP4K2 selective inhibitors such as II.  Some of these inhibitors possess good pharmacokinetic properties that will enable their use in pharmacol. studies in vivo.  A 2.4 Å cocrystal structure of TAK1 in complex with 1 confirms that the activation loop of TAK1 assumes the DFG-out conformation characteristic of type II inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzjzVF_V_qSLVg90H21EOLACvtfcHk0li76F4I-6TkLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyiurrJ&md5=288a6be4b9b4a5a6a5b925673cadd47a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm500480k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500480k%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DNomanbhoy%26aufirst%3DT.%26aulast%3DGurbani%26aufirst%3DD.%26aulast%3DPatricelli%26aufirst%3DM.%26aulast%3DHunter%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DJ.%26aulast%3DHerhaus%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPauls%26aufirst%3DE.%26aulast%3DHam%26aufirst%3DY.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DSapkota%26aufirst%3DG.%26aulast%3DWestover%26aufirst%3DK.%2BD.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520type%2520II%2520inhibitors%2520of%2520TGF%25CE%25B2-activated%2520kinase%25201%2520%2528TAK1%2529%2520and%2520mitogen-activated%2520protein%2520kinase%2520kinase%2520kinase%2520kinase%25202%2520%2528MAP4K2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D183%26epage%3D196%26doi%3D10.1021%2Fjm500480k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Meijere, A.</span></span> <span> </span><span class="NLM_article-title">Bonding properties of cyclopropane and their chemical consequences</span>. <i>Angew. Chem., Int. Ed. Engl.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">826</span>, <span class="refDoi"> DOI: 10.1002/anie.197908093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1002%2Fanie.197908093" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1979&pages=809-826&author=A.+de%0AMeijere&title=Bonding+properties+of+cyclopropane+and+their+chemical+consequences&doi=10.1002%2Fanie.197908093"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fanie.197908093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.197908093%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BMeijere%26aufirst%3DA.%26atitle%3DBonding%2520properties%2520of%2520cyclopropane%2520and%2520their%2520chemical%2520consequences%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%2520Engl.%26date%3D1979%26volume%3D18%26spage%3D809%26epage%3D826%26doi%3D10.1002%2Fanie.197908093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span> <span> </span><span class="NLM_article-title">A pyrazolo [3, 4-<i>d</i>] pyrimidin-4-amine derivative containing an isoxazole moiety is a selective and potent inhibitor of RET gatekeeper mutants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">373</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01522</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01522" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=358-373&author=H.+Yoonauthor=Y.+Kwakauthor=S.+Choiauthor=H.+Choauthor=N.+D.+Kimauthor=T.+Sim&title=A+pyrazolo+%5B3%2C+4-d%5D+pyrimidin-4-amine+derivative+containing+an+isoxazole+moiety+is+a+selective+and+potent+inhibitor+of+RET+gatekeeper+mutants&doi=10.1021%2Facs.jmedchem.5b01522"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01522%26sid%3Dliteratum%253Aachs%26aulast%3DYoon%26aufirst%3DH.%26aulast%3DKwak%26aufirst%3DY.%26aulast%3DChoi%26aufirst%3DS.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DSim%26aufirst%3DT.%26atitle%3DA%2520pyrazolo%2520%255B3%252C%25204-d%255D%2520pyrimidin-4-amine%2520derivative%2520containing%2520an%2520isoxazole%2520moiety%2520is%2520a%2520selective%2520and%2520potent%2520inhibitor%2520of%2520RET%2520gatekeeper%2520mutants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D358%26epage%3D373%26doi%3D10.1021%2Facs.jmedchem.5b01522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Hare, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loriaux, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbin, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaramoorthi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snodgrass, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Commodore, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span> <span> </span><span class="NLM_article-title">AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2009.09.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1016%2Fj.ccr.2009.09.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=19878872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFKltb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=401-412&author=T.+O%E2%80%99Hareauthor=W.+C.+Shakespeareauthor=X.+Zhuauthor=C.+A.+Eideauthor=V.+M.+Riveraauthor=F.+Wangauthor=L.+T.+Adrianauthor=T.+Zhouauthor=W.+S.+Huangauthor=Q.+Xuauthor=C.+A.+Metcalfauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=A.+S.+Corbinauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+A.+Keatsauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=M.+Thomasauthor=D.+Zhouauthor=J.+Snodgrassauthor=L.+Commodoreauthor=T.+K.+Sawyerauthor=D.+C.+Dalgarnoauthor=M.+W.+N.+Deiningerauthor=B.+J.+Drukerauthor=T.+Clackson&title=AP24534%2C+a+pan-BCR-ABL+inhibitor+for+chronic+myeloid+leukemia%2C+potently+inhibits+the+T315I+mutant+and+overcomes+mutation-based+resistance&doi=10.1016%2Fj.ccr.2009.09.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</span></div><div class="casAuthors">O'Hare, Thomas; Shakespeare, William C.; Zhu, Xiaotian; Eide, Christopher A.; Rivera, Victor M.; Wang, Frank; Adrian, Lauren T.; Zhou, Tianjun; Huang, Wei-Sheng; Xu, Qihong; Metcalf, Chester A., III; Tyner, Jeffrey W.; Loriaux, Marc M.; Corbin, Amie S.; Wardwell, Scott; Ning, Yaoyu; Keats, Jeffrey A.; Wang, Yihan; Sundaramoorthi, Raji; Thomas, Mathew; Zhou, Dong; Snodgrass, Joseph; Commodore, Lois; Sawyer, Tomi K.; Dalgarno, David C.; Deininger, Michael W. N.; Druker, Brian J.; Clackson, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">401-412</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to relapse and a switch to second-line therapy with nilotinib or dasatinib.  Despite three approved therapeutic options, the cross-resistant BCR-ABLT315I mutation and compd. mutants selected on sequential inhibitor therapy remain major clin. challenges.  We report design and preclin. evaluation of AP24534, a potent, orally available multitargeted kinase inhibitor active against T315I and other BCR-ABL mutants.  AP24534 inhibited all tested BCR-ABL mutants in cellular and biochem. assays, suppressed BCR-ABLT315I-driven tumor growth in mice, and completely abrogated resistance in cell-based mutagenesis screens.  Our work supports clin. evaluation of AP24534 as a pan-BCR-ABL inhibitor for treatment of CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox3g7ZYNXwLbVg90H21EOLACvtfcHk0li76F4I-6TkLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFKltb3N&md5=62a383734fc345b97647ba71aa7aee04</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2009.09.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2009.09.028%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DSnodgrass%26aufirst%3DJ.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%2BN.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26atitle%3DAP24534%252C%2520a%2520pan-BCR-ABL%2520inhibitor%2520for%2520chronic%2520myeloid%2520leukemia%252C%2520potently%2520inhibits%2520the%2520T315I%2520mutant%2520and%2520overcomes%2520mutation-based%2520resistance%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26spage%3D401%26epage%3D412%26doi%3D10.1016%2Fj.ccr.2009.09.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugochukwu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Delft, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2359</span>– <span class="NLM_lpage">2367</span>, <span class="refDoi"> DOI: 10.1021/jm101506n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101506n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2359-2367&author=E.+Salahauthor=E.+Ugochukwuauthor=A.+J.+Barrauthor=F.+von+Delftauthor=S.+Knappauthor=J.+M.+Elkins&title=Crystal+structures+of+ABL-related+gene+%28ABL2%29+in+complex+with+imatinib%2C+tozasertib+%28VX-680%29%2C+and+a+type+I+inhibitor+of+the+triazole+carbothioamide+class&doi=10.1021%2Fjm101506n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm101506n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101506n%26sid%3Dliteratum%253Aachs%26aulast%3DSalah%26aufirst%3DE.%26aulast%3DUgochukwu%26aufirst%3DE.%26aulast%3DBarr%26aufirst%3DA.%2BJ.%26aulast%3Dvon%2BDelft%26aufirst%3DF.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26atitle%3DCrystal%2520structures%2520of%2520ABL-related%2520gene%2520%2528ABL2%2529%2520in%2520complex%2520with%2520imatinib%252C%2520tozasertib%2520%2528VX-680%2529%252C%2520and%2520a%2520type%2520I%2520inhibitor%2520of%2520the%2520triazole%2520carbothioamide%2520class%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2359%26epage%3D2367%26doi%3D10.1021%2Fjm101506n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otwinowski, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minor, W.</span></span> <span> </span><span class="NLM_article-title">Processing of X-ray diffraction data collected in oscillation mode</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1016/S0076-6879(97)76066-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=27754618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=307-326&author=Z.+Otwinowskiauthor=W.+Minor&title=Processing+of+X-ray+diffraction+data+collected+in+oscillation+mode&doi=10.1016%2FS0076-6879%2897%2976066-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of x-ray diffraction data collected in oscillation mode</span></div><div class="casAuthors">Otwinowski, Zbyszek; Minor, Wladek</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">Macromolecular Crystallography, Part A</span>),
    <span class="NLM_cas:pages">307-326</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Macromol. crystallog. is an iterative process.  Rarely do the first crystals provide all the necessary data to solve the biol. problem being studied.  Each step benefits from experience learned in previous steps.  To monitor the progress, the HKL package provides 2 tools: (1) statistics, both weighted (χ2) and unweighted (R-merge), are provided, and the Bayesian reasoning and multicomponent error model facilitates obtaining the proper error ests. and (2) visualization of the process plays a double role by helping the operator to confirm that the process of data redn., including the resulting statistics, is correct, and allowing one to evaluate problems for which there are no good statistical criteria.  Visualization also provides confidence that the point of diminishing returns in data collection and redn. has been reached.  At that point, the effort should be directed to solving the structure.  The methods presented here have been applied to solve a large variety of problems, from inorg. mols. with 5 Å unit cell to rotavirus of 700 Å diam. crystd. in 700 × 1000 × 1400 Å cell.  Overall quality of the method was tested by many researchers by successful application of the programs to MAD structure detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3fvBOHqhhrVg90H21EOLACvtfcHk0lgxit7ojF4APw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D&md5=c9536971d4e32cc35352c40fb9368131</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DMinor%26aufirst%3DW.%26atitle%3DProcessing%2520of%2520X-ray%2520diffraction%2520data%2520collected%2520in%2520oscillation%2520mode%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326%26doi%3D10.1016%2FS0076-6879%2897%2976066-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skubák, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebedev, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannu, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A. A.</span></span> <span> </span><span class="NLM_article-title">REFMAC5 for the refinement of macromolecular crystal structures</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1107/S0907444911001314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1107%2FS0907444911001314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=21460454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=355-367&author=G.+N.+Murshudovauthor=P.+Skub%C3%A1kauthor=A.+A.+Lebedevauthor=N.+S.+Pannuauthor=R.+A.+Steinerauthor=R.+A.+Nichollsauthor=M.+D.+Winnauthor=F.+Longauthor=A.+A.+Vagin&title=REFMAC5+for+the+refinement+of+macromolecular+crystal+structures&doi=10.1107%2FS0907444911001314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">REFMAC5 for the refinement of macromolecular crystal structures</span></div><div class="casAuthors">Murshudov, Garib N.; Skubak, Pavol; Lebedev, Andrey A.; Pannu, Navraj S.; Steiner, Roberto A.; Nicholls, Robert A.; Winn, Martyn D.; Long, Fei; Vagin, Alexei A.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">355-367</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">This paper describes various components of the macromol. crystallog. refinement program REFMAC5, which is distributed as part of the CCP4 suite.  REFMAC5 utilizes different likelihood functions depending on the diffraction data employed (amplitudes or intensities), the presence of twinning and the availability of SAD/SIRAS exptl. diffraction data.  To ensure chem. and structural integrity of the refined model, REFMAC5 offers several classes of restraints and choices of model parameterization.  Reliable models at resolns. at least as low as 4 Å can be achieved thanks to low-resoln. refinement tools such as secondary-structure restraints, restraints to known homologous structures, automatic global and local NCS restraints, 'jelly-body' restraints and the use of novel long-range restraints on at. displacement parameters (ADPs) based on the Kullback-Leibler divergence.  REFMAC5 addnl. offers TLS parameterization and, when high-resoln. data are available, fast refinement of anisotropic ADPs.  Refinement in the presence of twinning is performed in a fully automated fashion.  REFMAC5 is a flexible and highly optimized refinement package that is ideally suited for refinement across the entire resoln. spectrum encountered in macromol. crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Jq-i2qIq5rVg90H21EOLACvtfcHk0lgxit7ojF4APw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqtbk%253D&md5=f8f3202d246908500057ad7c71015b7b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1107%2FS0907444911001314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444911001314%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DSkub%25C3%25A1k%26aufirst%3DP.%26aulast%3DLebedev%26aufirst%3DA.%2BA.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DSteiner%26aufirst%3DR.%2BA.%26aulast%3DNicholls%26aufirst%3DR.%2BA.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DLong%26aufirst%3DF.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26atitle%3DREFMAC5%2520for%2520the%2520refinement%2520of%2520macromolecular%2520crystal%2520structures%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D355%26epage%3D367%26doi%3D10.1107%2FS0907444911001314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohkamp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Features and development of Coot</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lgxit7ojF4APw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b','cit2c','cit2d','cit2e'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6a','cit6b','cit6c'],'ref7':['cit7a','cit7b','cit7c'],'ref8':['cit8'],'ref9':['cit9a','cit9b'],'ref10':['cit10a','cit10b'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13a','cit13b'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Namkyoung  Kim</span>, <span class="hlFld-ContribAuthor ">Injae  Shin</span>, <span class="hlFld-ContribAuthor ">Jiwon  Lee</span>, <span class="hlFld-ContribAuthor ">Eunhye  Jeon</span>, <span class="hlFld-ContribAuthor ">Younghoon  Kim</span>, <span class="hlFld-ContribAuthor ">Seongshick  Ryu</span>, <span class="hlFld-ContribAuthor ">Eunhye  Ju</span>, <span class="hlFld-ContribAuthor ">Wonjeong  Cho</span>, <span class="hlFld-ContribAuthor ">Taebo  Sim</span>. </span><span class="cited-content_cbyCitation_article-title">Novel and Potent Small Molecules against Melanoma Harboring BRAF Class I/II/III Mutants for Overcoming Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (7)
                                     , 3783. <a href="https://doi.org/10.3390/ijms22073783" title="DOI URL">https://doi.org/10.3390/ijms22073783</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22073783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22073783%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DNovel%252Band%252BPotent%252BSmall%252BMolecules%252Bagainst%252BMelanoma%252BHarboring%252BBRAF%252BClass%252BI%25252FII%25252FIII%252BMutants%252Bfor%252BOvercoming%252BDrug%252BResistance%26aulast%3DKim%26aufirst%3DNamkyoung%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D7%26spage%3D3783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shaista  Amin</span>, <span class="hlFld-ContribAuthor ">M. Mumtaz  Alam</span>, <span class="hlFld-ContribAuthor ">Mymoona  Akhter</span>, <span class="hlFld-ContribAuthor ">A. K.  Najmi</span>, <span class="hlFld-ContribAuthor ">Nadeem  Siddiqui</span>, <span class="hlFld-ContribAuthor ">Asif  Husain</span>, <span class="hlFld-ContribAuthor ">M.  Shaquiquzzaman</span>. </span><span class="cited-content_cbyCitation_article-title">A review on synthetic procedures and applications of phosphorus oxychloride (POCl
              3
              ) in the last biennial period (2018–19). </span><span class="cited-content_cbyCitation_journal-name">Phosphorus, Sulfur, and Silicon and the Related Elements</span><span> <strong>2021,</strong> <em>196 </em>
                                    (3)
                                     , 211-274. <a href="https://doi.org/10.1080/10426507.2020.1831499" title="DOI URL">https://doi.org/10.1080/10426507.2020.1831499</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10426507.2020.1831499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10426507.2020.1831499%26sid%3Dliteratum%253Aachs%26jtitle%3DPhosphorus%252C%2520Sulfur%252C%2520and%2520Silicon%2520and%2520the%2520Related%2520Elements%26atitle%3DA%252Breview%252Bon%252Bsynthetic%252Bprocedures%252Band%252Bapplications%252Bof%252Bphosphorus%252Boxychloride%252B%252528POCl%252B3%252B%252529%252Bin%252Bthe%252Blast%252Bbiennial%252Bperiod%252B%2525282018%2525E2%252580%25259319%252529%26aulast%3DAmin%26aufirst%3DShaista%26date%3D2021%26date%3D2020%26volume%3D196%26issue%3D3%26spage%3D211%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shujuan  Wang</span>, <span class="hlFld-ContribAuthor ">Zhenzhen  Wu</span>, <span class="hlFld-ContribAuthor ">Tao  Li</span>, <span class="hlFld-ContribAuthor ">Yafei  Li</span>, <span class="hlFld-ContribAuthor ">Weiqiong  Wang</span>, <span class="hlFld-ContribAuthor ">Qianqian  Hao</span>, <span class="hlFld-ContribAuthor ">Xinsheng  Xie</span>, <span class="hlFld-ContribAuthor ">Dingming  Wan</span>, <span class="hlFld-ContribAuthor ">Zhongxing  Jiang</span>, <span class="hlFld-ContribAuthor ">Chong  Wang</span>, <span class="hlFld-ContribAuthor ">Yanfang  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Mutational spectrum and prognosis in NRAS-mutated acute myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-69194-6" title="DOI URL">https://doi.org/10.1038/s41598-020-69194-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-69194-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-69194-6%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DMutational%252Bspectrum%252Band%252Bprognosis%252Bin%252BNRAS-mutated%252Bacute%252Bmyeloid%252Bleukemia%26aulast%3DWang%26aufirst%3DShujuan%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Seung-Hye  Choi</span>, <span class="hlFld-ContribAuthor ">Injae  Shin</span>, <span class="hlFld-ContribAuthor ">Namdoo  Kim</span>, <span class="hlFld-ContribAuthor ">Yunju  Nam</span>, <span class="hlFld-ContribAuthor ">Taebo  Sim</span>. </span><span class="cited-content_cbyCitation_article-title">The first small molecules capable of strongly suppressing proliferation of cancer cells harboring BRAF class I/II/III mutations. </span><span class="cited-content_cbyCitation_journal-name">Biochemical and Biophysical Research Communications</span><span> <strong>2020,</strong> <em>532 </em>
                                    (2)
                                     , 315-320. <a href="https://doi.org/10.1016/j.bbrc.2020.07.110" title="DOI URL">https://doi.org/10.1016/j.bbrc.2020.07.110</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbrc.2020.07.110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbrc.2020.07.110%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520and%2520Biophysical%2520Research%2520Communications%26atitle%3DThe%252Bfirst%252Bsmall%252Bmolecules%252Bcapable%252Bof%252Bstrongly%252Bsuppressing%252Bproliferation%252Bof%252Bcancer%252Bcells%252Bharboring%252BBRAF%252Bclass%252BI%25252FII%25252FIII%252Bmutations%26aulast%3DChoi%26aufirst%3DSeung-Hye%26date%3D2020%26volume%3D532%26issue%3D2%26spage%3D315%26epage%3D320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xia  Qin</span>, <span class="hlFld-ContribAuthor ">Longmiao  Hu</span>, <span class="hlFld-ContribAuthor ">Shen-nan  Shi</span>, <span class="hlFld-ContribAuthor ">Xiaofei  Chen</span>, <span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Wen  Zhang</span>, <span class="hlFld-ContribAuthor ">Siriporn  Jitkaew</span>, <span class="hlFld-ContribAuthor ">Xiufeng  Pang</span>, <span class="hlFld-ContribAuthor ">Jianqiang  Yu</span>, <span class="hlFld-ContribAuthor ">Ye-xiong  Tan</span>, <span class="hlFld-ContribAuthor ">Hong-yang  Wang</span>, <span class="hlFld-ContribAuthor ">Zhenyu  Cai</span>. </span><span class="cited-content_cbyCitation_article-title">The Bcr-Abl inhibitor GNF-7 inhibits necroptosis and ameliorates acute kidney injury by targeting RIPK1 and RIPK3 kinases. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2020,</strong> <em>177 </em>, 113947. <a href="https://doi.org/10.1016/j.bcp.2020.113947" title="DOI URL">https://doi.org/10.1016/j.bcp.2020.113947</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2020.113947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2020.113947%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DThe%252BBcr-Abl%252Binhibitor%252BGNF-7%252Binhibits%252Bnecroptosis%252Band%252Bameliorates%252Bacute%252Bkidney%252Binjury%252Bby%252Btargeting%252BRIPK1%252Band%252BRIPK3%252Bkinases%26aulast%3DQin%26aufirst%3DXia%26date%3D2020%26volume%3D177%26spage%3D113947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of GNF-7 (left) and representative GNF-7 analogues (right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of GNF-7, <b>10a</b>–<b>k</b>, and <b>11a</b>–<b>i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagent and conditions: (A) POCl<sub>3</sub>, DIPEA, toluene, 110 °C, 77%; (B) 2-methyl-5-nitroaniline, NaI, K<sub>2</sub>CO<sub>3</sub>, acetone, 50 °C, 74%; (C) MeNH<sub>2</sub> (2 M in MeOH solution), DIPEA, 1,4-dioxane, 60 °C, 77%; (D) triphosgene, TEA, THF, 70 °C, 63%; (E) Fe powder, NH<sub>4</sub>Cl, THF/MeOH/H<sub>2</sub>O, 80 °C, 87%; (F) 3-(trifluoromethyl)benzoyl chloride, K<sub>2</sub>CO<sub>3</sub>, DCM, rt, 73%; (G) various amines, K<sub>2</sub>CO<sub>3</sub>, Xphos, Pd<sub>2</sub>(dba)<sub>3</sub>, 2-butanol, 100 °C, 13–84% or ammonia solution, DMSO, 150 °C, 28%; (H) 6-methylpyridin-3-amine, K<sub>2</sub>CO<sub>3</sub>, Xphos, Pd<sub>2</sub>(dba)<sub>3</sub>, 2-butanol, 100 °C, 65%; (I) Fe powder, NH<sub>4</sub>Cl, THF/MeOH/H<sub>2</sub>O, 80 °C, 81%; (J) various carboxylic acids, HATU, DIPEA, DMF, rt, 30–61%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>15a</b>–<b>e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagent and conditions: (A) <i>N</i>-(3-amino-4-methylphenyl)-3-(trifluoromethyl)benzamide, NaI, K<sub>2</sub>CO<sub>3</sub>, acetone, 50 °C, 69%; (B) various amines, THF, 60 °C or aniline, TEA, <i>n</i>-butanol, 120 °C; (C) triphosgene, TEA, THF, 70 °C; (D) 6-methylpyridin-3-amine, K<sub>2</sub>CO<sub>3</sub>, Xphos, Pd<sub>2</sub>(dba)<sub>3</sub>, 2-butanol, 100 °C, 12–27% over 3 steps.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>17a</b>–<b>e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagent and condition: (A) 4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)benzoic acid, HATU, DIPEA,DMF, rt, 65%; (B) various amines, K<sub>2</sub>CO<sub>3</sub>, Xphos, Pd<sub>2</sub>(dba)<sub>3</sub>, 2-butanol, 100 °C, 34–62%.</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0002.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding models of inhibitors on ACK1 (left) and GCK (right). (a) GNF-7, (b) <b>10d</b>, (c) <b>10k</b>, and (d) <b>11a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0003.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray crystal structure of <b>10d</b> bound to ACK1 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZXB">5ZXB</a>). (a) Overall fold of the ACK1-<b>10d</b> complex structure. Some residues (135–137, 161–169, and 272–292) are missing in the structure due to a lack of electron density. (b) Protein residues are represented by white, and <b>10d</b> is designated by gold. Sulfur is displayed in yellow, nitrogen in blue, oxygen in red, and fluoride in cyan. Lys158 is eliminated for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0004.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Kinome-wide selectivity profiling of <b>10k</b> at 1 μM. Kinases showing >90% inhibition are indicated with red circles. Illustration is reproduced courtesy of Cell Signaling Technology, Inc. (<a href="http://www.cellsignal.com" class="extLink">www.cellsignal.com</a>). (b) The list of 33 kinases out of 351 kinases showing >90% inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0005.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect on downstream signaling inhibition. The phospho-p70S6K1, phospho-AKT (S473), phospho-JNK, and phospho-p38 levels in Ba/F3-NRAS-G12D (a) and OCI-AML3 (b) treated with indicated compounds for 2 h. Compounds at 1 μM attenuated phosphorylation of each molecule. Actin was used for loading control. (c) <b>10d</b> and <b>10k</b> block both AKT/mTOR signaling and GCK signaling in a dose-dependent manner in OCI-AML3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0006.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effect on the cell apoptosis. (a) Western blot for apoptotic molecules in Ba/F3-NRAS-G12D (upper panel) and OCI-AML3 (low panel) treated with indicated compounds for 24 h. Cleaved PARP form was induced by each compound at 1 μM in OCI-AML3. Cleaved caspase 3 was increased by 1 μM of <b>10d</b> and GNF-7 in Ba/F3-NRAS-G12D cells (upper panel). Actin was used for loading control. (b) Percent of apoptotic cells detected by FACS analysis in Ba/F3-NRAS-G12D (upper panel) and OCI-AML3 (low panel). Apoptotic cells were determined via dual-staining of FITC-conjugated annexin V and propidium iodide after 24 h treatment of indicated compounds at 1 μM. All experiments were performed three times, and the bar graph represents the average (<i>n</i> = 3) and SD. One-Way ANOVA; ** <i>P</i> < 0.05. (c) Dose dependent increase of apoptotic cells by compound <b>10k</b> in Ba/F3-NRAS-G12D (upper panel) and OCI-AML3 (low panel). Each cell line was treated with indicated concentrations of <b>10k</b> for 24 h and subjected to flow cytometry analysis. All experiments were performed in three times, and bar graph represents the average (<i>n</i> = 3) and SD. One-Way ANOVA; ** <i>P</i> < 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0007.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Induction of G0–G1 arrest after compound treatment. (a,b) OCI-AML3 were treated with indicated concentration of each compound for 24 h, and the percentage of each cell cycle phase were analyzed by flow cytometry after propidium iodide staining; 1 μM of each compound significantly increases population of G0–G1 phase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0008.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Anchorage independent growth inhibition of <b>10d</b>, <b>10k</b>, and <b>11i</b> in OCI-AML3. (a) Cells embedded in 0.7% low melting agar were incubated with the indicated concentrations of compounds for 2 weeks, and colonies were observed (<i>n</i> = 3 experiment per condition). (b) Average number of colonies per well was automatically counted using ImageJ software and shown in the bar graph (± SD, One-Way ANOVA; **** <i>p</i> < 0.0001, *** <i>p</i> < 0.0005, ** <i>p</i> < 0.05). (c) Average size of colonies per well was automatically measured using ImageJ software and shown in the bar graph (± SD, One-Way ANOVA; **** <i>p</i> < 0.0001, *** <i>p</i> < 0.0005, ** <i>p</i> < 0.05).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/medium/jm-2018-00882s_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0009.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Antileukemic efficacy of vehicle alone, GNF-7, and <b>10k</b> in Ba/F3-NRAS-G12D blood circulating model and OCI-AML3 xenograft model. (a) Bioluminescence images of mice administered with vehicle only, GNF-7, or <b>10k</b> once daily (<i>n</i> = 4 per cohort). Immunodeficient mice were tail intravenously injected with Ba/F3-NRAS-G12D/Luc cells and treated with vehicle, GNF-7 (8 mg/kg/day, po, qd), or <b>10k</b> (15 mg/kg/day, po, qd) for 3 weeks. Bioluminescence images were obtained once every 2 days using IVIS spectrum (PerkinElmer) after administration of luciferin (150 mg/kg). (b) Ba/F3-NRAS-G12D/Luc cell progression was monitored by quantitative biophotonic imaging analysis of control and compound-treatment groups. Quantitation from the in vivo imaging using Opti-view software (version 2.02, ART Inc.). Results represent mean ± SEM, <i>n</i> = 4 per group, **<i>p</i> < 0.05. The mean values and their 95% confidence intervals (error bars) are given. (c) Comparison of lifespan of mice orally administered with vehicle, GNF-7, and <b>10k</b> in AML mouse model bearing Ba/F3-NRAS-G12D. Immunodeficient mice were injected with BaF3-NRAS-G12D cells via the lateral tail vein, and compound administration was initiated 6 d after implantation. Mice were treated with vehicle, GNF-7 (8 mg/kg/day, qd), or <b>10k</b> (15 or 25 mg/kg/day, qd) for 8 weeks. Survival of the mice is represented by a Kaplan–Meier plot. <i>P</i> = 0.05 for mice treated <b>10k</b> oral administrated group with the vehicle control mice. (d) Body weight change during the lifespan measurement. (e) Mouse xenograft study. Immuno-deficient mice were subcutaneously injected with OCI-AML3 cells with 50% Matrigel and treated with vehicle, GNF-7, or <b>10k</b> (15 or 25 mg/kg/day, po, qd) for 3 w (<i>n</i> = 5 per group). Mouse tumor size was measured once every 2 days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-18/acs.jmedchem.8b00882/20180920/images/large/jm-2018-00882s_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00882&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i88">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57310" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57310" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 32 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolias, P.</span></span> <span> </span><span class="NLM_article-title">Recent advances in cancer drug discovery targeting RAS</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1915</span>– <span class="NLM_lpage">1919</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1016%2Fj.drudis.2016.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=27506872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlaiu73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=1915-1919&author=C.+Y.+Wilsonauthor=P.+Tolias&title=Recent+advances+in+cancer+drug+discovery+targeting+RAS&doi=10.1016%2Fj.drudis.2016.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in cancer drug discovery targeting RAS</span></div><div class="casAuthors">Wilson, Candice Y.; Tolias, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1915-1919</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Mutated RAS is present in 30% of human tumors, appearing in 90% of pancreatic, 45% of colon and 35% of lung cancers.  These high occurrences make RAS one of the most important drug targets in oncol.  Three decades of effort to target RAS have been unsuccessful in generating drug therapies suggesting that it might represent an 'undruggable' target.  However, recent reports highlighting new approaches for targeting RAS have uncovered more information on protein structure and identified new binding pockets.  Efforts to target the KRAS G12C mutation specifically have shown promising results whereas other approaches have targeted various protein complexes.  These advances could lead to development of new effective cancer drugs targeting RAS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJnoLMitHbsrVg90H21EOLACvtfcHk0lh74O5lUPc_WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlaiu73P&md5=5bcad00948b76112248f9ebc332a8d73</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DC.%2BY.%26aulast%3DTolias%26aufirst%3DP.%26atitle%3DRecent%2520advances%2520in%2520cancer%2520drug%2520discovery%2520targeting%2520RAS%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D1915%26epage%3D1919%26doi%3D10.1016%2Fj.drudis.2016.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span> <span> </span><span class="NLM_article-title">Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4186</span>– <span class="NLM_lpage">4192</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-3270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1158%2F1078-0432.CCR-13-3270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=24895460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCltr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=4186-4192&author=D.+B.+Johnsonauthor=K.+S.+Smalleyauthor=J.+A.+Sosman&title=Molecular+pathways%3A+targeting+NRAS+in+melanoma+and+acute+myelogenous+leukemia&doi=10.1158%2F1078-0432.CCR-13-3270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous Leukemia</span></div><div class="casAuthors">Johnson, Douglas B.; Smalley, Keiran S. M.; Sosman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4186-4192</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Successful targeting of specific oncogenic "driver" mutations with small-mol. inhibitors has represented a major advance in cancer therapeutics over the past 10 to 15 years.  The most common activating oncogene in human malignancy, RAS (rat sarcoma), has proved to be an elusive target.  Activating mutations in RAS induce mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase-AKT pathway signaling and drive malignant progression in up to 30% of cancers.  Oncogenic NRAS mutations occur in several cancer types, notably melanoma, acute myelogenous leukemia (AML), and less commonly, colon adenocarcinoma, thyroid carcinoma, and other hematol. malignancies.  Although NRAS-mutant tumors have been recalcitrant to targeted therapeutic strategies historically, newer agents targeting MAP/ERK kinase 1 (MEK1)/2 have recently shown signs of clin. efficacy as monotherapy.  Combination strategies of MEK inhibitors with other targeted agents have strong preclin. support and are being evaluated in clin. trials.  This review discusses the recent preclin. and clin. studies about the role of NRAS in cancer, with a focus on melanoma and AML.  Clin Cancer Res; 20(16); 4186-92. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHb9TN00_uU7Vg90H21EOLACvtfcHk0lh74O5lUPc_WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCltr%252FK&md5=4656a7aa671cfa3989c09d93f4d60226</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-3270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-3270%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BB.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26atitle%3DMolecular%2520pathways%253A%2520targeting%2520NRAS%2520in%2520melanoma%2520and%2520acute%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D4186%26epage%3D4192%26doi%3D10.1158%2F1078-0432.CCR-13-3270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowens, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1038/leu.2014.149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2Fleu.2014.149" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=27-37&author=E.+Weisbergauthor=A.+Nonamiauthor=Z.+Chenauthor=F.+Liuauthor=J.+Zhangauthor=M.+Sattlerauthor=E.+Nelsonauthor=K.+Cowensauthor=A.+L.+Christieauthor=C.+Mitsiadesauthor=K.-K.+Wongauthor=Q.+Liuauthor=N.+Grayauthor=J.+D.+Griffin&title=Identification+of+Wee1+as+a+novel+therapeutic+target+for+mutant+RAS-driven+acute+leukemia+and+other+malignancies&doi=10.1038%2Fleu.2014.149"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1038%2Fleu.2014.149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2014.149%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DNonami%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DNelson%26aufirst%3DE.%26aulast%3DCowens%26aufirst%3DK.%26aulast%3DChristie%26aufirst%3DA.%2BL.%26aulast%3DMitsiades%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DIdentification%2520of%2520Wee1%2520as%2520a%2520novel%2520therapeutic%2520target%2520for%2520mutant%2520RAS-driven%2520acute%2520leukemia%2520and%2520other%2520malignancies%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26spage%3D27%26epage%3D37%26doi%3D10.1038%2Fleu.2014.149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sachs, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaRue, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, N. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz-Flores, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathe, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarver, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendall, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, N. GA.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diers, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">NOlan, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Largaespada, D. A.</span></span> <span> </span><span class="NLM_article-title">NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">3274</span>– <span class="NLM_lpage">3283</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-08-521708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1182%2Fblood-2013-08-521708" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=3274-3283&author=Z.+Sachsauthor=R.+S.+LaRueauthor=H.+T.+Nguyenauthor=K.+Sachsauthor=K.+E.+Nobleauthor=N.+A.+M.+Hassanauthor=E.+Diaz-Floresauthor=S.+K.+Ratheauthor=A.+L.+Sarverauthor=S.+C.+Bendallauthor=N.+GA.+Haauthor=M.+D.+Diersauthor=G.+D.+NOlanauthor=K.+M.+Shannonauthor=D.+A.+Largaespada&title=NRASG12V+oncogene+facilitates+self-renewal+in+a+murine+model+of+acute+myelogenous+leukemia&doi=10.1182%2Fblood-2013-08-521708"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-08-521708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-08-521708%26sid%3Dliteratum%253Aachs%26aulast%3DSachs%26aufirst%3DZ.%26aulast%3DLaRue%26aufirst%3DR.%2BS.%26aulast%3DNguyen%26aufirst%3DH.%2BT.%26aulast%3DSachs%26aufirst%3DK.%26aulast%3DNoble%26aufirst%3DK.%2BE.%26aulast%3DHassan%26aufirst%3DN.%2BA.%2BM.%26aulast%3DDiaz-Flores%26aufirst%3DE.%26aulast%3DRathe%26aufirst%3DS.%2BK.%26aulast%3DSarver%26aufirst%3DA.%2BL.%26aulast%3DBendall%26aufirst%3DS.%2BC.%26aulast%3DHa%26aufirst%3DN.%2BGA.%26aulast%3DDiers%26aufirst%3DM.%2BD.%26aulast%3DNOlan%26aufirst%3DG.%2BD.%26aulast%3DShannon%26aufirst%3DK.%2BM.%26aulast%3DLargaespada%26aufirst%3DD.%2BA.%26atitle%3DNRASG12V%2520oncogene%2520facilitates%2520self-renewal%2520in%2520a%2520murine%2520model%2520of%2520acute%2520myelogenous%2520leukemia%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D3274%26epage%3D3283%26doi%3D10.1182%2Fblood-2013-08-521708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haigis, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDaniel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding-Theobald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogan, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akagi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacks, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, K.</span></span> <span> </span><span class="NLM_article-title">Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">2022</span>– <span class="NLM_lpage">2032</span>, <span class="refDoi"> DOI: 10.1182/blood-2010-04-280750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1182%2Fblood-2010-04-280750" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=2022-2032&author=Q.+Liauthor=K.+M.+Haigisauthor=A.+McDanielauthor=E.+Harding-Theobaldauthor=S.+C.+Koganauthor=K.+Akagiauthor=J.+C.+Wongauthor=B.+S.+Braunauthor=L.+Wolffauthor=T.+Jacksauthor=K.+Shannon&title=Hematopoiesis+and+leukemogenesis+in+mice+expressing+oncogenic+NrasG12D+from+the+endogenous+locus&doi=10.1182%2Fblood-2010-04-280750"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-04-280750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-04-280750%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DHaigis%26aufirst%3DK.%2BM.%26aulast%3DMcDaniel%26aufirst%3DA.%26aulast%3DHarding-Theobald%26aufirst%3DE.%26aulast%3DKogan%26aufirst%3DS.%2BC.%26aulast%3DAkagi%26aufirst%3DK.%26aulast%3DWong%26aufirst%3DJ.%2BC.%26aulast%3DBraun%26aufirst%3DB.%2BS.%26aulast%3DWolff%26aufirst%3DL.%26aulast%3DJacks%26aufirst%3DT.%26aulast%3DShannon%26aufirst%3DK.%26atitle%3DHematopoiesis%2520and%2520leukemogenesis%2520in%2520mice%2520expressing%2520oncogenic%2520NrasG12D%2520from%2520the%2520endogenous%2520locus%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3D2022%26epage%3D2032%26doi%3D10.1182%2Fblood-2010-04-280750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, S. J.</span></span> <span> </span><span class="NLM_article-title">Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>504</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">147</span>, <span class="refDoi"> DOI: 10.1038/nature12830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2Fnature12830" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=504&publication_year=2013&pages=143-147&author=Q.+Liauthor=N.+Bohinauthor=T.+Wenauthor=V.+Ngauthor=J.+Mageeauthor=S.+C.+Chenauthor=K.+Shannonauthor=S.+J.+Morrison&title=Oncogenic+Nras+has+bimodal+effects+on+stem+cells+that+sustainably+increase+competitiveness&doi=10.1038%2Fnature12830"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2e&amp;dbid=16384&amp;doi=10.1038%2Fnature12830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12830%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DBohin%26aufirst%3DN.%26aulast%3DWen%26aufirst%3DT.%26aulast%3DNg%26aufirst%3DV.%26aulast%3DMagee%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%2BC.%26aulast%3DShannon%26aufirst%3DK.%26aulast%3DMorrison%26aufirst%3DS.%2BJ.%26atitle%3DOncogenic%2520Nras%2520has%2520bimodal%2520effects%2520on%2520stem%2520cells%2520that%2520sustainably%2520increase%2520competitiveness%26jtitle%3DNature%26date%3D2013%26volume%3D504%26spage%3D143%26epage%3D147%26doi%3D10.1038%2Fnature12830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nonami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patricelli, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saur, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">3133</span>– <span class="NLM_lpage">3143</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-12-615906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1182%2Fblood-2014-12-615906" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=3133-3143&author=A.+Nonamiauthor=M.+Sattlerauthor=E.+Weisbergauthor=Q.+Liuauthor=J.+Zhangauthor=M.+P.+Patricelliauthor=A.+L.+Christieauthor=A.+M.+Saurauthor=N.+E.+Kohlauthor=A.+L.+Kungauthor=H.+Yoonauthor=T.+Simauthor=N.+S.+Grayauthor=J.+D.+Griffin&title=Identification+of+novel+therapeutic+targets+in+acute+leukemias+with+NRAS+mutations+using+a+pharmacologic+approach&doi=10.1182%2Fblood-2014-12-615906"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-12-615906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-12-615906%26sid%3Dliteratum%253Aachs%26aulast%3DNonami%26aufirst%3DA.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPatricelli%26aufirst%3DM.%2BP.%26aulast%3DChristie%26aufirst%3DA.%2BL.%26aulast%3DSaur%26aufirst%3DA.%2BM.%26aulast%3DKohl%26aufirst%3DN.%2BE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DYoon%26aufirst%3DH.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DIdentification%2520of%2520novel%2520therapeutic%2520targets%2520in%2520acute%2520leukemias%2520with%2520NRAS%2520mutations%2520using%2520a%2520pharmacologic%2520approach%26jtitle%3DBlood%26date%3D2015%26volume%3D125%26spage%3D3133%26epage%3D3143%26doi%3D10.1182%2Fblood-2014-12-615906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, T. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björkholm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, P. C.</span></span> <span> </span><span class="NLM_article-title">Survival and cure of acute myeloid leukaemia in England, 1971–2006: a population–based study</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1111/bjh.12425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1111%2Fbjh.12425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=23786647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A280%3ADC%252BC3sjks1eqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2013&pages=509-516&author=A.+Shahauthor=T.+M.+L.+Anderssonauthor=B.+Rachetauthor=M.+Bj%C3%B6rkholmauthor=P.+C.+Lambert&title=Survival+and+cure+of+acute+myeloid+leukaemia+in+England%2C+1971%E2%80%932006%3A+a+population%E2%80%93based+study&doi=10.1111%2Fbjh.12425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study</span></div><div class="casAuthors">Shah Anjali; Andersson Therese M-L; Rachet Bernard; Bjorkholm Magnus; Lambert Paul C</div><div class="citationInfo"><span class="NLM_cas:title">British journal of haematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">509-16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The 5-year relative survival of adults diagnosed with acute myeloid leukaemia (AML) was less than 10% during the 1970s and 1980s in England.  This population-based study estimated the 5-year relative survival and 'cure' for 48 380 adult patients diagnosed with AML in England during 1971-2006.  Relative survival and cure mixture models were used to produce estimates of 5-year relative survival and the percentage 'cured'. 'Cure' was defined as the proportion of a group of survivors for whom there is no excess mortality compared with the general population.  The 5-year relative survival and the percentage 'cured' increased for patients aged under 70 years at diagnosis during 1971-2006, but advancing age was associated with poorer outcome.  During the study period a dramatic increase in 5-year relative survival occurred in those aged 15-24 years, from 7% to 53%.  The percentage 'cured' was less than 10% for all ages in 1975, but increased to 45% for those aged 15-24 years in 2000.  Cure could not be estimated for patients over 70 years, because survival was consistently low (<5%).  The long-term outcome of patients with AML has improved substantially, particularly in younger patients.  The potential exists for further increasing levels of 'cure'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRGi030miilreWhZTslLrfffW6udTcc2eZQ0b2hDUK8l7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjks1eqsA%253D%253D&md5=513555d4c7e42dd36720d51691222734</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fbjh.12425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.12425%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DA.%26aulast%3DAndersson%26aufirst%3DT.%2BM.%2BL.%26aulast%3DRachet%26aufirst%3DB.%26aulast%3DBj%25C3%25B6rkholm%26aufirst%3DM.%26aulast%3DLambert%26aufirst%3DP.%2BC.%26atitle%3DSurvival%2520and%2520cure%2520of%2520acute%2520myeloid%2520leukaemia%2520in%2520England%252C%25201971%25E2%2580%25932006%253A%2520a%2520population%25E2%2580%2593based%2520study%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2013%26volume%3D162%26spage%3D509%26epage%3D516%26doi%3D10.1111%2Fbjh.12425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Podoltsev, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeidan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gore, S. D.</span></span> <span> </span><span class="NLM_article-title">Selecting initial treatment of acute myeloid leukaemia in older adults</span>. <i>Blood Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1016/j.blre.2016.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1016%2Fj.blre.2016.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=27745715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A280%3ADC%252BC2srgvV2gtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=43-62&author=N.+A.+Podoltsevauthor=M.+Stahlauthor=A.+M.+Zeidanauthor=S.+D.+Gore&title=Selecting+initial+treatment+of+acute+myeloid+leukaemia+in+older+adults&doi=10.1016%2Fj.blre.2016.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Selecting initial treatment of acute myeloid leukaemia in older adults</span></div><div class="casAuthors">Podoltsev Nikolai A; Zeidan Amer M; Gore Steven D; Stahl Maximilian</div><div class="citationInfo"><span class="NLM_cas:title">Blood reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">43-62</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">More than half of the patients with acute myeloid leukaemia (AML) are older than 60years.  The treatment outcomes in this group remain poor with a median overall survival of <1year.  Selecting initial treatment for these patients involves an assessment of 'fitness' for induction chemotherapy.  This is done based on patient and disease-related characteristics which help to estimate treatment-related mortality and chance of complete remission with induction chemotherapy.  If the risk of treatment-related mortality is high and/or the likelihood of a patient achieving a complete remission is low, lower-intensity treatment (low-dose cytarabine, decitabine and azacitidine) should be discussed.  As outcomes in both groups of patients remain poor, enrolment into clinical trials of novel agents with varying mechanisms of action should be considered for all older adults with AML.  Novel agents in Phase III development include CPX-351, guadecitabine (SGI-110), quizartinib, crenolanib, sapacitabine, vosaroxin and volasertib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSOTEk4l7FYFxKDYG3bNImrfW6udTcc2eZzZEG8U-NxyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srgvV2gtw%253D%253D&md5=0b21bc450b84f8107469ec038be759f9</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.blre.2016.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.blre.2016.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DPodoltsev%26aufirst%3DN.%2BA.%26aulast%3DStahl%26aufirst%3DM.%26aulast%3DZeidan%26aufirst%3DA.%2BM.%26aulast%3DGore%26aufirst%3DS.%2BD.%26atitle%3DSelecting%2520initial%2520treatment%2520of%2520acute%2520myeloid%2520leukaemia%2520in%2520older%2520adults%26jtitle%3DBlood%2520Rev.%26date%3D2017%26volume%3D31%26spage%3D43%26epage%3D62%26doi%3D10.1016%2Fj.blre.2016.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Saygin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carraway, H. E.</span></span> <span> </span><span class="NLM_article-title">Emerging therapies for acute myeloid leukemia</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">93</span>, <span class="refDoi"> DOI: 10.1186/s13045-017-0463-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1186%2Fs13045-017-0463-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=28420416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A280%3ADC%252BC1cvovFWhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=93&author=C.+Sayginauthor=H.+E.+Carraway&title=Emerging+therapies+for+acute+myeloid+leukemia&doi=10.1186%2Fs13045-017-0463-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging therapies for acute myeloid leukemia</span></div><div class="casAuthors">Saygin Caner; Carraway Hetty E; Carraway Hetty E</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">93</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity.  Despite the advances in our understanding of its pathobiology, the chemotherapy-directed management has remained largely unchanged in the past 40 years.  However, various novel agents have demonstrated clinical activity, either as single agents (e.g., isocitrate dehydrogenase (IDH) inhibitors, vadastuximab) or in combination with standard induction/consolidation at diagnosis and with salvage regimens at relapse.  The classes of agents described in this review include novel cytotoxic chemotherapies (CPX-351 and vosaroxin), epigenetic modifiers (guadecitabine, IDH inhibitors, histone deacetylase (HDAC) inhibitors, bromodomain and extraterminal (BET) inhibitors), FMS-like tyrosine kinase receptor 3 (FLT3) inhibitors, and antibody-drug conjugates (vadastuximab), as well as cell cycle inhibitors (volasertib), B-cell lymphoma 2 (BCL-2) inhibitors, and aminopeptidase inhibitors.  These agents are actively undergoing clinical investigation alone or in combination with available chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_EeV9zuCZfTdblLE_E9PWfW6udTcc2eZzZEG8U-NxyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvovFWhuw%253D%253D&md5=3c1c9d98886f14e32c9e8d9e1d47823a</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1186%2Fs13045-017-0463-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-017-0463-6%26sid%3Dliteratum%253Aachs%26aulast%3DSaygin%26aufirst%3DC.%26aulast%3DCarraway%26aufirst%3DH.%2BE.%26atitle%3DEmerging%2520therapies%2520for%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2017%26volume%3D10%26spage%3D93%26doi%3D10.1186%2Fs13045-017-0463-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubielecka, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghunathan, V. M.</span></span> <span> </span><span class="NLM_article-title">Molecular targeting in acute myeloid leukemia</span>. <i>J. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1186/s12967-017-1281-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1186%2Fs12967-017-1281-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=28851395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A280%3ADC%252BC1cbis1Omtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=183-196&author=S.+H.+Limauthor=P.+M.+Dubieleckaauthor=V.+M.+Raghunathan&title=Molecular+targeting+in+acute+myeloid+leukemia&doi=10.1186%2Fs12967-017-1281-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular targeting in acute myeloid leukemia</span></div><div class="casAuthors">Lim Seah H; Dubielecka Patrycja M; Raghunathan Vikram M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of translational medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">183</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acute myeloid leukemia (AML) is a heterogenous disease associated with distinct genetic and molecular abnormalities.  Somatic mutations result in dysregulation of intracellular signaling pathways, epigenetics, and apoptosis of the leukemia cells.  Understanding the basis for the dysregulated processes provides the platform for the design of novel targeted therapy for AML patients.  The effort to devise new targeted therapy has been helped by recent advances in methods for high-throughput genomic screening and the availability of computer-assisted techniques for the design of novel agents that are predicted to specifically inhibit the mutant molecules involved in these intracellular events.  In this review, we will provide the scientific basis for targeting the dysregulated molecular mechanisms and discuss the agents currently being investigated, alone or in combination with chemotherapy, for treating patients with AML.  Successes in molecular targeting will ultimately change the treatment paradigm for the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ8xkAkzMDBjHqj_yg7twvpfW6udTcc2eZzZEG8U-NxyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbis1Omtg%253D%253D&md5=d646ab2d344c55fc913fc87aedbdb673</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1186%2Fs12967-017-1281-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12967-017-1281-x%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DS.%2BH.%26aulast%3DDubielecka%26aufirst%3DP.%2BM.%26aulast%3DRaghunathan%26aufirst%3DV.%2BM.%26atitle%3DMolecular%2520targeting%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Transl.%2520Med.%26date%3D2017%26volume%3D15%26spage%3D183%26epage%3D196%26doi%3D10.1186%2Fs12967-017-1281-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">De Kouchkovsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul-Hay, M.</span></span> <span> </span><span class="NLM_article-title">Acute myeloid leukemia: a comprehensive review and 2016 update</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">e441</span>, <span class="refDoi"> DOI: 10.1038/bcj.2016.50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2Fbcj.2016.50" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=27367478" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=e441&author=I.+De+Kouchkovskyauthor=M.+Abdul-Hay&title=Acute+myeloid+leukemia%3A+a+comprehensive+review+and+2016+update&doi=10.1038%2Fbcj.2016.50"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2016.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2016.50%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BKouchkovsky%26aufirst%3DI.%26aulast%3DAbdul-Hay%26aufirst%3DM.%26atitle%3DAcute%2520myeloid%2520leukemia%253A%2520a%2520comprehensive%2520review%2520and%25202016%2520update%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2016%26volume%3D6%26spage%3De441%26doi%3D10.1038%2Fbcj.2016.50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Baines, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Ras for cancer treatment: the search continues</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1787</span>– <span class="NLM_lpage">1808</span>, <span class="refDoi"> DOI: 10.4155/fmc.11.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.4155%2Ffmc.11.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=22004085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlertbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1787-1808&author=A.+T.+Bainesauthor=D.+Xuauthor=C.+J.+Der&title=Inhibition+of+Ras+for+cancer+treatment%3A+the+search+continues&doi=10.4155%2Ffmc.11.121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Ras for cancer treatment: the search continues</span></div><div class="casAuthors">Baines, Antonio T.; Xu, Dapeng; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1787-1808</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The RAS oncogenes (HRAS, NRAS and KRAS) comprise the most frequently mutated class of oncogenes in human cancers (33%), thus stimulating intensive effort in developing anti-Ras inhibitors for cancer treatment.  Despite intensive effort, to date, no effective anti-Ras strategies have successfully made it to the clinic.  We present an overview of past and ongoing strategies to inhibit oncogenic Ras in cancer.  Since approaches to directly target mutant Ras have not been successful, most efforts have focused on indirect approaches to block Ras membrane assocn. or downstream effector signaling.  While inhibitors of effector signaling are currently under clin. evaluation, genome-wide unbiased genetic screens have identified novel directions for future anti-Ras drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGSljlfnR2TbVg90H21EOLACvtfcHk0lh-Z4O11M56xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlertbjJ&md5=bb810b0cf2b8dc975d5a476907f5c2ec</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.121%26sid%3Dliteratum%253Aachs%26aulast%3DBaines%26aufirst%3DA.%2BT.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DInhibition%2520of%2520Ras%2520for%2520cancer%2520treatment%253A%2520the%2520search%2520continues%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D1787%26epage%3D1808%26doi%3D10.4155%2Ffmc.11.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieu, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messersmith, W. A.</span></span> <span> </span><span class="NLM_article-title">Therapeutic approaches to RAS mutation</span>. <i>Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1097/PPO.0000000000000187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1097%2FPPO.0000000000000187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=27341593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCltLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=165-174&author=A.+J.+Scottauthor=C.+H.+Lieuauthor=W.+A.+Messersmith&title=Therapeutic+approaches+to+RAS+mutation&doi=10.1097%2FPPO.0000000000000187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Approaches to RAS Mutation</span></div><div class="casAuthors">Scott, Aaron J.; Lieu, Christopher H.; Messersmith, Wells A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Journal (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">165-174</span>CODEN:
                <span class="NLM_cas:coden">CAJOCB</span>;
        ISSN:<span class="NLM_cas:issn">1528-9117</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The study of oncogenic RAS mutations has led to crucial discoveries regarding cancer mol. biol. and behavior and has been integral in shaping the era of targeted cancer therapy.  RAS mutations are one of the most common oncogenic drivers in human cancer, and intense efforts to find a clin. effective inhibitor are ongoing.  Despite these efforts, targeting RAS mutations has remained elusive, so much so that some have termed oncogenic RAS mutations as "undruggable.  " In this review, we will summarize current understanding of RAS biol., explore strategies to inhibit RAS oncoproteins and its downstream effectors, and discuss recently described complexities that have shed new light on this pursuit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokgFYmAV2BQLVg90H21EOLACvtfcHk0lgCbMqVlfIwbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCltLjF&md5=eaa1ed8b15c77758cb9f174acc0f99c8</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1097%2FPPO.0000000000000187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FPPO.0000000000000187%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DA.%2BJ.%26aulast%3DLieu%26aufirst%3DC.%2BH.%26aulast%3DMessersmith%26aufirst%3DW.%2BA.%26atitle%3DTherapeutic%2520approaches%2520to%2520RAS%2520mutation%26jtitle%3DCancer%2520J.%26date%3D2016%26volume%3D22%26spage%3D165%26epage%3D174%26doi%3D10.1097%2FPPO.0000000000000187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Athuluri-Divakar, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasquez-Del Carpio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosenza, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogt, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulholland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span> <span> </span><span class="NLM_article-title">A small molecule RAS-mimetic disrupts RAS association with effector proteins to block signaling</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">655</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2016.03.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1016%2Fj.cell.2016.03.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=27104980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslShtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=643-655&author=S.+K.+Athuluri-Divakarauthor=R.+Vasquez-Del+Carpioauthor=K.+Duttaauthor=S.+J.+Bakerauthor=S.+C.+Cosenzaauthor=I.+Basuauthor=Y.+K.+Guptaauthor=M.+R.+Reddyauthor=L.+Uenoauthor=J.+R.+Hartauthor=P.+K.+Vogtauthor=D.+Mulhollandauthor=C.+Guhaauthor=A.+K.+Aggarwalauthor=E.+P.+Reddy&title=A+small+molecule+RAS-mimetic+disrupts+RAS+association+with+effector+proteins+to+block+signaling&doi=10.1016%2Fj.cell.2016.03.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling</span></div><div class="casAuthors">Athuluri-Divakar, Sai Krishna; Vasquez-Del Carpio, Rodrigo; Dutta, Kaushik; Baker, Stacey J.; Cosenza, Stephen C.; Basu, Indranil; Gupta, Yogesh K.; Reddy, M. V. Ramana; Ueno, Lynn; Hart, Jonathan R.; Vogt, Peter K.; Mulholland, David; Guha, Chandan; Aggarwal, Aneel K.; Reddy, E. Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">643-655</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Oncogenic activation of RAS genes via point mutations occurs in 20%-30% of human cancers.  The development of effective RAS inhibitors has been challenging, necessitating new approaches to inhibit this oncogenic protein.  Functional studies have shown that the switch region of RAS interacts with a large no. of effector proteins contg. a common RAS-binding domain (RBD).  Because RBD-mediated interactions are essential for RAS signaling, blocking RBD assocn. with small mols. constitutes an attractive therapeutic approach.  Here, the authors present evidence that rigosertib, a styryl-benzyl sulfone, acts as a RAS-mimetic and interacts with the RBDs of RAF kinases, resulting in their inability to bind to RAS, disruption of RAF activation, and inhibition of the RAS-RAF-MEK pathway.  The authors also find that ribosertib binds to the RBDs of Ral-GDS and PI3Ks.  These results suggest that targeting of RBDs across multiple signaling pathways by rigosertib may represent an effective strategy for inactivation of RAS signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa5skbfbqCQrVg90H21EOLACvtfcHk0lgCbMqVlfIwbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslShtbs%253D&md5=c79482e4a9cc6819034dd9117348b8bc</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.03.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.03.045%26sid%3Dliteratum%253Aachs%26aulast%3DAthuluri-Divakar%26aufirst%3DS.%2BK.%26aulast%3DVasquez-Del%2BCarpio%26aufirst%3DR.%26aulast%3DDutta%26aufirst%3DK.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DBasu%26aufirst%3DI.%26aulast%3DGupta%26aufirst%3DY.%2BK.%26aulast%3DReddy%26aufirst%3DM.%2BR.%26aulast%3DUeno%26aufirst%3DL.%26aulast%3DHart%26aufirst%3DJ.%2BR.%26aulast%3DVogt%26aufirst%3DP.%2BK.%26aulast%3DMulholland%26aufirst%3DD.%26aulast%3DGuha%26aufirst%3DC.%26aulast%3DAggarwal%26aufirst%3DA.%2BK.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DA%2520small%2520molecule%2520RAS-mimetic%2520disrupts%2520RAS%2520association%2520with%2520effector%2520proteins%2520to%2520block%2520signaling%26jtitle%3DCell%26date%3D2016%26volume%3D165%26spage%3D643%26epage%3D655%26doi%3D10.1016%2Fj.cell.2016.03.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ledford, H.</span></span> <span> </span><span class="NLM_article-title">The ras renaissance</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>520</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1038/520278a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2F520278a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=520&publication_year=2015&pages=278-280&author=H.+Ledford&title=The+ras+renaissance&doi=10.1038%2F520278a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2F520278a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F520278a%26sid%3Dliteratum%253Aachs%26aulast%3DLedford%26aufirst%3DH.%26atitle%3DThe%2520ras%2520renaissance%26jtitle%3DNature%26date%3D2015%26volume%3D520%26spage%3D278%26epage%3D280%26doi%3D10.1038%2F520278a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesik, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimmelman, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">Drugging the undruggable RAS: mission possible?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">828</span>– <span class="NLM_lpage">851</span>, <span class="refDoi"> DOI: 10.1038/nrd4389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2Fnrd4389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=25323927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslKmu7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=828-851&author=A.+D.+Coxauthor=S.+W.+Fesikauthor=A.+C.+Kimmelmanauthor=J.+Luoauthor=C.+J.+Der&title=Drugging+the+undruggable+RAS%3A+mission+possible%3F&doi=10.1038%2Fnrd4389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging the undruggable RAS: Mission Possible?</span></div><div class="casAuthors">Cox, Adrienne D.; Fesik, Stephen W.; Kimmelman, Alec C.; Luo, Ji; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">828-851</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite more than three decades of intensive effort, no effective pharmacol. inhibitors of the RAS oncoproteins have reached the clinic, prompting the widely held perception that RAS proteins are 'undruggable'.  However, recent data from the lab. and the clinic have renewed our hope for the development of RAS-inhibitory mols.  In this Review, we summarize the progress and the promise of five key approaches.  Firstly, we focus on the prospects of using direct inhibitors of RAS.  Secondly, we address the issue of whether blocking RAS membrane assocn. is a viable approach.  Thirdly, we assess the status of targeting RAS downstream effector signalling, which is arguably the most favorable current approach.  Fourthly, we address whether the search for synthetic lethal interactors of mutant RAS still holds promise.  Finally, RAS-mediated changes in cell metab. have recently been described and we discuss whether these changes could be exploited for new therapeutic directions.  We conclude with perspectives on how addnl. complexities, which are not yet fully understood, may affect each of these approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvWzW1JqxN4LVg90H21EOLACvtfcHk0lgCbMqVlfIwbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslKmu7zE&md5=6c8645293b079023de7d31011ae1a192</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1038%2Fnrd4389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4389%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DA.%2BD.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26aulast%3DKimmelman%26aufirst%3DA.%2BC.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DDrugging%2520the%2520undruggable%2520RAS%253A%2520mission%2520possible%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D828%26epage%3D851%26doi%3D10.1038%2Fnrd4389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cromm, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossmann, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldmann, H.</span></span> <span> </span><span class="NLM_article-title">Small-molecule modulation of Ras signaling</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">613</span>– <span class="NLM_lpage">622</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2Fnchembio.1560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=24929527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslGisbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=613-622&author=J.+Spiegelauthor=P.+M.+Crommauthor=G.+Zimmermannauthor=T.+N.+Grossmannauthor=H.+Waldmann&title=Small-molecule+modulation+of+Ras+signaling&doi=10.1038%2Fnchembio.1560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule modulation of Ras signaling</span></div><div class="casAuthors">Spiegel, Jochen; Cromm, Philipp M.; Zimmermann, Gunther; Grossmann, Tom N.; Waldmann, Herbert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">613-622</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite intense efforts in pharmaceutical industry and academia, a therapeutic grip on oncogenic Ras proteins has remained elusive.  Mutated Ras is assocd. with ∼20-30% of all human cancers often not responsive to established therapies.  In particular, K-Ras, the most frequently mutated Ras isoform, is considered one of the most important but 'undruggable' targets in cancer research.  Recently, new cavities on Ras for small-mol. ligands were identified, and selective direct targeting of mutated K-RasG12C has become possible for what is to our knowledge the first time.  In addn., impairment of Ras spatial organization, in particular via targeting the prenyl-binding Ras chaperone PDEδ, has opened a fresh perspective in anticancer research.  These recent advances fuel hopes for the development of new drugs targeting Ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTcp4dzeVKK7Vg90H21EOLACvtfcHk0ljCoXO7DkrZ2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslGisbw%253D&md5=f8d84f054e1b392cf6bfe55d5e235c28</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1560%26sid%3Dliteratum%253Aachs%26aulast%3DSpiegel%26aufirst%3DJ.%26aulast%3DCromm%26aufirst%3DP.%2BM.%26aulast%3DZimmermann%26aufirst%3DG.%26aulast%3DGrossmann%26aufirst%3DT.%2BN.%26aulast%3DWaldmann%26aufirst%3DH.%26atitle%3DSmall-molecule%2520modulation%2520of%2520Ras%2520signaling%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D613%26epage%3D622%26doi%3D10.1038%2Fnchembio.1560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pratilas, C.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span> <span> </span><span class="NLM_article-title">Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3329</span>– <span class="NLM_lpage">3334</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-3064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1158%2F1078-0432.CCR-09-3064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=20472680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1Wlsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=3329-3334&author=C.%0AA.+Pratilasauthor=D.+B.+Solit&title=Targeting+the+mitogen-activated+protein+kinase+pathway%3A+physiological+feedback+and+drug+response&doi=10.1158%2F1078-0432.CCR-09-3064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response</span></div><div class="casAuthors">Pratilas, Christine A.; Solit, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3329-3334</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Mitogen-activated protein kinase (MAPK) pathway activation is a frequent event in human cancer and is often the result of activating mutations in the BRAF and RAS oncogenes.  Targeted inhibitors of BRAF and its downstream effectors are in various stages of preclin. and clin. development.  These agents offer the possibility of greater efficacy and less toxicity than current therapies for tumors driven by oncogenic mutations in the MAPK pathway.  Early clin. results with the BRAF-selective inhibitor PLX4032 suggest that this strategy will prove successful in a select group of patients whose tumors are driven by V600E BRAF.  Relief of physiol. feedback upon pathway inhibition may, however, attenuate drug response and contribute to the development of acquired resistance.  An improved understanding of the adaptive response of cancer cells to MAPK pathway inhibition may thus aid in the identification of those patients most likely to respond to targeted pathway inhibitors and provide a rational basis for tailored combination strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg94UtFJDa8rVg90H21EOLACvtfcHk0ljCoXO7DkrZ2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1Wlsbw%253D&md5=afdeddfefff1ac57f16556753541f3be</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-3064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-3064%26sid%3Dliteratum%253Aachs%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DTargeting%2520the%2520mitogen-activated%2520protein%2520kinase%2520pathway%253A%2520physiological%2520feedback%2520and%2520drug%2520response%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D3329%26epage%3D3334%26doi%3D10.1158%2F1078-0432.CCR-09-3064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Durrant, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D. K.</span></span> <span> </span><span class="NLM_article-title">Targeting the Raf kinases in human cancer: the Raf dimer dilemma</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1038/bjc.2017.399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2Fbjc.2017.399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=29235562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFKhu7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2018&pages=3-8&author=D.+E.+Durrantauthor=D.+K.+Morrison&title=Targeting+the+Raf+kinases+in+human+cancer%3A+the+Raf+dimer+dilemma&doi=10.1038%2Fbjc.2017.399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Raf kinases in human cancer: the Raf dimer dilemma</span></div><div class="casAuthors">Durrant, David E.; Morrison, Deborah K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-8</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The Raf protein kinases are key intermediates in cellular signal transduction, functioning as direct effectors of the Ras GTPases and as the initiating kinases in the ERK cascade.  In human cancer, Raf activity is frequently dysregulated due to mutations in the Raf family member B-Raf or to alterations in upstream Raf regulators, including Ras and receptor tyrosine kinases.  First-generation Raf inhibitors, such as vemurafenib and dabrafenib, have yielded dramatic responses in malignant melanomas contg. B-Raf mutations; however, their overall usefulness has been limited by both intrinsic and acquired drug resistance.  In particular, issues related to the dimerization of the Raf kinases can impact the efficacy of these compds. and are a primary cause of drug resistance.  Here, we will review the importance of Raf dimerization in cell signalling as well as its effects on Raf inhibitor therapy, and we will present the new strategies that are being pursued to overcome the 'Raf Dimer Dilemma'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHTShTLpMLiLVg90H21EOLACvtfcHk0ljCoXO7DkrZ2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFKhu7vL&md5=186dbe3ee9006a384d9b50831000e144</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2017.399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2017.399%26sid%3Dliteratum%253Aachs%26aulast%3DDurrant%26aufirst%3DD.%2BE.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26atitle%3DTargeting%2520the%2520Raf%2520kinases%2520in%2520human%2520cancer%253A%2520the%2520Raf%2520dimer%2520dilemma%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2018%26volume%3D118%26spage%3D3%26epage%3D8%26doi%3D10.1038%2Fbjc.2017.399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span> <span> </span><span class="NLM_article-title">The clinical development of MEK inhibitors</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">385</span>– <span class="NLM_lpage">400</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2014.83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2Fnrclinonc.2014.83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=24840079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVyqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=385-400&author=Y.+Zhaoauthor=A.+A.+Adjei&title=The+clinical+development+of+MEK+inhibitors&doi=10.1038%2Fnrclinonc.2014.83"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical development of MEK inhibitors</span></div><div class="casAuthors">Zhao, Yujie; Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">385-400</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Aberrant activation of the RAS-RAF-MEK-ERK1/2 pathway occurs in more than 30% of human cancers.  As part of this pathway, MEK1 and MEK2 have crucial roles in tumorigenesis, cell proliferation and inhibition of apoptosis and, therefore, MEK1/2 inhibition is an attractive therapeutic strategy in a no. of cancers.  Highly selective and potent non-ATP-competitive allosteric MEK1/2 inhibitors have been developed and assessed in numerous clin. studies over the past decade.  These agents are not efficacious in a broad range of unselected cancers, although single-agent antitumor activity has been detected mainly in tumors that harbor mutations in genes encoding the members of the RAS and RAF protein families, such as certain melanomas.  Combinations of MEK1/2 inhibitors and cytotoxic chemotherapy, and/or other targeted agents are being studied to expand the efficacy of this class of agents.  Identifying predictive biomarkers, and delineating de novo and acquired resistance mechanisms are essential for the future clin. development of MEK inhibitors.  We discuss the clin. experience with MEK inhibitors to date, and consider the novel approaches to MEK-inhibitor therapy that might improve outcomes and lead to the wider use of such treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjbK3B6OzVbVg90H21EOLACvtfcHk0lhx1S8NL92mhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVyqtbo%253D&md5=c81e0a5f52a8d4d482b7d617901d67eb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2014.83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2014.83%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DThe%2520clinical%2520development%2520of%2520MEK%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D11%26spage%3D385%26epage%3D400%26doi%3D10.1038%2Fnrclinonc.2014.83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Restaino, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayananth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNunzio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windsor, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angagaw, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinheiro, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipps, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paliwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daublain, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutterbach, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philippar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siliphaivanh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschmeier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicklin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samatar, A. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1158%2F2159-8290.CD-13-0070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=23614898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=742-750&author=E.+J.+Morrisauthor=S.+Jhaauthor=C.+R.+Restainoauthor=P.+Dayananthauthor=H.+Zhuauthor=A.+Cooperauthor=D.+Carrauthor=Y.+Dengauthor=W.+Jinauthor=S.+Blackauthor=B.+Longauthor=J.+Liuauthor=E.+DiNunzioauthor=W.+Windsorauthor=R.+Zhangauthor=S.+Zhaoauthor=M.+H.+Angagawauthor=E.+M.+Pinheiroauthor=J.+Desaiauthor=L.+Xiaoauthor=G.+Shippsauthor=A.+Hruzaauthor=J.+Wangauthor=J.+Kellyauthor=S.+Paliwalauthor=X.+Gaoauthor=B.+S.+Babuauthor=L.+Zhuauthor=P.+Daublainauthor=L.+Zhangauthor=B.+A.+Lutterbachauthor=M.+R.+Pelletierauthor=U.+Philipparauthor=P.+Siliphaivanhauthor=D.+Witterauthor=P.+Kirschmeierauthor=W.+R.+Bishopauthor=D.+Hicklinauthor=D.+G.+Gillilandauthor=L.+Jayaramanauthor=L.+Zawelauthor=S.+Fawellauthor=A.+A.+Samatar&title=Discovery+of+a+novel+ERK+inhibitor+with+activity+in+models+of+acquired+resistance+to+BRAF+and+MEK+inhibitors&doi=10.1158%2F2159-8290.CD-13-0070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors</span></div><div class="casAuthors">Morris, Erick J.; Jha, Sharda; Restaino, Clifford R.; Dayananth, Priya; Zhu, Hugh; Cooper, Alan; Carr, Donna; Deng, Yongi; Jin, Weihong; Black, Stuart; Long, Brian; Liu, Jenny; DiNunzio, Edward; Windsor, William; Zhang, Rumin; Zhao, Shuxia; Angagaw, Minilik H.; Pinheiro, Elaine M.; Desai, Jagdish; Xiao, Li; Shipps, Gerald; Hruza, Alan; Wang, James; Kelly, Joe; Paliwal, Sunil; Gao, Xiaolei; Babu, Boga Sobhana; Zhu, Liang; Daublain, Pierre; Zhang, Ling; Lutterbach, Bart A.; Pelletier, Marc R.; Philippar, Ulrike; Siliphaivanh, Phieng; Witter, David; Kirschmeier, Paul; Bishop, W. Robert; Hicklin, Daniel; Gilliland, D. Gary; Jayaraman, Lata; Zawel, Leigh; Fawell, Stephen; Samatar, Ahmed A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">742-750</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The high frequency of activating RAS or BRAF mutations in cancer provides strong rationale for targeting the mitogen-activated protein kinase (MAPK) pathway.  Selective BRAF and MAP-ERK kinase (MEK) inhibitors have shown clin. efficacy in patients with melanoma.  However, the majority of responses are transient, and resistance is often assocd. with pathway reactivation of the extracellular signal-regulated kinase (ERK) signaling pathway.  Here, we describe the identification and characterization of SCH772984, a novel and selective inhibitor of ERK1/2 that displays behaviors of both type I and type II kinase inhibitors.  SCH772984 has nanomolar cellular potency in tumor cells with mutations in BRAF, NRA5, or KRAS and induces tumor regressions in xenograft models at tolerated doses.  Importantly, SCH772984 effectively inhibited MAPK signaling and cell proliferation in BRAF or MEK inhibitor-resistant models as well as in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors.  These data support the clin. development of ERK inhibitors for tumors refractory to MAPK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4HJ4HhYmLL7Vg90H21EOLACvtfcHk0lhx1S8NL92mhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE&md5=1f26a4a5bb1fab64bdd6c38c16b3f4e3</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0070%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DE.%2BJ.%26aulast%3DJha%26aufirst%3DS.%26aulast%3DRestaino%26aufirst%3DC.%2BR.%26aulast%3DDayananth%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DW.%26aulast%3DBlack%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDiNunzio%26aufirst%3DE.%26aulast%3DWindsor%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DAngagaw%26aufirst%3DM.%2BH.%26aulast%3DPinheiro%26aufirst%3DE.%2BM.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DShipps%26aufirst%3DG.%26aulast%3DHruza%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DKelly%26aufirst%3DJ.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DBabu%26aufirst%3DB.%2BS.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDaublain%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLutterbach%26aufirst%3DB.%2BA.%26aulast%3DPelletier%26aufirst%3DM.%2BR.%26aulast%3DPhilippar%26aufirst%3DU.%26aulast%3DSiliphaivanh%26aufirst%3DP.%26aulast%3DWitter%26aufirst%3DD.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DBishop%26aufirst%3DW.%2BR.%26aulast%3DHicklin%26aufirst%3DD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DJayaraman%26aufirst%3DL.%26aulast%3DZawel%26aufirst%3DL.%26aulast%3DFawell%26aufirst%3DS.%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520ERK%2520inhibitor%2520with%2520activity%2520in%2520models%2520of%2520acquired%2520resistance%2520to%2520BRAF%2520and%2520MEK%2520inhibitors%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D742%26epage%3D750%26doi%3D10.1158%2F2159-8290.CD-13-0070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Asati, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahapatra, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharti, S. K.</span></span> <span> </span><span class="NLM_article-title">K-ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.09.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1016%2Fj.ejmech.2016.09.049" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2017&pages=299-314&author=V.+Asatiauthor=D.+K.+Mahapatraauthor=S.+K.+Bharti&title=K-ras+and+its+inhibitors+towards+personalized+cancer+treatment%3A+Pharmacological+and+structural+perspectives&doi=10.1016%2Fj.ejmech.2016.09.049"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.09.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.09.049%26sid%3Dliteratum%253Aachs%26aulast%3DAsati%26aufirst%3DV.%26aulast%3DMahapatra%26aufirst%3DD.%2BK.%26aulast%3DBharti%26aufirst%3DS.%2BK.%26atitle%3DK-ras%2520and%2520its%2520inhibitors%2520towards%2520personalized%2520cancer%2520treatment%253A%2520Pharmacological%2520and%2520structural%2520perspectives%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D125%26spage%3D299%26epage%3D314%26doi%3D10.1016%2Fj.ejmech.2016.09.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Samatar, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">Targeting RAS–ERK signalling in cancer: promises and challenges</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">928</span>– <span class="NLM_lpage">942</span>, <span class="refDoi"> DOI: 10.1038/nrd4281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2Fnrd4281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=25435214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2lsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=928-942&author=A.+A.+Samatarauthor=P.+I.+Poulikakos&title=Targeting+RAS%E2%80%93ERK+signalling+in+cancer%3A+promises+and+challenges&doi=10.1038%2Fnrd4281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAS-ERK signalling in cancer: promises and challenges</span></div><div class="casAuthors">Samatar, Ahmed A.; Poulikakos, Poulikos I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">928-942</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumors, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes.  Recently, the use of compds. targeting components of ERK signalling, such as RAF or MEK inhibitors, has led to substantial improvement in clin. outcome in metastatic melanoma and has shown promising clin. activity in addnl. tumor types.  However, response rates are highly variable and the efficacy of these drugs is primarily limited by the development of resistance.  Both intrinsic and acquired resistance to RAF and MEK inhibitors are frequently assocd. with the persistence of ERK signalling in the presence of the drug, implying the need for more innovative approaches to target the pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL4UeXNUJnYbVg90H21EOLACvtfcHk0li5sVbbh1eBDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2lsrrI&md5=ab4038893612f438cf4406680ab2e4f4</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1038%2Fnrd4281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4281%26sid%3Dliteratum%253Aachs%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DTargeting%2520RAS%25E2%2580%2593ERK%2520signalling%2520in%2520cancer%253A%2520promises%2520and%2520challenges%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D928%26epage%3D942%26doi%3D10.1038%2Fnrd4281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fruman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rommel, C.</span></span> <span> </span><span class="NLM_article-title">PI3K and cancer: lessons, challenges and opportunities</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1038/nrd4204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2Fnrd4204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=24481312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=140-156&author=D.+A.+Frumanauthor=C.+Rommel&title=PI3K+and+cancer%3A+lessons%2C+challenges+and+opportunities&doi=10.1038%2Fnrd4204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K and cancer: lessons, challenges and opportunities</span></div><div class="casAuthors">Fruman, David A.; Rommel, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-156</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The central role of phosphoinositide 3-kinase (PI3K) activation in tumor cell biol. has prompted a sizeable effort to target PI3K and/or downstream kinases such as AKT and mammalian target of rapamycin (mTOR) in cancer.  However, emerging clin. data show limited single-agent activity of inhibitors targeting PI3K, AKT or mTOR at tolerated doses.  One exception is the response to PI3Kδ inhibitors in chronic lymphocytic leukemia, where a combination of cell-intrinsic and -extrinsic activities drive efficacy.  Here, we review key challenges and opportunities for the clin. development of inhibitors targeting the PI3K-AKT-mTOR pathway.  Through a greater focus on patient selection, increased understanding of immune modulation and strategic application of rational combinations, it should be possible to realize the potential of this promising class of targeted anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlD2rY54m9LbVg90H21EOLACvtfcHk0li5sVbbh1eBDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D&md5=c4f6b4b9f9fcacd6ef55eb17d3a4f425</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrd4204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4204%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%2BA.%26aulast%3DRommel%26aufirst%3DC.%26atitle%3DPI3K%2520and%2520cancer%253A%2520lessons%252C%2520challenges%2520and%2520opportunities%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D140%26epage%3D156%26doi%3D10.1038%2Fnrd4204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karoulia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavathiotis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">New perspectives for targeting RAF kinase in human cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">676</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1038/nrc.2017.79</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2Fnrc.2017.79" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=28984291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Sqt7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=676-691&author=Z.+Karouliaauthor=E.+Gavathiotisauthor=P.+I.+Poulikakos&title=New+perspectives+for+targeting+RAF+kinase+in+human+cancer&doi=10.1038%2Fnrc.2017.79"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">New perspectives for targeting RAF kinase in human cancer</span></div><div class="casAuthors">Karoulia, Zoi; Gavathiotis, Evripidis; Poulikakos, Poulikos I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">676-691</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The discovery that a subset of human tumors is dependent on mutationally deregulated BRAF kinase intensified the development of RAF inhibitors to be used as potential therapeutics.  The US Food and Drug Administration (FDA)-approved second-generation RAF inhibitors vemurafenib and dabrafenib have elicited remarkable responses and improved survival of patients with BRAF-V600E/K melanoma, but their effectiveness is limited by resistance.  Beyond melanoma, current clin. RAF inhibitors show modest efficacy when used for colorectal and thyroid BRAF-V600E tumors or for tumors harboring BRAF alterations other than the V600 mutation.  Accumulated exptl. and clin. evidence indicates that the complex biochem. mechanisms of RAF kinase signalling account both for the effectiveness of RAF inhibitors and for the various mechanisms of tumor resistance to them.  Recently, a no. of next-generation RAF inhibitors, with diverse structural and biochem. properties, have entered preclin. and clin. development.  In this Review, we discuss the current understanding of RAF kinase regulation, mechanisms of inhibitor action and related clin. resistance to these drugs.  The recent elucidation of crit. structural and biochem. aspects of RAF inhibitor action, combined with the availability of a no. of structurally diverse RAF inhibitors currently in preclin. and clin. development, will enable the design of more effective RAF inhibitors and RAF-inhibitor-based therapeutic strategies, tailored to different clin. contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEUrKAljS7SrVg90H21EOLACvtfcHk0li5sVbbh1eBDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Sqt7fN&md5=7e8ee4222467a2d5c12b23ccce99fc62</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2017.79&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2017.79%26sid%3Dliteratum%253Aachs%26aulast%3DKaroulia%26aufirst%3DZ.%26aulast%3DGavathiotis%26aufirst%3DE.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DNew%2520perspectives%2520for%2520targeting%2520RAF%2520kinase%2520in%2520human%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2017%26volume%3D17%26spage%3D676%26epage%3D691%26doi%3D10.1038%2Fnrc.2017.79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klochkov, S. G.</span>; <span class="NLM_string-name">Neganova, M. E.</span>; <span class="NLM_string-name">Yarla, N. S.</span>; <span class="NLM_string-name">Parvathaneni, M.</span>; <span class="NLM_string-name">Sharma, B.</span>; <span class="NLM_string-name">Tarasov, V. V.</span>; <span class="NLM_string-name">Barreto, G.</span>; <span class="NLM_string-name">Bachurin, S. O.</span>; <span class="NLM_string-name">Ashraf, G. M.</span>; <span class="NLM_string-name">Aliev, G.</span></span> <span> </span><span class="NLM_article-title">Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy</span>.  <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span> <span class="refDoi"> DOI: 10.1016/j.semcancer.2017.10.010</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1016%2Fj.semcancer.2017.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=29100957" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=S.+G.+Klochkov&author=M.+E.+Neganova&author=N.+S.+Yarla&author=M.+Parvathaneni&author=B.+Sharma&author=V.+V.+Tarasov&author=G.+Barreto&author=S.+O.+Bachurin&author=G.+M.+Ashraf&author=G.+Aliev&title=Implications+of+farnesyltransferase+and+its+inhibitors+as+a+promising+strategy+for+cancer+therapy&doi=10.1016%2Fj.semcancer.2017.10.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2017.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2017.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DKlochkov%26aufirst%3DS.%2BG.%26atitle%3DImplications%2520of%2520farnesyltransferase%2520and%2520its%2520inhibitors%2520as%2520a%2520promising%2520strategy%2520for%2520cancer%2520therapy%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2017%26doi%3D10.1016%2Fj.semcancer.2017.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scholl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fröhling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinzel, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadlow, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaswamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Root, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacks, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">834</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1016%2Fj.cell.2009.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=19490892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVCltLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2009&pages=821-834&author=C.+Schollauthor=S.+Fr%C3%B6hlingauthor=I.+F.+Dunnauthor=A.+C.+Schinzelauthor=D.+A.+Barbieauthor=S.+Y.+Kimauthor=S.+J.+Silverauthor=P.+Tamayoauthor=R.+C.+Wadlowauthor=S.+Ramaswamyauthor=K.+D%C3%B6hnerauthor=L.+Bullingerauthor=P.+Sandyauthor=J.+S.+Boehmauthor=D.+E.+Rootauthor=T.+Jacksauthor=W.+C.+Hahnauthor=D.+G.+Gilliland&title=Synthetic+lethal+interaction+between+oncogenic+KRAS+dependency+and+STK33+suppression+in+human+cancer+cells&doi=10.1016%2Fj.cell.2009.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells</span></div><div class="casAuthors">Scholl, Claudia; Frohling, Stefan; Dunn, Ian F.; Schinzel, Anna C.; Barbie, David A.; Kim, So Young; Silver, Serena J.; Tamayo, Pablo; Wadlow, Raymond C.; Ramaswamy, Sridhar; Dohner, Konstanze; Bullinger, Lars; Sandy, Peter; Boehm, Jesse S.; Root, David E.; Jacks, Tyler; Hahn, William C.; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">821-834</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">An alternative to therapeutic targeting of oncogenes is to perform "synthetic lethality" screens for genes that are essential only in the context of specific cancer-causing mutations.  We used high-throughput RNA interference (RNAi) to identify synthetic lethal interactions in cancer cells harboring mutant KRAS, the most commonly mutated human oncogene.  We find that cells that are dependent on mutant KRAS exhibit sensitivity to suppression of the serine/threonine kinase STK33 irresp. of tissue origin, whereas STK33 is not required by KRAS-independent cells.  STK33 promotes cancer cell viability in a kinase activity-dependent manner by regulating the suppression of mitochondrial apoptosis mediated through S6K1-induced inactivation of the death agonist BAD selectively in mutant KRAS-dependent cells.  These observations identify STK33 as a target for treatment of mutant KRAS-driven cancers and demonstrate the potential of RNAi screens for discovering functional dependencies created by oncogenic mutations that may enable therapeutic intervention for cancers with "undruggable" genetic alterations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2ijlOPM8WN7Vg90H21EOLACvtfcHk0lgghZvMreYEFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVCltLc%253D&md5=478f083a4815b8d57cee8d3b07042400</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DScholl%26aufirst%3DC.%26aulast%3DFr%25C3%25B6hling%26aufirst%3DS.%26aulast%3DDunn%26aufirst%3DI.%2BF.%26aulast%3DSchinzel%26aufirst%3DA.%2BC.%26aulast%3DBarbie%26aufirst%3DD.%2BA.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DSilver%26aufirst%3DS.%2BJ.%26aulast%3DTamayo%26aufirst%3DP.%26aulast%3DWadlow%26aufirst%3DR.%2BC.%26aulast%3DRamaswamy%26aufirst%3DS.%26aulast%3DD%25C3%25B6hner%26aufirst%3DK.%26aulast%3DBullinger%26aufirst%3DL.%26aulast%3DSandy%26aufirst%3DP.%26aulast%3DBoehm%26aufirst%3DJ.%2BS.%26aulast%3DRoot%26aufirst%3DD.%2BE.%26aulast%3DJacks%26aufirst%3DT.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DSynthetic%2520lethal%2520interaction%2520between%2520oncogenic%2520KRAS%2520dependency%2520and%2520STK33%2520suppression%2520in%2520human%2520cancer%2520cells%26jtitle%3DCell%26date%3D2009%26volume%3D137%26spage%3D821%26epage%3D834%26doi%3D10.1016%2Fj.cell.2009.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, N. P.</span></span> <span> </span><span class="NLM_article-title">ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">4162</span>– <span class="NLM_lpage">4167</span>, <span class="refDoi"> DOI: 10.1038/onc.2014.350</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2Fonc.2014.350" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=25347744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVWmsLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=4162-4167&author=K.+Mahajanauthor=N.+P.+Mahajan&title=ACK1%2FTNK2+tyrosine+kinase%3A+molecular+signaling+and+evolving+role+in+cancers&doi=10.1038%2Fonc.2014.350"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers</span></div><div class="casAuthors">Mahajan, K.; Mahajan, N. P.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">4162-4167</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulated tyrosine kinase signaling alters cellular homeostasis to drive cancer progression.  The emergence of a non-receptor tyrosine kinase (non-RTK), ACK1 (also known as activated Cdc42-assocd. kinase 1 or TNK2) as an oncogenic kinase, has uncovered novel mechanisms by which tyrosine kinase signaling promotes cancer progression.  Although early studies focused on ACK1 as a cytosolic effector of activated transmembrane RTKs, wherein it shuttles between the cytosol and the nucleus to rapidly transduce extracellular signals from the RTKs to the intracellular effectors, recent data unfold a new aspect of its functionality as an epigenetic regulator.  ACK1 interacts with the estrogen receptor (ER)/histone demethylase KDM3A (JHDM2a) complex, which modifies KDM3A by tyrosine phosphorylation to regulate the transcriptional outcome at HOXA1 locus to promote the growth of tamoxifen-resistant breast cancer.  It is also well established that ACK1 regulates the activity of androgen receptor (AR) by tyrosine phosphorylation to fuel the growth of hormone-refractory prostate cancers.  Further, recent explosion in genomic sequencing has revealed recurrent ACK1 gene amplification and somatic mutations in a variety of human malignancies, providing a mol. basis for its role in neoplastic transformation.  In this review, we will discuss the various facets of ACK1 signaling, including its newly uncovered epigenetic regulator function, which enables cells to bypass the blockade to major survival pathways to promote resistance to std. cancer treatments.  Not surprisingly, cancer cells appear to acquire an 'addiction' to ACK1-mediated survival, particularly under stress conditions, such as growth factor deprivation or genotoxic insults or hormone deprivation.  With the accelerated development of potent and selective ACK1 inhibitors, targeted treatment for cancers harboring aberrant ACK1 activity may soon become a clin. reality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQZA9Fv5H3LLVg90H21EOLACvtfcHk0lgghZvMreYEFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVWmsLjK&md5=b6376cc52eb148e8726197c14279cdf1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fonc.2014.350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2014.350%26sid%3Dliteratum%253Aachs%26aulast%3DMahajan%26aufirst%3DK.%26aulast%3DMahajan%26aufirst%3DN.%2BP.%26atitle%3DACK1%252FTNK2%2520tyrosine%2520kinase%253A%2520molecular%2520signaling%2520and%2520evolving%2520role%2520in%2520cancers%26jtitle%3DOncogene%26date%3D2015%26volume%3D34%26spage%3D4162%26epage%3D4167%26doi%3D10.1038%2Fonc.2014.350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, N. P.</span></span> <span> </span><span class="NLM_article-title">PI3K-independent AKT activation in cancers: A treasure trove for novel therapeutics</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>227</i></span>,  <span class="NLM_fpage">3178</span>– <span class="NLM_lpage">3184</span>, <span class="refDoi"> DOI: 10.1002/jcp.24065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1002%2Fjcp.24065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=22307544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1KntL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=227&publication_year=2012&pages=3178-3184&author=K.+Mahajanauthor=N.+P.+Mahajan&title=PI3K-independent+AKT+activation+in+cancers%3A+A+treasure+trove+for+novel+therapeutics&doi=10.1002%2Fjcp.24065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K-independent AKT activation in cancers: A treasure trove for novel therapeutics</span></div><div class="casAuthors">Mahajan, Kiran; Mahajan, Nupam P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">227</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3178-3184</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  AKT/PKB serine threonine kinase, a crit. signaling mol. promoting cell growth and survival pathways, is frequently dysregulated in many cancers.  Although phosphatidylinositol-3-OH kinase (PI3K), a lipid kinase, is well characterized as a major regulator of AKT activation in response to a variety of ligands, recent studies highlight a diverse group of tyrosine (Ack1/TNK2, Src, PTK6) and serine/threonine (TBK1, IKBKE, DNAPKcs) kinases that activate AKT directly to promote its pro-proliferative signaling functions.  While some of these alternate AKT activating kinases respond to growth factors, others respond to inflammatory and genotoxic stimuli.  A common theme emerging from these studies is that aberrant or hyperactivation of these alternate kinases is often assocd. with malignancy.  Consequently, evaluating the use of small mol. inhibitors against these alternate AKT activating kinases at earlier stages of cancer therapy may overcome the pressing problem of drug resistance surfacing esp. in patients treated with PI3K inhibitors.  J. Cell. Physiol. 227: 3178-3184, 2012. © 2012 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkNt3Lfr5PxrVg90H21EOLACvtfcHk0liYiyuZ6t5DNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1KntL4%253D&md5=3e21f9af43df4cf664fa5a5ff60f9eb8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fjcp.24065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.24065%26sid%3Dliteratum%253Aachs%26aulast%3DMahajan%26aufirst%3DK.%26aulast%3DMahajan%26aufirst%3DN.%2BP.%26atitle%3DPI3K-independent%2520AKT%2520activation%2520in%2520cancers%253A%2520A%2520treasure%2520trove%2520for%2520novel%2520therapeutics%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2012%26volume%3D227%26spage%3D3178%26epage%3D3184%26doi%3D10.1002%2Fjcp.24065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pombo, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehrl, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avruch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zon, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodgett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Force, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyriakis, J. M.</span></span> <span> </span><span class="NLM_article-title">Activation of the SAPK pathway by the human STE20 homologue germinal centre kinase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">750</span>– <span class="NLM_lpage">754</span>, <span class="refDoi"> DOI: 10.1038/377750a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1038%2F377750a0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=1995&pages=750-754&author=C.+M.+Pomboauthor=J.+H.+Kehrlauthor=I.+S%C3%A1nchezauthor=P.+Katzauthor=J.+Avruchauthor=L.+I.+Zonauthor=J.+R.+Woodgettauthor=T.+Forceauthor=J.+M.+Kyriakis&title=Activation+of+the+SAPK+pathway+by+the+human+STE20+homologue+germinal+centre+kinase&doi=10.1038%2F377750a0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2F377750a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F377750a0%26sid%3Dliteratum%253Aachs%26aulast%3DPombo%26aufirst%3DC.%2BM.%26aulast%3DKehrl%26aufirst%3DJ.%2BH.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DI.%26aulast%3DKatz%26aufirst%3DP.%26aulast%3DAvruch%26aufirst%3DJ.%26aulast%3DZon%26aufirst%3DL.%2BI.%26aulast%3DWoodgett%26aufirst%3DJ.%2BR.%26aulast%3DForce%26aufirst%3DT.%26aulast%3DKyriakis%26aufirst%3DJ.%2BM.%26atitle%3DActivation%2520of%2520the%2520SAPK%2520pathway%2520by%2520the%2520human%2520STE20%2520homologue%2520germinal%2520centre%2520kinase%26jtitle%3DNature%26date%3D1995%26volume%3D377%26spage%3D750%26epage%3D754%26doi%3D10.1038%2F377750a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span> <span> </span><span class="NLM_article-title">A type-II kinase inhibitor capable of inhibiting the T315I “gatekeeper” mutant of Bcr-Abl</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5439</span>– <span class="NLM_lpage">5448</span>, <span class="refDoi"> DOI: 10.1021/jm901808w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901808w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5439-5448&author=H.+G.+Choiauthor=P.+Renauthor=F.+Adrianauthor=F.+Sunauthor=H.+S.+Leeauthor=X.+Wangauthor=Q.+Dingauthor=G.+Zhangauthor=Y.+Xieauthor=J.+Zhangauthor=Y.+Liuauthor=T.+Tuntlandauthor=M.+Warmuthauthor=P.+W.+Manleyauthor=J.+Mestanauthor=N.+S.+Grayauthor=T.+Sim&title=A+type-II+kinase+inhibitor+capable+of+inhibiting+the+T315I+%E2%80%9Cgatekeeper%E2%80%9D+mutant+of+Bcr-Abl&doi=10.1021%2Fjm901808w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm901808w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901808w%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DAdrian%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSim%26aufirst%3DT.%26atitle%3DA%2520type-II%2520kinase%2520inhibitor%2520capable%2520of%2520inhibiting%2520the%2520T315I%2520%25E2%2580%259Cgatekeeper%25E2%2580%259D%2520mutant%2520of%2520Bcr-Abl%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5439%26epage%3D5448%26doi%3D10.1021%2Fjm901808w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span>; <span class="NLM_string-name">Lee, H.
S.</span>; <span class="NLM_string-name">Ren, P.</span>; <span class="NLM_string-name">Ding, Q.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Uno, T.</span>; <span class="NLM_string-name">Zhang, G.</span>; <span class="NLM_string-name">Liu, Y.</span>; <span class="NLM_string-name">Li, B.</span>; <span class="NLM_string-name">Li, L.</span>; <span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Compounds and Compositions as Protein Kinase Inhibitors</span>. WO Patent <span class="NLM_patent">2005/011597</span>, Feb 10, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=T.+Sim&author=H.%0AS.+Lee&author=P.+Ren&author=Q.+Ding&author=X.+Wang&author=T.+Uno&author=G.+Zhang&author=Y.+Liu&author=B.+Li&author=L.+Li&author=N.+S.+Gray&title=Compounds+and+Compositions+as+Protein+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSim%26aufirst%3DT.%26atitle%3DCompounds%2520and%2520Compositions%2520as%2520Protein%2520Kinase%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xian, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">A structure-guided approach to creating covalent FGFR inhibitors</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1016%2Fj.chembiol.2010.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=20338520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=285-295&author=W.+Zhouauthor=W.+Hurauthor=U.+McDermottauthor=A.+Duttauthor=W.+Xianauthor=S.+B.+Ficarroauthor=J.+Zhangauthor=S.+V.+Sharmaauthor=J.+Bruggeauthor=M.+Meyersonauthor=J.+Settlemanauthor=N.+S.+Gray&title=A+structure-guided+approach+to+creating+covalent+FGFR+inhibitors&doi=10.1016%2Fj.chembiol.2010.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">A Structure-Guided Approach to Creating Covalent FGFR Inhibitors</span></div><div class="casAuthors">Zhou, Wenjun; Hur, Wooyoung; McDermott, Ultan; Dutt, Amit; Xian, Wa; Ficarro, Scott B.; Zhang, Jianming; Sharma, Sreenath V.; Brugge, Joan; Meyerson, Matthew; Settleman, Jeffrey; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-295</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The fibroblast growth factor receptor tyrosine kinases (FGFR1, 2, 3, and 4) represent promising therapeutic targets in a no. of cancers.  We have developed the first potent and selective irreversible inhibitor of FGFR1, 2, 3, and 4, which we named FIIN-1 that forms a covalent bond with cysteine 486 located in the P loop of the FGFR1 ATP binding site.  We demonstrated that the inhibitor potently inhibits Tel-FGFR1-transformed Ba/F3 cells (EC50 = 14 nM) as well as numerous FGFR-dependent cancer cell lines.  A biotin-derivatized version of the inhibitor, FIIN-1-biotin, was shown to covalently label FGFR1 at Cys486.  FIIN-1 is a useful probe of FGFR-dependent cellular phenomena and may provide a starting point of the development of therapeutically relevant irreversible inhibitors of wild-type and drug-resistant forms of FGFR kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqxMZh8QQP47Vg90H21EOLACvtfcHk0liYiyuZ6t5DNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D&md5=0b7b084a073b1c6f30f38565a0e4db81</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DDutt%26aufirst%3DA.%26aulast%3DXian%26aufirst%3DW.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBrugge%26aufirst%3DJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520structure-guided%2520approach%2520to%2520creating%2520covalent%2520FGFR%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D285%26epage%3D295%26doi%3D10.1016%2Fj.chembiol.2010.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guagnano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spanka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Douget, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brueggen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wartmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghausen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drueckes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graus Porta, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-(2, 6-dichloro-3, 5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7066</span>– <span class="NLM_lpage">7083</span>, <span class="refDoi"> DOI: 10.1021/jm2006222</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2006222" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7066-7083&author=V.+Guagnanoauthor=P.+Furetauthor=C.+Spankaauthor=V.+Bordasauthor=M.+Le+Dougetauthor=C.+Stammauthor=J.+Brueggenauthor=M.+R.+Jensenauthor=C.+Schnellauthor=H.+Schmidauthor=M.+Wartmannauthor=J.+Berghausenauthor=P.+Drueckesauthor=A.+Zimmerlinauthor=D.+Bussiereauthor=J.+Murrayauthor=D.+Graus+Porta&title=Discovery+of+3-%282%2C+6-dichloro-3%2C+5-dimethoxy-phenyl%29-1-%7B6-%5B4-%284-ethyl-piperazin-1-yl%29-phenylamino%5D-pyrimidin-4-yl%7D-1-methyl-urea+%28NVP-BGJ398%29%2C+a+potent+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+family+of+receptor+tyrosine+kinase&doi=10.1021%2Fjm2006222"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm2006222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2006222%26sid%3Dliteratum%253Aachs%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DSpanka%26aufirst%3DC.%26aulast%3DBordas%26aufirst%3DV.%26aulast%3DLe%2BDouget%26aufirst%3DM.%26aulast%3DStamm%26aufirst%3DC.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DSchmid%26aufirst%3DH.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DBerghausen%26aufirst%3DJ.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DGraus%2BPorta%26aufirst%3DD.%26atitle%3DDiscovery%2520of%25203-%25282%252C%25206-dichloro-3%252C%25205-dimethoxy-phenyl%2529-1-%257B6-%255B4-%25284-ethyl-piperazin-1-yl%2529-phenylamino%255D-pyrimidin-4-yl%257D-1-methyl-urea%2520%2528NVP-BGJ398%2529%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520family%2520of%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7066%26epage%3D7083%26doi%3D10.1021%2Fjm2006222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomanbhoy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurbani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patricelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herhaus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ham, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrlage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapkota, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westover, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1021/jm500480k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500480k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyiurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=183-196&author=L.+Tanauthor=T.+Nomanbhoyauthor=D.+Gurbaniauthor=M.+Patricelliauthor=J.+Hunterauthor=J.+Gengauthor=L.+Herhausauthor=J.+Zhangauthor=E.+Paulsauthor=Y.+Hamauthor=H.+G.+Choiauthor=T.+Xieauthor=X.+Dengauthor=S.+J.+Buhrlageauthor=T.+Simauthor=P.+Cohenauthor=G.+Sapkotaauthor=K.+D.+Westoverauthor=N.+S.+Gray&title=Discovery+of+type+II+inhibitors+of+TGF%CE%B2-activated+kinase+1+%28TAK1%29+and+mitogen-activated+protein+kinase+kinase+kinase+kinase+2+%28MAP4K2%29&doi=10.1021%2Fjm500480k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Type II Inhibitors of TGFβ-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2)</span></div><div class="casAuthors">Tan, Li; Nomanbhoy, Tyzoon; Gurbani, Deepak; Patricelli, Matthew; Hunter, John; Geng, Jiefei; Herhaus, Lina; Zhang, Jianming; Pauls, Eduardo; Ham, Youngjin; Choi, Hwan Geun; Xie, Ting; Deng, Xianming; Buhrlage, Sara J.; Sim, Taebo; Cohen, Philip; Sapkota, Gopal; Westover, Kenneth D.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">183-196</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors developed a pharmacophore model for type II inhibitors that was used to guide the construction of a library of kinase inhibitors.  Kinome-wide selectivity profiling of the library resulted in the identification of a series of 4-substituted 1H-pyrrolo[2,3-b]pyridines that exhibited potent inhibitory activity against two mitogen-activated protein kinases (MAPKs), TAK1 (MAP3K7) and MAP4K2, as well as pharmacol. well interrogated kinases such as p38α (MAPK14) and ABL.  Further investigation of the structure-activity relationship (SAR) resulted in the identification effect two potent dual TAK1 and MAP4K2 inhibitors such as I as well as two MAP4K2 selective inhibitors such as II.  Some of these inhibitors possess good pharmacokinetic properties that will enable their use in pharmacol. studies in vivo.  A 2.4 Å cocrystal structure of TAK1 in complex with 1 confirms that the activation loop of TAK1 assumes the DFG-out conformation characteristic of type II inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzjzVF_V_qSLVg90H21EOLACvtfcHk0li00Rum015ULw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyiurrJ&md5=288a6be4b9b4a5a6a5b925673cadd47a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm500480k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500480k%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DNomanbhoy%26aufirst%3DT.%26aulast%3DGurbani%26aufirst%3DD.%26aulast%3DPatricelli%26aufirst%3DM.%26aulast%3DHunter%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DJ.%26aulast%3DHerhaus%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPauls%26aufirst%3DE.%26aulast%3DHam%26aufirst%3DY.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DSapkota%26aufirst%3DG.%26aulast%3DWestover%26aufirst%3DK.%2BD.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520type%2520II%2520inhibitors%2520of%2520TGF%25CE%25B2-activated%2520kinase%25201%2520%2528TAK1%2529%2520and%2520mitogen-activated%2520protein%2520kinase%2520kinase%2520kinase%2520kinase%25202%2520%2528MAP4K2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D183%26epage%3D196%26doi%3D10.1021%2Fjm500480k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Meijere, A.</span></span> <span> </span><span class="NLM_article-title">Bonding properties of cyclopropane and their chemical consequences</span>. <i>Angew. Chem., Int. Ed. Engl.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">826</span>, <span class="refDoi"> DOI: 10.1002/anie.197908093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1002%2Fanie.197908093" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1979&pages=809-826&author=A.+de%0AMeijere&title=Bonding+properties+of+cyclopropane+and+their+chemical+consequences&doi=10.1002%2Fanie.197908093"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fanie.197908093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.197908093%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BMeijere%26aufirst%3DA.%26atitle%3DBonding%2520properties%2520of%2520cyclopropane%2520and%2520their%2520chemical%2520consequences%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%2520Engl.%26date%3D1979%26volume%3D18%26spage%3D809%26epage%3D826%26doi%3D10.1002%2Fanie.197908093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span> <span> </span><span class="NLM_article-title">A pyrazolo [3, 4-<i>d</i>] pyrimidin-4-amine derivative containing an isoxazole moiety is a selective and potent inhibitor of RET gatekeeper mutants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">373</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01522</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01522" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=358-373&author=H.+Yoonauthor=Y.+Kwakauthor=S.+Choiauthor=H.+Choauthor=N.+D.+Kimauthor=T.+Sim&title=A+pyrazolo+%5B3%2C+4-d%5D+pyrimidin-4-amine+derivative+containing+an+isoxazole+moiety+is+a+selective+and+potent+inhibitor+of+RET+gatekeeper+mutants&doi=10.1021%2Facs.jmedchem.5b01522"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01522%26sid%3Dliteratum%253Aachs%26aulast%3DYoon%26aufirst%3DH.%26aulast%3DKwak%26aufirst%3DY.%26aulast%3DChoi%26aufirst%3DS.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DSim%26aufirst%3DT.%26atitle%3DA%2520pyrazolo%2520%255B3%252C%25204-d%255D%2520pyrimidin-4-amine%2520derivative%2520containing%2520an%2520isoxazole%2520moiety%2520is%2520a%2520selective%2520and%2520potent%2520inhibitor%2520of%2520RET%2520gatekeeper%2520mutants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D358%26epage%3D373%26doi%3D10.1021%2Facs.jmedchem.5b01522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Hare, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loriaux, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbin, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaramoorthi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snodgrass, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Commodore, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span> <span> </span><span class="NLM_article-title">AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2009.09.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1016%2Fj.ccr.2009.09.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=19878872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFKltb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=401-412&author=T.+O%E2%80%99Hareauthor=W.+C.+Shakespeareauthor=X.+Zhuauthor=C.+A.+Eideauthor=V.+M.+Riveraauthor=F.+Wangauthor=L.+T.+Adrianauthor=T.+Zhouauthor=W.+S.+Huangauthor=Q.+Xuauthor=C.+A.+Metcalfauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=A.+S.+Corbinauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+A.+Keatsauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=M.+Thomasauthor=D.+Zhouauthor=J.+Snodgrassauthor=L.+Commodoreauthor=T.+K.+Sawyerauthor=D.+C.+Dalgarnoauthor=M.+W.+N.+Deiningerauthor=B.+J.+Drukerauthor=T.+Clackson&title=AP24534%2C+a+pan-BCR-ABL+inhibitor+for+chronic+myeloid+leukemia%2C+potently+inhibits+the+T315I+mutant+and+overcomes+mutation-based+resistance&doi=10.1016%2Fj.ccr.2009.09.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</span></div><div class="casAuthors">O'Hare, Thomas; Shakespeare, William C.; Zhu, Xiaotian; Eide, Christopher A.; Rivera, Victor M.; Wang, Frank; Adrian, Lauren T.; Zhou, Tianjun; Huang, Wei-Sheng; Xu, Qihong; Metcalf, Chester A., III; Tyner, Jeffrey W.; Loriaux, Marc M.; Corbin, Amie S.; Wardwell, Scott; Ning, Yaoyu; Keats, Jeffrey A.; Wang, Yihan; Sundaramoorthi, Raji; Thomas, Mathew; Zhou, Dong; Snodgrass, Joseph; Commodore, Lois; Sawyer, Tomi K.; Dalgarno, David C.; Deininger, Michael W. N.; Druker, Brian J.; Clackson, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">401-412</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to relapse and a switch to second-line therapy with nilotinib or dasatinib.  Despite three approved therapeutic options, the cross-resistant BCR-ABLT315I mutation and compd. mutants selected on sequential inhibitor therapy remain major clin. challenges.  We report design and preclin. evaluation of AP24534, a potent, orally available multitargeted kinase inhibitor active against T315I and other BCR-ABL mutants.  AP24534 inhibited all tested BCR-ABL mutants in cellular and biochem. assays, suppressed BCR-ABLT315I-driven tumor growth in mice, and completely abrogated resistance in cell-based mutagenesis screens.  Our work supports clin. evaluation of AP24534 as a pan-BCR-ABL inhibitor for treatment of CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox3g7ZYNXwLbVg90H21EOLACvtfcHk0liOe_7DVUNZWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFKltb3N&md5=62a383734fc345b97647ba71aa7aee04</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2009.09.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2009.09.028%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DSnodgrass%26aufirst%3DJ.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%2BN.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26atitle%3DAP24534%252C%2520a%2520pan-BCR-ABL%2520inhibitor%2520for%2520chronic%2520myeloid%2520leukemia%252C%2520potently%2520inhibits%2520the%2520T315I%2520mutant%2520and%2520overcomes%2520mutation-based%2520resistance%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26spage%3D401%26epage%3D412%26doi%3D10.1016%2Fj.ccr.2009.09.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugochukwu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Delft, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2359</span>– <span class="NLM_lpage">2367</span>, <span class="refDoi"> DOI: 10.1021/jm101506n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101506n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2359-2367&author=E.+Salahauthor=E.+Ugochukwuauthor=A.+J.+Barrauthor=F.+von+Delftauthor=S.+Knappauthor=J.+M.+Elkins&title=Crystal+structures+of+ABL-related+gene+%28ABL2%29+in+complex+with+imatinib%2C+tozasertib+%28VX-680%29%2C+and+a+type+I+inhibitor+of+the+triazole+carbothioamide+class&doi=10.1021%2Fjm101506n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm101506n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101506n%26sid%3Dliteratum%253Aachs%26aulast%3DSalah%26aufirst%3DE.%26aulast%3DUgochukwu%26aufirst%3DE.%26aulast%3DBarr%26aufirst%3DA.%2BJ.%26aulast%3Dvon%2BDelft%26aufirst%3DF.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26atitle%3DCrystal%2520structures%2520of%2520ABL-related%2520gene%2520%2528ABL2%2529%2520in%2520complex%2520with%2520imatinib%252C%2520tozasertib%2520%2528VX-680%2529%252C%2520and%2520a%2520type%2520I%2520inhibitor%2520of%2520the%2520triazole%2520carbothioamide%2520class%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2359%26epage%3D2367%26doi%3D10.1021%2Fjm101506n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otwinowski, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minor, W.</span></span> <span> </span><span class="NLM_article-title">Processing of X-ray diffraction data collected in oscillation mode</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1016/S0076-6879(97)76066-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=27754618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=307-326&author=Z.+Otwinowskiauthor=W.+Minor&title=Processing+of+X-ray+diffraction+data+collected+in+oscillation+mode&doi=10.1016%2FS0076-6879%2897%2976066-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of x-ray diffraction data collected in oscillation mode</span></div><div class="casAuthors">Otwinowski, Zbyszek; Minor, Wladek</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">Macromolecular Crystallography, Part A</span>),
    <span class="NLM_cas:pages">307-326</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Macromol. crystallog. is an iterative process.  Rarely do the first crystals provide all the necessary data to solve the biol. problem being studied.  Each step benefits from experience learned in previous steps.  To monitor the progress, the HKL package provides 2 tools: (1) statistics, both weighted (χ2) and unweighted (R-merge), are provided, and the Bayesian reasoning and multicomponent error model facilitates obtaining the proper error ests. and (2) visualization of the process plays a double role by helping the operator to confirm that the process of data redn., including the resulting statistics, is correct, and allowing one to evaluate problems for which there are no good statistical criteria.  Visualization also provides confidence that the point of diminishing returns in data collection and redn. has been reached.  At that point, the effort should be directed to solving the structure.  The methods presented here have been applied to solve a large variety of problems, from inorg. mols. with 5 Å unit cell to rotavirus of 700 Å diam. crystd. in 700 × 1000 × 1400 Å cell.  Overall quality of the method was tested by many researchers by successful application of the programs to MAD structure detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3fvBOHqhhrVg90H21EOLACvtfcHk0liOe_7DVUNZWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D&md5=c9536971d4e32cc35352c40fb9368131</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DMinor%26aufirst%3DW.%26atitle%3DProcessing%2520of%2520X-ray%2520diffraction%2520data%2520collected%2520in%2520oscillation%2520mode%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326%26doi%3D10.1016%2FS0076-6879%2897%2976066-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skubák, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebedev, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannu, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A. A.</span></span> <span> </span><span class="NLM_article-title">REFMAC5 for the refinement of macromolecular crystal structures</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1107/S0907444911001314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1107%2FS0907444911001314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=21460454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=355-367&author=G.+N.+Murshudovauthor=P.+Skub%C3%A1kauthor=A.+A.+Lebedevauthor=N.+S.+Pannuauthor=R.+A.+Steinerauthor=R.+A.+Nichollsauthor=M.+D.+Winnauthor=F.+Longauthor=A.+A.+Vagin&title=REFMAC5+for+the+refinement+of+macromolecular+crystal+structures&doi=10.1107%2FS0907444911001314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">REFMAC5 for the refinement of macromolecular crystal structures</span></div><div class="casAuthors">Murshudov, Garib N.; Skubak, Pavol; Lebedev, Andrey A.; Pannu, Navraj S.; Steiner, Roberto A.; Nicholls, Robert A.; Winn, Martyn D.; Long, Fei; Vagin, Alexei A.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">355-367</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">This paper describes various components of the macromol. crystallog. refinement program REFMAC5, which is distributed as part of the CCP4 suite.  REFMAC5 utilizes different likelihood functions depending on the diffraction data employed (amplitudes or intensities), the presence of twinning and the availability of SAD/SIRAS exptl. diffraction data.  To ensure chem. and structural integrity of the refined model, REFMAC5 offers several classes of restraints and choices of model parameterization.  Reliable models at resolns. at least as low as 4 Å can be achieved thanks to low-resoln. refinement tools such as secondary-structure restraints, restraints to known homologous structures, automatic global and local NCS restraints, 'jelly-body' restraints and the use of novel long-range restraints on at. displacement parameters (ADPs) based on the Kullback-Leibler divergence.  REFMAC5 addnl. offers TLS parameterization and, when high-resoln. data are available, fast refinement of anisotropic ADPs.  Refinement in the presence of twinning is performed in a fully automated fashion.  REFMAC5 is a flexible and highly optimized refinement package that is ideally suited for refinement across the entire resoln. spectrum encountered in macromol. crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Jq-i2qIq5rVg90H21EOLACvtfcHk0lh5EAq6ZAqj_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqtbk%253D&md5=f8f3202d246908500057ad7c71015b7b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1107%2FS0907444911001314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444911001314%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DSkub%25C3%25A1k%26aufirst%3DP.%26aulast%3DLebedev%26aufirst%3DA.%2BA.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DSteiner%26aufirst%3DR.%2BA.%26aulast%3DNicholls%26aufirst%3DR.%2BA.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DLong%26aufirst%3DF.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26atitle%3DREFMAC5%2520for%2520the%2520refinement%2520of%2520macromolecular%2520crystal%2520structures%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D355%26epage%3D367%26doi%3D10.1107%2FS0907444911001314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohkamp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Features and development of Coot</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lh5EAq6ZAqj_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZXB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZXB','PDB','5ZXB'); return false;">PDB: 5ZXB</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IK3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IK3','PDB','3IK3'); return false;">PDB: 3IK3</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GVU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GVU','PDB','3GVU'); return false;">PDB: 3GVU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EWH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EWH','PDB','4EWH'); return false;">PDB: 4EWH</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i83"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00882">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_44016"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b00882">10.1021/acs.jmedchem.8b00882</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">In vitro selectivity profiling of <b>10k</b> at 1 μΜ against 351 human kinases, antiproliferative activity of selected compounds in ACK1/GCK double knockdown OCI-AML3 cells, dose-dependent induction of apoptosis by compound <b>10k</b>, FACS analysis for the selected compounds in Ba/F3-NRAS-G12D and OCI-AML3 cell lines (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00882/suppl_file/jm8b00882_si_001.pdf">PDF</a>)</p></li><li><p class="inline">PDB-formatted coordinates for computational models (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00882/suppl_file/jm8b00882_si_002.zip">ZIP</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00882/suppl_file/jm8b00882_si_003.xlsx">XLSX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00882/suppl_file/jm8b00882_si_001.pdf">jm8b00882_si_001.pdf (793.77 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00882/suppl_file/jm8b00882_si_002.zip">jm8b00882_si_002.zip (331.39 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00882/suppl_file/jm8b00882_si_003.xlsx">jm8b00882_si_003.xlsx (11.42 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB ID code for ACK1-<b>10d</b> complex is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZXB">5ZXB</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00882&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00882%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-18%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00882" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a99c1b932247f","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
